

AMERICAN PANCREATIC ASSOCIATION

# *46th Annual Meeting*

NOVEMBER 4-7, 2015 SAN DIEGO, CALIFORNIA



AMERICAN PANCREATIC  
ASSOCIATION

## SUPPORTERS

---

*The American Pancreatic Association would like to extend a special thank you to the following organizations for their support of this meeting through educational grants —*

### PLATINUM SUPPORTERS

Abbvie  
Celgene  
ChiRhoClin

### GOLD SUPPORTERS

Hirshberg Foundation for Pancreatic Cancer Research  
Kenner Family Research Fund

### SILVER SUPPORTERS

Aduro Biotech  
Astra Zeneca  
Cook Endoscopy  
Halozyme Therapeutics  
Vay Liang W. Go, Pancreas Journal

### BRONZE SUPPORTERS

Digestive Care  
Merrimack  
National Pancreas Foundation  
Threshold Pharmaceuticals

*The American Pancreatic Association would like to thank the following companies for providing marketing and exhibit support —*

Abbvie  
Boston Scientific  
Celgene  
ChiRhoClin  
Cook Endoscopy  
Digestive Care  
Foundation Medicine  
Fisher Scientific

***Please visit our exhibitors' booths in the Commodore Ballroom Foyer***

*Image on cover courtesy of SanDiego.org*



**AMERICAN PANCREATIC  
ASSOCIATION**

**AMERICAN PANCREATIC ASSOCIATION**

**GOVERNING BOARD**

Anirban Maitra, MBBS, President  
Ashok Saluja, PhD, Secretary-Treasurer  
Carlos Fernandez-del Castillo, MD, President-Elect  
Stephen Pandol, MD, Past President  
Miklos Sahin-Toth, PhD, Councilor  
Darwin Conwell, MD, Councilor  
Margaret Tempero, MD, Councilor

**APA CONTACT INFORMATION**

Ashok K. Saluja, PhD  
*APA Secretary-Treasurer*  
*Professor & Vice Chair, Surgery*  
*University of Minnesota*

PO Box 14906  
Minneapolis, MN 55414

T | 612-626-9797  
F | 612-625-7700  
E | [apa@umn.edu](mailto:apa@umn.edu)

[www.american-pancreatic-association.org](http://www.american-pancreatic-association.org)

## MESSAGE FROM THE PRESIDENT

### WELCOME!

On behalf of the rest of the board, I am so pleased you have joined us for our 46th Annual Meeting. I remember first attending an APA annual meeting as a junior faculty, and being overwhelmed by the warmth accorded to me as a relative newcomer. In the dozens upon dozens of national meetings I have attended over the last 15 years, I cannot recall a scientific meeting comparable to the APA, where “everybody knows your name” and you are treated with such unsurpassed hospitality. Over the years, as the organization has grown, I have come to recognize its unique vantage point in the universe of pancreatic diseases, serving as a “melting pot” for clinical researchers and basic scientists of all hues.



We have put together what I hope you will find to be an exciting program. We value the opportunity to work together with the entire pancreas community in putting on this meeting. Agi Hirshberg & the Hirshberg Foundation are important champions of the meeting, continuing this year with their support of the opening Hirshberg Symposium. Additionally, we are pleased to continue our partnership with Barbara Kenner & the Kenner Family Research Fund for a Forum on Early Detection Methods, looking at lessons learned in other cancers.

As always, an important part of our mission is making sure we are bringing people together regardless of their discipline, location or stature. We have always felt that meals and events are important places for these less formal meetings and scientific discussions to take place, which is why we are so appreciative of our supporters who allow us to keep the registration reasonable despite the social events. Additionally, more formal networking opportunities have been added this year. We have added “Meet the Expert” breakfast sessions. A special thank you to Anil Rustgi for the suggestion and organizing those sessions.

This year will no doubt be our largest single meeting to date, with over 330 abstracts being presented from 20 different countries. We are thrilled with the continued interest and excitement about this meeting. We are also enormously grateful to all of our symposia organizers and invited speakers, truly a who’s who in the field of pancreatology. I would also like to thank the APA Board and in particular, Ashok Saluja. Thank you for joining us for what will undoubtedly be an superb meeting!

Anirban Maitra, MBBS  
Sheikh Ahmed Pancreatic Cancer Research Center  
UT MD Anderson Cancer Center  
Houston, Texas

**WEDNESDAY, NOVEMBER 4**

7:00 a.m. - 8:00 a.m.	Breakfast
8:00 a.m. - 1:00 p.m.	Pre-Meeting - Application of Molecular Diagnostics to Pancreatic Cancer
1:00 p.m. - 2:00 p.m.	Lunch
2:00 p.m. - 4:30 p.m.	Pre-Meeting - Early Detection: Lessons Learned from Other Cancers
5:30 p.m. - 7:00 p.m.	Hirshberg Opening Symposium: Immunobiology of Pancreatic Cancer
7:00 p.m. - 9:00 p.m.	Presidential Reception

**THURSDAY, NOVEMBER 5**

7:00 a.m. - 8:30 a.m.	Breakfast & Poster Viewing
8:30 a.m. - 10:00 a.m.	Abstract Session: Pancreatic Cancer
10:15 a.m. - 11:30 a.m.	Mini Symposium: Chronic Pancreatitis to Pancreatic Cancer
11:30 a.m. - 12:00 p.m.	Frank Brooks State of the Art Lecture
12:00 p.m. - 2:00 p.m.	Lunch & Poster Session
2:00 p.m. - 3:20 p.m.	Abstract Session: Pancreatitis
3:20 p.m. - 4:30 p.m.	Mini Symposium: Basic & Translational Research on Tobacco and Pancreatic Diseases
4:45 p.m. - 6:00 p.m.	Mini Symposium: Young Investigator Symposium - PanCAN: Pathway to Leadership Awardees
7:00 p.m. - 10:00 p.m.	Reception & Awards Dinner

**FRIDAY, NOVEMBER 6**

7:00 a.m. - 8:30 a.m.	Breakfast & Poster Viewing
8:30 a.m. - 10:00 a.m.	Abstract Session: Pancreatitis
10:15 a.m. - 11:30 a.m.	Mini Symposium: Obesity, Metabolism, and Pancreatic Diseases
11:30 a.m. - 12:00 p.m.	Paul Webster Clinical State of the Art
12:00 p.m. - 2:00 p.m.	Lunch & Poster Session
2:00 p.m. - 2:30 p.m.	Business Meeting
2:30 p.m. - 3:45 p.m.	Mini Symposium: Multimodality Management of Pancreatic Cancer
4:00 p.m. - 5:15 p.m.	Parallel Sessions: <i>Clinical Controversy: Management of Branch Duct IPMNs &amp; Basic Science Controversy: Does Alcohol Cause Pancreatitis?</i>
5:15 p.m. - 6:30 p.m.	Parallel Sessions: <i>Clinical Science Abstracts &amp; Basic Science Abstracts</i>
7:00 p.m.	Women in Pancreas Reception & Dinner

**SATURDAY, NOVEMBER 7**

7:00 a.m. - 8:30 a.m.	Breakfast
8:30 a.m. - 10:20 a.m.	Abstract Session: Pancreatic Cancer
10:35 a.m. - 12:00 p.m.	Mini Symposium: Management of Recurrent Acute Pancreatitis
12:00 p.m. - 1:30 p.m.	Mini Symposium: Biology and Translational Implications of Metastatic Pancreatic Cancer
1:30 p.m.	Lunch

## MEETING INFORMATION

### ON SITE REGISTRATION HOURS

**Location** | Commodore Foyer

Wednesday, 11/4	7:00 am – 7:00 pm
Thursday, 11/5	7:00 am – 6:00 pm
Friday, 11/6	7:00 am – 6:30 pm
Saturday, 11/7	7:00 am – 1:30 pm

### ABSTRACT SELECTION COMMITTEE

*The APA Board would like to thank the following for reviewing the over 300 abstracts received:*

Sulagna Banerjee - University of Minnesota	Kazuichi Okazaki - Kansai University
Howard Crawford - University of Michigan	Marina Pasca di Magliano - University of Michigan
Vikas Dudeja - University of Minnesota	Nageshwar Reddy - AIG, India
Carlos Fernandez-del Castillo - Harvard/MGH	Miklos Sahin-Toth - Boston University
Toru Furukawa - Tokyo Women's Medical University	Veena Sangwan - McGill, Canada
Pramod Garg - AIIMS, India	Vijay Singh - Mayo Arizona
Guy Groblewski - UW, Madison	Vikesh Singh - Johns Hopkins
Anna Gukovskaya - UCLA	Kyoko Shimizu - Tokyo Women's Medical University
Aida Habtezion - Stanford	Kyoichi Takaori - Kyoto University, Japan
Peter Hegyi - University of Szeged, Hungary	Masao Tanaka - Kyushu University, Japan
Joe Hines - UCLA	Margaret Tempero - UCSF
Karen Horvath - UW Seattle	Aliye Uc - University of Iowa
Sohail Hussain - Children's Hospital Pittsburgh	Huaizhi Wang - Southwest Hospital, Third Military Medical University, China
Myung-Hwan Kim - Asan Medical Center, Korea	Andrea Wang-Gilliam - Washington University
Min Li - Oklahoma University	Christopher Wolfgang - Johns Hopkins
Anirban Maitra - MD Anderson	Bechien Wu - Kaiser Permanente
Atsushi Masamune - Tohoku University	Yianjun Yu - Fudan University, China
Julia Mayerle - University of Greifswald, Germany	
Nipun Merchant - University of Miami	

### SOCIAL EVENTS

#### PRESIDENTIAL RECEPTION

Wednesday, November 4, 7:00 p.m. - 9:00 p.m.

*Location* | Bay Terrace

The Presidential Reception is held in honor of APA President Anirban Maitra. Catch up with friends and colleagues while taking advantage of the weather and enjoying the ocean view.

#### AWARDS DINNER & RECEPTION

Thursday, November 5, 7:00 p.m. - 10:00 p.m.

Reception 7:00 p.m. - 8:00 p.m. *Location* | Bay Terrace

Dinner 8:00 p.m. - 10:00 p.m. *Location* | Commodore CDE

During the dinner, awards will be given for the top abstracts in Pancreatitis and Pancreatic Cancer. Additionally, those receiving young investigator travel awards will be acknowledged. The Distinguished Service Award and the Vay Liang & Frisca Go Award for Lifetime Achievement will both be presented.

#### WOMEN IN PANCREAS RECEPTION & DINNER

Friday, November 6, 7:00 p.m.

Reception *Location* | Bay Terrace, Dinner *Location* | Britannia/Cambria

All women are invited to attend this event. RSVPs are required; please check in with the registration desk if you have not RSVPed. A keynote will be given by Helen Torley, MB, ChB, MRCP, CEO & President of Halozyme Therapeutics



## ASSOCIATED MEETINGS

### PRE-MEETING - APPLICATION OF MOLECULAR DIAGNOSTICS TO PANCREATIC CANCER

Wednesday, November 4 - 8:00 am - 1:00 pm

*Location | Constellation Ballroom*

This special meeting is being organized by the APA Leadership to address the burgeoning use of molecular techniques in diagnosis, prognosis and therapeutic stratification in pancreatic cancer and other variant tumors of the pancreas. The meeting format will be comprised of two thematic sessions and two plenary talks, with ample time for panel-based discussions and audience participation.

Highlighting the plenary talks are Dr. Sam Gambhir from Stanford University, who will lecture on innovative early detection strategies for pancreatic cancer, and Dr. Andrew Biankin from the University of Glasgow who will lecture on the most recent advances in identifying molecular phenotypes in pancreatic cancer, work accomplished through the International Cancer Genome Consortium (ICGC). Bookending the two plenary lectures will be sessions of pancreatic cystic lesions and practical issues in application of precision medicine paradigms to pancreatic cancer. Attendees will be able to gain significant new knowledge on how to interface molecular diagnostics and novel technologies into real time clinical decision making. The target audience for this special meeting is fairly broad and includes the entire spectrum of pancreatic researchers from basic scientists to clinicians.

### KFRF/APA FORUM - EARLY DETECTION: LESSONS LEARNED FROM OTHER CANCERS

Wednesday, November 4 - 2:00 pm - 4:30 pm

*Location | Constellation Ballroom*

A Strategic Map for Innovation was formulated as a result of the 2014 Early Detection of Sporadic Pancreatic Cancer Summit Conference. The aggregate results from the efforts detailed in the post-summit white paper are aligned to improve survival for those individuals with pancreatic cancer. The integration of knowledge, partner engagement, and intentionality of discovery are imperative to move the field forward.

The 2015 Forum entitled Early Detection: Lessons Learned from Other Cancers is an important step in the implementation of the Strategic Map for Innovation. Recognizing progress made in other cancers is critical to overcoming barriers in early detection of pancreatic cancer. The Forum provides an opportunity for attendees to gain information from a historical perspective and for leading experts in the areas of breast, prostate, colon, and lung cancer to engage in vital discussions.

Kenner Family Research Fund (a registered 501(c)3 organization) is committed to investing in initiatives to establish an early detection protocol for pancreatic cancer. The fund was formed by family and friends in memory of Peter Kenner.

## APA FOUNDATION

The APA Foundation was officially launched two years ago with the purpose of providing education, research, and charitable support to the APA mission and initiatives. Our society continues to provide a forum for communications and support for young investigators to present their outstanding research work in pancreatic diseases. Our society is now celebrating its 46th annual meeting this year. Our foundation has an excellent start in creating an endowment fund. Thank you to the Board of Directors and the APA members whose generosity has contributed to our foundation. The future of our society and its mission is in our own hands. Please send your contributions to the APA Foundation, 1020 Tyrol Trail, Golden Valley, MN 55416.

The Board of Directors, Steve Pandol MD, Ashok Saluja MD, Edward Bradley MD, William Chey MD, Edward D. Purich PhD, Agi Hirshberg, Barbara Kenner PhD, Peter Banks MD, Howard Reber MD, Andrew Warshaw MD, Paul Webster MD, and Vay Liang Go MD, Chair, would like to express our heartfelt gratitude for your support.

**YOUNG INVESTIGATOR AWARDS**

Junichi Akao	Suprit Gupta	Mila Kovacheva-Slavova	Raghuwansh Sah
Nivedita Arora	Max Heckler	Jian Li	Amanda Salzwedel
Jennifer Behzadi	Audrey Hendley	Wei qin Lu	Veena Sangwan
Anca Botezatu	Wei Huang	Sudarshan Malla	Nikita Sharma
Puneet Chhabra	Brad Jakubison	Nagaraj Nagathihalli	Si Shi
Susanna de Geus	Tao Jin	Akifumi Nakagawa	Guru Trikudanathan
Kali Deans	Shunqian Jin	Lucy Oldfield	Virginia Vanasco
Narendra Dhaka	Kazumichi Kawakubo	Jean Park	Mu Xu
Andrea Geisz	Vanaja Konduri	Melissa Pruski	Jingxuan Yang


**DISTINGUISHED SERVICE AWARD**

**MUSHTAQ A. KHAN, DVM, PHD**

Dr. Mushtaq A. Khan is the Scientific Review Officer of the Clinical, Integrative and Molecular Gastroenterology (CIMG) Study Section and former Chief of Digestive, Kidney and Urological Systems (DKUS) Integrated Review Group at the Center for Scientific Review. He was born in Faisalabad, Pakistan and obtained his veterinary degree from the University of Punjab in 1960, master’s degree from Montana State University in 1962, and a Ph.D. in endocrine physiology from Washington State University in 1968. Dr. Khan then returned to Pakistan to teach at the University of Agriculture, Faculty of Veterinary Medicine where he last served as the Chairman of the department of Physiology and Pharmacology. He immigrated to the US in 1972 and was recruited as an assistant professor of Pediatric Research at the University of Maryland Medical School at Baltimore.

In 1978, Dr. Khan took a position at the FDA and served as Head of Perinatal Toxicology unit at the FDA’s Beltsville Research Facility. At the FDA and University of Maryland, Dr. Khan conducted research in the area of Nutritional Toxicology including cholesterol metabolism and atherosclerosis. He developed a computerized automatic feeding system (Autosow) for liquid diets for neonatal miniature swine. In July 1988, he joined the Division of Research Grants (Currently CSR) to take over the General Medicine A-2 Study Section (GMA-2) where he oversaw the extensive metamorphosis and expansion of the field of gastroenterology.

Dr. Khan has mentored many investigators and researchers in gastroenterology in their NIH grant applications and research and has contributed significantly to the progress of our discipline. Dr. Khan is retiring after completing over 38 years of Federal Government service of which 27 years relate to Gastroenterology.







## DISTINGUISHED SERVICE AWARD

### JOSE SERRANO, MD, PHD

Dr. Jose Serrano is the director of the Pancreas Program in the Division of Digestive Diseases and Nutrition of the NIDDK, National Institutes of Health (NIH). He was born in Callosa de Segura, Alicante, Spain and was raised in Valencia and Barcelona, Spain before coming to the United States in 1985. He graduated from the Universidad Autonoma de Barcelona (UAB), Barcelona, Spain with a PhD in molecular biology and biochemistry, followed by an MD degree from the UAB.

Dr. Serrano came to the NIH in 1985 as a Research Fellow (1985-87) and Research Associate (1987-1990) in the Diabetes Branch of NIDDK. Dr. Serrano completed residency training in internal medicine at the Medstar-Georgetown Hospitals followed by a gastroenterology and hepatology fellowship training through a combined NIH-Georgetown University program in 1998.

Dr. Serrano moved to his current position in the extramural Division of Digestive Diseases and Nutrition (DDDN) in 1998 where he serves as director for the pancreas, liver and GI neuroendocrinology programs. Dr. Serrano has managed one of the most complex research portfolios of the Division, comprising basic biology, translational and clinical research projects in digestive diseases. The program includes a diverse array of large and small grants including multiple multicenter clinical trials.

Dr. Serrano plays a critical role in NIDDK grants administration and guiding applicants through the NIH peer-review system. He provides fiscal and managerial oversight of more than 90 grants within his portfolio. Dr. Serrano has been instrumental in helping both young and established GI investigators navigate the grants review process. He has actively participated in the annual American Pancreatic Association Meeting for many years, often coordinating one-on-one meetings between NIDDK staff and investigators interested in learning about opportunities for NIH support. Furthermore, he has been a regular participant in annual career development mentoring workshops for K awardees and new RO1 investigators. He has long been a strong advocate that funding opportunities are available so that young gastroenterologists and PhD scientists can make substantial progress in the field of pancreatology.

Dr. Serrano, working alongside leaders of the scientific community, NIDDK Advisory Council members, DDDN staff, and staff from other Institutes, has championed the NIH efforts to accelerate and expand research in pancreatic diseases. Through his efforts, and those of his collaborators, the NIDDK has recently sponsored individual research workshops on pancreatitis, pancreatic cancer, and diabetes and on total pancreatectomy and auto-islet cell transplantation.

Dr. Serrano has been instrumental in the genesis and development of a new initiative, sponsored jointly by NIDDK and the NCI to create a clinical research group, the Consortium to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CSCPDP), which will conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. This clinical research network with an annual budget of \$5.8M was awarded in September 2015.

In addition to his basic biology research, Dr. Serrano has published a number of peer-reviewed studies on the epidemiology and pathophysiology of Zollinger-Ellison Syndrome, the clinical characterization and genetics of Drug Induced Liver Injury and advances in pancreatic research. He is the author of more than 60 scientific publications. He is the recipient of a number of commendations, including the PHS Commendation Medal, the NIH Director's Award, and the AGA Research Service Award.

In addition to his many scientific administration responsibilities, Dr. Serrano has remained an active clinician by serving as an attending physician in NIH's Clinical Center, where he is responsible for supervising GI fellows in the NIH fellowship program.

## VAY LIANG & FRISCA GO AWARD FOR LIFETIME ACHIEVEMENT STEPHEN PANDOL, MD

Stephen Pandol was born in Bakersfield, CA and grew up in the Central Valley of California working on the farm with his sister and brothers. His favorite classes in high school were his different chemistry classes. He was destined to return to the family business and applied to only one college, the University of California, Davis, which is the premier agricultural school in California for studies in agricultural business and sciences. Within a week of arriving at Davis, he changed his major to biochemistry following his love of chemistry he had acquired in high school from his teachers there.

Stephen flourished in his chemistry classes at Davis and wanted to become a researcher of some sort. As his senior year approached and he had to make a decision on his next step, he chose to pursue an MD degree at Saint Louis University. He returned to California to complete his clinical training in internal medicine and gastroenterology at the Wadsworth VA Medical Center and the University of California, Los Angeles (UCLA). He was surrounded by a wonderful and exceptional faculty in gastroenterology and gastrointestinal research. Jon Isenberg and Andrew Soll mentored and supported this passion and introduced him to Jerry Gardner who was the chief of the Digestive Diseases Division at the National Institutes of Health (NIH). Jerry chose him to come to the Bethesda campus at NIH for dedicated research training. Jerry, with the help of Bob Jensen and Denis McCarthy, mentored him and worked on taking his curiosity and science interest to convert him into a functioning and proficient biomedical researcher.



Stephen took his first faculty position at the University of California, San Diego (UCSD). UCSD allowed Stephen to become active in teaching GI physiology, pathophysiology as well as training residents and fellows. Also, his research program accelerated in the environment and he took on administrative roles including Chief of the GI division at the Veterans Hospital. He was even selected to attend Joint Commission School to learn how to prepare hospitals for accreditation. During this time, he developed a very productive collaboration with Shmuel Muallem who was in Los Angeles. They took turns commuting between San Diego and Los Angeles weekly to carry out experiments to investigate calcium signaling pathways in pancreatic acinar cells. The information would ultimately lead to the basis for understanding the role of pathologic calcium signaling in the mechanism of pancreatitis. Also, during this time, an enduring and incredible scientific collaboration and friendship started with Fred Gorelick now spanning 3 decades. The ideas and projects flow when they encounter each other. Several have resulted in important papers and grants. During the time in San Diego he recruited Anna Gukovskaya from the former Soviet Union starting a remarkable and sustained collaboration on several topics in pancreatic disease. They moved to Los Angeles in 1996 and were joined by Anna's husband, Ilya. The laboratory research group was blessed by several visiting scientists with some staying and becoming faculty members including Aurelia Lugea and Mouad Edderkaoui. Pandol also continued administrative roles as Director of Research at the VA and overseeing preparedness for hospital accreditation. Importantly, he continues to have the opportunity to work with Agi Hirshberg, Bill Go and Howard Reber, starting the Agi Hirshberg Foundation which has provided critical support to direct the enlarging group of pancreatic researchers to expand their efforts to better understand and treat pancreatic cancer. Another strong and continuing collaboration for several years has been with Hide Tsukamoto at USC developing and expanding alcohol research center for studies in alcoholic liver and pancreatic diseases.

Most recently, Pandol was appointed as Director, Basic and Translational Research at Cedars-Sinai Medical Center in Los Angeles. Along with Simon Lo and a multidisciplinary team of clinical and basic scientists at Cedars and talented investigators in medical centers in the greater Los Angeles region they are embarking on a journey with the goal of developing new therapies for pancreatic diseases.

Last year Stephen had the honor of being the President of the APA, an organization he has been involved with for many years; and was fortunate to work with the JPS President Tooru Shimosegawa and APA Secretary-Treasurer Ashok Saluja to put on an incredible international meeting in Hawaii representing the 45th anniversary of both JPS and APA.

Pandol was fortunate to grow up in an environment where his parents and family put no barriers on what is possible and what you can achieve with hard work and integrity. His mother Winnie is to this day able to show her support still resides in Bakersfield. He is blessed with two lovely children, Jennifer and Andrew and now with wife Erin there are two gorgeous grandchildren, Lucy and Oliver. Stephen is married to his loving, caring wife, Marnell, who provides Stephen with comfort and encouragement. She is his support, sounding board and secret weapon.

## LEARNING OBJECTIVES

*This activity is designed for physicians and researchers.*

*Upon completion of this course, participants will be able to:*

1. Create collaborative opportunities between clinical and basic scientists interested in diseases of the pancreas.
2. Understand the link between chronic pancreatitis to pancreatic cancer including how diabetes affects both diseases.
3. Recognize the current research on the effects of tobacco and alcohol on pancreatic diseases.
4. Discuss the latest research on the immunobiology of pancreatic cancer.
5. Describe how obesity and metabolism affect pancreatic cancer and pancreatitis.
6. Appraise the multi-disciplinary options for managing pancreatic cancer.
7. Compare and contrast the varying options for management of branch duct IPMNs.
8. Discuss the most up to date research on the management of recurrent acute pancreatitis.
9. Explain the biology and translational implications of metastatic pancreatic cancer.
10. Extrapolate the next steps in early detection methods research based on successes and failures in other cancers.
11. Explain the advances in molecular diagnostics and its application to pancreatic cystic lesions.
12. Understand the practical issues in precision medicine in pancreatic cancer.

### CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

#### **Accreditation**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Surgeons and the American Pancreatic Association. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

#### **AMA PRA Category 1 Credits™**

The American College of Surgeons designates this live activity for a maximum of 26.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**AMERICAN COLLEGE OF SURGEONS**  
Inspiring Quality: Highest Standards, Better Outcomes



**AMERICAN COLLEGE OF SURGEONS  
DIVISION OF EDUCATION**  
Accredited with Commendation by the  
Accreditation Council for Continuing Medical Education

## DISCLOSURE INFORMATION

In compliance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the insert to this program for the complete disclosure list.

**APPLICATION OF MOLECULAR DIAGNOSTICS TO PANCREATIC CANCER**

**APA PRE-MEETING | SAN DIEGO 2015**

Wednesday, November 4

*Constellation Ballroom*

**7:00- 8:00 a.m.**

**Breakfast**

*Location | Mistral*

**8:00-9:20 a.m.**

**Pancreatic Cystic Lesions**

*Location | Constellation Ballroom*

Chairs | Tooru Shimosegawa and Suresh Chari

**Masao Tanaka, MD** Kyushu University Graduate School of Medical Sciences  
*The Consensus Criteria*

**Aatur D. Singhi, MD, PhD** University of Pittsburgh Medical Center  
*Molecular Diagnostics in Pancreatic Cystic Neoplasia – Is It Ready for Prime Time?*

**Anne Marie Lennon, MB, PhD** Johns Hopkins Medical Institutions  
*Incorporating Molecular Diagnostics into Cyst Management – Real Life Examples*

**Carlos Fernandez-del Castillo, MD** Massachusetts General Hospital  
*When Do I Anticipate Needing Molecular Diagnostics Support for Cyst Management? A Surgeon’s Perspective*

**9:20-9:50 a.m.**

**Panel Discussion**

**9:50-10:10 a.m.**

**Break**

*Location | Constellation Foyer*

**10:10-10:50 a.m.**

**Plenary Talk 1**

*Location | Constellation Foyer*

**Sanjiv Sam Gambhir, MD, PhD** Stanford University School of Medicine  
*New Strategies for the Early Detection of Cancer*

**10:50-11:30 a.m.**

**Plenary Talk 2**

*Location | Constellation Foyer*

**Andrew Biankin, MD, PhD** University of Glasgow  
*What Have We Learned About Clinical Actionability in Pancreatic Cancer?*

**11:30-11:45 a.m.**

**Break**

*Location | Constellation Foyer*

**11:45-1:00 p.m.**

**Practical Issues in Precision Medicine for Pancreatic Cancer**

*Location | Constellation Ballroom*

Chairs | Kyoichi Takaori and Nipun Merchant

**Kyoichi Takaori, MD, PhD** Kyoto University  
*Molecular Diagnosis in Pancreatic Cancer: Perspectives from Japanese Familial Pancreatic Cancer*

**Anirban Maitra, MBBS** UT MD Anderson Cancer Center  
*Liquid Biopsies in Pancreatic Cancer Diagnosis*

**Keren Paz, PhD** (Champions Oncology)  
*Developing PDX Models of Pancreatic Cancer for Precision Medicine*

**12:45-1:00 p.m.** Panel Discussion

**1:00-2:00 p.m.** Lunch  
 Location | Pool/Marina Terrace

## EARLY DETECTION: LESSONS LEARNED FROM OTHER CANCERS

PRESENTED BY KENNER FAMILY RESEARCH FUND IN PARTNERSHIP  
 WITH THE AMERICAN PANCREATIC ASSOCIATION

2:00-4:30 pm  
 Constellation Ballroom

**2:00-2:10 p.m.** Early Detection of Sporadic Pancreatic Cancer: Strategic Map for Innovation  
*Vay Liang W Go, MD & Barbara Kenner, PhD*

**2:10-2:15 p.m.** Introduction of Presenters  
*Barbara Kenner, PhD*

**2:15-2:40 p.m.** Significant Accomplishments in Breast Cancer  
*Seema Khan, MD Northwestern University*

**2:40-3:05 p.m.** Significant Accomplishments in Prostate Cancer  
*Daniel Lin, MD University of Washington*

**3:05-3:10 p.m.** Break  
 Location | Constellation Ballroom

**3:10-3:35 p.m.** Significant Accomplishments in Colon and Lung Cancers  
*Graham Lidgard, PhD Exact Sciences*

**3:35-4:20 p.m.** Open Conversation  
*Khan, Lin, Lidgard, Audience*

**4:20-4:30 p.m.** Summary  
*Vay Liang W Go, MD & Suresh T Chari, MD*

# THE AMERICAN PANCREATIC ASSOCIATION'S *46th Annual Meeting*

## WEDNESDAY, NOVEMBER 4

**5:30-7:00 p.m.** **Hirshberg Opening Symposium: Immunobiology of Pancreatic Cancer**

*Location | Commodore Ballroom CDE*  
Moderators | Anirban Maitra & Ashok Saluja

**Gregory Beatty, MD, PhD** University of Pennsylvania Perelman School of Medicine  
*Unraveling Immune Escape Mechanisms in Pancreatic Carcinoma*

**Lisa M. Coussens, PhD** Knight Cancer Institute, Oregon Health and Science University  
*Immune Cells as Targets for Therapy in Pancreas Cancer*

**Michael Karin, PhD** University of California, San Diego  
*Autophagy in Pancreatitis and Pancreatic Cancer: The Good, the Bad and the Ugly*

**7:00-9:00 p.m.** **Presidential Reception**

*Location | Bay Terrace*

## THURSDAY, NOVEMBER 5

**7:00-8:30 a.m.** **Breakfast & Poster Viewing**

*Breakfast*

*Location | Pool/Marina Terrace*

*Meet the Experts Round Tables*

**Pramod Garg, MD** *Diagnostics and therapeutics in pancreatitis*

**Fred Gorelick, MD** *Animal Models of pancreatitis*

**Matthias Hebrok, PhD** *Mouse models of pancreatic cancer*

**Andy Rhim, MD** *Circulating tumor cells and other biomarkers for early diagnosis of pancreatic cancer*

**Gregory Beatty, MD PhD** *Immunotherapy of pancreatic cancer*

*Poster Viewing*

*Location | Commodore Ballroom AB & Commodore Foyer*



**8:30-10:00 a.m. Pancreatic Cancer Abstract Session**

Location | Commodore CDE

Moderators | Johanna Laukkarinen &amp; Kim Kelly

**Radical Surgery of Pancreatic Cancer with Concomitant Resectable Metastasis**W. Niesen, U.Hinz, O. Strobel, A. Ulrich, M.W. Büchler, and T. Hackert. *Department of Surgery, University of Heidelberg, Heidelberg, Germany***Discriminating Pancreatic Cyst Type and Grade Using Clinical Criteria: the Results of a Large Retrospective Cohort**D.L. Masica<sup>\*1,2,9</sup>, M. Dal Molin<sup>\*3,9</sup>, C.L. Wolfgang<sup>3,4,6</sup>, T. Tomita<sup>1,2</sup>, M.R. Ostovaneh<sup>5</sup>, A. Blackford<sup>7</sup>, R.A. Moran<sup>5</sup>, J.K. Law<sup>5</sup>, T. Barkley<sup>3</sup>, M. Goggins<sup>3,5,6,9</sup>, M.I. Canto<sup>5</sup>, M. Pittman<sup>3,8</sup>, J.R. Eshleman<sup>3,8,10</sup>, S.Z. Ali<sup>3</sup>, E.K. Fishman<sup>7</sup>, I.R. Kamel<sup>7</sup>, S.P. Raman<sup>7</sup>, A. Zaheer<sup>7</sup>, N. Ahuja<sup>4</sup>, M. A. Makary<sup>4</sup>, M. J. Weiss<sup>4</sup>, K. Hirose<sup>4</sup>, J. L. Cameron<sup>4</sup>, N. Rezaee<sup>4</sup>, J. He<sup>4</sup>, Y.J. Ahn<sup>4</sup>, W. Wu<sup>4</sup>, Y. Wang<sup>9,10</sup>, S. Springer<sup>9,10</sup>, L.L. Diaz Jr. <sup>9,10</sup>, N. Papadopoulos<sup>9,10</sup>, R.H. Hruban<sup>3,9,10</sup>, K.W. Kinzler<sup>10</sup>, B. Vogelstein<sup>1,9,10</sup>, R. Karchin<sup>1,2,6,9</sup>, and A.M. Lennon<sup>1,4,5,9</sup> *The Institute for Computational Medicine<sup>1</sup>; The Johns Hopkins University and Departments of Biomedical Engineering<sup>2</sup>; Pathology<sup>3</sup>; Surgery<sup>4</sup>; Medicine<sup>5</sup>; Oncology<sup>6</sup>; Radiology<sup>7</sup>; Biostatistics and Bioinformatics<sup>8</sup>; The Sol Goldman Pancreatic Cancer Research Center<sup>9</sup>; and The Ludwig Center and Howard Hughes Medical Institute<sup>10</sup> at the Sidney Kimmel Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland***Recent-Onset Diabetes in IPMN: an Independent Predictor of Invasive Carcinoma and Intestinal-Type Histology**V. Morales-Oyarvide<sup>1</sup>, M. Mino-Kenudson<sup>2</sup>, C.R. Ferrone<sup>1</sup>, A.L. Warshaw<sup>1</sup>, K.D. Lillemoe<sup>1</sup>, and C. Fernández-del Castillo<sup>1</sup>. *<sup>1</sup>Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; <sup>2</sup>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.***Post-pancreaticoduodenectomy Complications in High-risk Patients Can Be Reduced with Hydrocortisone Treatment. A Randomized Controlled Trial**M. Laaninen, J. Sand, K. Vasama, J. Laukkarinen. *Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland***Preclinical Testing of Anti-EZH2 Targeting Therapy for Pancreatic Cancer**G. Lomberk, A. Mathison, A. Salmonson, M. Missfeldt, T. Christensen, and R. Urrutia. *Epigenetics and Chromatin Dynamics Laboratory, Translational Epigenomics Program (CIM), GIH Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota***Dual Inhibitor of HDAC and GSK-3 $\beta$  Prevents Pancreatic Cancer Progression**C. Chheda, B. Soufi, C. Fall, R. Murali, S.J. Pandol, M. Edderkaoui. *Cedars-Sinai Medical Center, UCLA and VA, Los Angeles.***Low Dose Gemcitabine plus T<sub>H</sub>1 Dendritic Cell Vaccination Generates Durable Cure in a Kras<sup>G12D</sup>/p53<sup>-/-</sup> Orthotopic Model of Pancreatic Ductal Adenocarcinoma**V. Konduri<sup>1</sup>, D. Li<sup>2</sup>, M.M. Halpert<sup>1</sup>, D. Liang<sup>1</sup>, J.M. Levitt<sup>1,3,4</sup>, Q.C. Yao<sup>1,2,4</sup>, and W.K. Decker<sup>1,4,5</sup>. *<sup>1</sup>Department of Pathology & Immunology, <sup>2</sup>Michael E. DeBakey Department of Surgery, <sup>3</sup>Scott Department of Urology, <sup>4</sup>Dan L. Duncan Cancer Center, <sup>5</sup>Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.***10:00-10:15 a.m. Break**

Location | Commodore Foyer

**10:15-11:30 a.m. MINI SYMPOSIUM: Chronic Pancreatitis to Pancreatic Cancer**

*Location | Commodore Ballroom CDE*  
Moderators | Zideng Feng & David Whitcomb

**Dana K. Andersen, MD** NIDDK, NIH  
*Type 3c Diabetes: Definition, Etiology, and Diagnosis*

**Suresh Chari, MD** Mayo Clinic  
*Diabetes and Pancreatic Cancer*

**Darwin Conwell, MD, MS** Ohio State University  
*Chronic Pancreatitis Management: Current and Future Directions*

**Julia Mayerle, MD** University Medicine Greifswald  
*Metabolic Biomarkers to Distinguish Pancreatic Cancer and Pancreatitis*

**Yi Miao, MD, PhD** Pancreas Center & Pancreas Institution, Nanjing Medical University  
*Inflammatory Disease or Neoplasm? Intra-operative Histological Evidence for Chronic Pancreatitis*

**11:30-12:00 p.m. Frank Brooks State of the Art Lecture**

*Location | Commodore Ballroom CDE*  
Introduction | Margaret Tempero

**Matthias Hebrok, PhD** University of California, San Francisco  
*Defining Progenitor Cells for Pancreatic Adenocarcinoma*

**12:00-2:00 p.m. Lunch & Poster Session**

*Lunch*  
*Location | Pool/Marina Terrace*

*Poster Session*  
**Guided viewing of the posters of distinction, 1:00-2:00 p.m.**  
*Location | Commodore AB & Commodore Foyer*

Adjudicators— Minoti Apte & Fred Gorelick, Jamie Barkin & Aliye Uc  
Meet at Registration

**2:00-3:20 p.m. Pancreatitis Abstract Session**

*Location | Commodore CDE*  
Moderators | Sohail Husain & Kazuichi Okazaki

**Ethanol Worsens Acute Pancreatitis(AP) via Increasing Bioavailability of Fatty Acids(FA), and Not via Fatty Acid Ethyl Esters(FAEE)**

K. Patel<sup>1</sup>, P. Noel<sup>1</sup>, A. Singh<sup>1</sup>, C. Durgampudi<sup>2</sup>, C. de Oliveira<sup>1</sup>, R. Trivedi<sup>1</sup>, and V.P. Singh<sup>1</sup>.  
<sup>1</sup>Department of Medicine, Mayo Clinic, Scottsdale, AZ; <sup>2</sup>Department of Medicine, UPMC Passavant, Pittsburgh, PA.

**Very Early Onset Acute Recurrent and Chronic Pancreatitis are Associated With PRSS1 or CTRC Mutations**

A. Uc<sup>1</sup>, M. Giefer<sup>2</sup>, M.E. Lowe<sup>3</sup>, and S. Werlin<sup>4</sup>, on behalf of INSPPIRE Consortium.  
<sup>1</sup>University of Iowa Children's Hospital, Iowa City, Iowa; <sup>2</sup>Seattle Children's Hospital, Seattle, Washington; <sup>3</sup>Children Hospital of Pittsburgh, Pittsburgh, Pennsylvania; <sup>4</sup>Medical College of Wisconsin, Milwaukee, Wisconsin.

**Refine the Basis for Classification Systems for Severity of Acute Pancreatitis: A Retrospectively Analysis of 1094 patients**

T. Jin<sup>1</sup>, W. Huang<sup>1,2</sup>, L. H. Deng<sup>1</sup>, X. X. Zhang<sup>1</sup>, N. Shi<sup>1</sup>, Z. Q. Lin<sup>1</sup>, J. Guo<sup>1</sup>, X. N. Yang<sup>1</sup>, and Q. Xia<sup>1</sup>. <sup>1</sup>Sichuan Provincial Pancreatitis Centre, Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China; <sup>2</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK;

**Epidemiology of Hospitalized Patients with Acute Pancreatitis: Etiological Changes over the Last Decade**

S.G. Krishna, A. Hinton, S. Eldika, P.A. Hart, and D.L. Conwell. *Section of Pancreatic Disorders, Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH*

**NEMO/ IKK $\gamma$  Ablation Promotes Fibrosis and Impairs Regeneration during Pancreatitis**

L.K. Chan, T. Wirth, H.J. Maier. *Institute of Physiological Chemistry, University of Ulm, Ulm, Germany*

**Insulin Protects Pancreatic Acinar Cells During Experimental Acute Pancreatitis.**

J.I.E. Bruce<sup>1,2</sup>, Sans<sup>2</sup>, H. Durairaj<sup>2</sup>, B. Holz<sup>2</sup>, B. Nielson<sup>2</sup>, S. Ernst<sup>2</sup>, and J.A. Williams<sup>2</sup>. <sup>1</sup>Faculty of Life Sciences, The University of Manchester, Manchester, UK; <sup>2</sup>Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor Michigan

**3:20 - 4:30pm****MINI SYMPOSIUM: Basic and Translational Research on Tobacco and Pancreatic Diseases**

*Location | Commodore CDE*

*Moderators | Al Lowenfels & Walter Park*

**Dhiraj Yadav, MD** University of Pittsburg Medical Center  
*Epidemiology of Smoking and the Pancreas*

**Stephen Pandol MD** Cedars Sinai  
*Cellular Mechanisms of Smoke-Induced Injury to the Pancreas*

**Christopher Heeschen, MD, PhD** Barts Cancer Institute, Queen Mary University of London  
*Molecular Mechanisms of Nicotine Induced Pancreatic Neoplasia*

**Surinder K. Batra, PhD** University of Nebraska Medical Center  
*Profibrogenic Effects of Endothelin Axis in Pancreatic Cancer*

**4:30-4:45 p.m.****Break**

*Location | Commodore Foyer*

**4:45-6:00 p.m. MINI SYMPOSIUM: Young Investigator Symposium - Pathway to Leadership Awardees**

**Collaboration with PanCAN**

*Location | Commodore CDE*

Moderators | Julie Fleshman & Anil Rustgi

*2012 The Daniel and Janet Mordecai Foundation – Pancreatic Cancer Action Network – AACR Pathway to Leadership Grant*

**Oliver McDonald, MD, PhD** Vanderbilt University

*Genome-wide Epigenetic Reprogramming During Evolution of Pancreatic Cancer*

*2012 Celgene Corporation - Pancreatic Cancer Action Network - AACR Pathway to Leadership Grant*

**Stephanie Dougan, PhD** Dana-Farber Cancer Institute

*Transnuclear Mice: Understanding the T Cell Response to Pancreatic Cancer*

*2013 Pancreatic Cancer Action Network - AACR Pathway to Leadership Grant*

**Costas Lyssiotis, PhD** University of Michigan

*Defining and Targeting of Metabolic Dependencies in Pancreatic Cancer*

*2013 Pancreatic Cancer Action Network - AACR Pathway to Leadership Grant*

**Yuliya Pylayeva-Gupta, PhD** University of North Carolina at Chapel Hill

*Immunomodulatory Mechanisms in Kras-driven Pancreatic Cancer*

**7:00-10:00 p.m. Awards Dinner & Reception**

**Reception** 7:00-8:00 p.m.

*Location | Bay Terrace*

**Dinner** 8:00-10:00 p.m.

*Location | Commodore CDE*

## FRIDAY, NOVEMBER 6

**7:00-8:30 a.m. Breakfast & Poster Viewing**

*Breakfast*

*Location | Pool/Marina Terrace*

*Meet the Experts Round Tables*

**Margaret Tempero, MD** *Therapy of pancreatic cancer*

**Aida Habtezion MD MSc** *Immunology of pancreatitis*

**Anirban Matira, MD** *Functional genomics and molecular pathology*

**Anil K. Rustgi, MD** *3D culture and mouse models of pancreatic cancer*

*EMT-MET and metastasis*

**Diane Simeone, MD** *Pancreatic cancer stem cell biology*

*Poster Viewing*

*Location | Commodore Ballroom AB & Commodore Foyer*

**8:30-10:00 a.m.****Pancreatitis Abstract Session***Location | Commodore CDE*

Moderators | Matt DiMagno &amp; Anna Gukovskaya

**Roles of Extracellular ATP in Promoting Systemic Inflammation During Acute Pancreatitis**

A.K. Dixit, J. George, Y. Ryu, Z. Yuan, A. Sareen, V. Dudeja, R. Dawra, and A.K. Saluja.  
*Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, Minnesota*

**The Difference in Mechanisms of Neutrophil Infiltration between Type 1 and Type 2 Autoimmune Pancreatitis**

K. Uchida<sup>1</sup>, T. Mitsuyama<sup>1</sup>, M. Yanagawa<sup>1</sup>, H. Miyoshi<sup>1</sup>, T. Ikeura<sup>1</sup>, M. Shimatani<sup>1</sup>, T. Fukui<sup>1</sup>, M. Takaoka<sup>1</sup>, A. Nishio<sup>1</sup>, N. Mizuno<sup>2</sup>, K. Notohara<sup>3</sup>, G. Zamboni<sup>4</sup>, L. Frulloni<sup>5</sup>, T. Shimosegawa<sup>6</sup>, and K. Okazaki<sup>1</sup>. <sup>1</sup>*Department of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Japan;* <sup>2</sup>*Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan;* <sup>3</sup>*Department of Pathology, Kurashiki Central Hospital, Kurashiki, Japan;* <sup>4</sup>*Department of Pathology, University of Verona, Verona, Italy;* <sup>5</sup>*Department of Medicine, University of Verona, Verona, Italy;* <sup>6</sup>*Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan*

**Human Recombinant Activated Protein C (XIGRIS) as a Disease Modifier Early in Severe Acute Pancreatitis: Final Results of a Case-Controlled Study (XIGAP 1).**

A.K. Siriwardena<sup>1</sup>, C.J. Miranda<sup>1</sup>, J.M. Mason<sup>3</sup>, A.J. Sheen<sup>1</sup>, J.M. Eddleston<sup>2</sup>, M.J. Parker<sup>2</sup>, and B.I. Babu<sup>1</sup>. <sup>1</sup>*Hepatobiliary Surgical Unit;* <sup>2</sup>*Critical Care Unit Manchester Royal Infirmary;* <sup>3</sup>*School of Medicine, University of Durham, United Kingdom*

**Clinical Outcomes of Combined Necrotizing Pancreatitis Versus Extrapancreatic Necrosis Alone**

M. Wang, A. Wei, Z. Zhang, and W. Hu *Department of Pancreatic Surgery, West China Hospital, Chengdu, Sichuan, China.*

**Atg5 Deficiency Worsens Cerulein Pancreatitis**

S.R. Malla,<sup>1</sup> Y. Qin,<sup>1</sup> O.A. Mareninova,<sup>1</sup> J.M. Elperin,<sup>1</sup> E.M. Lotshaw,<sup>1</sup> M. Ohmuraya,<sup>2</sup> S.W. French,<sup>3</sup> A.S. Gukovskaya,<sup>1</sup> I. Gukovsky.<sup>1</sup> <sup>1</sup>*VA Greater Los Angeles Healthcare System and University of California at Los Angeles;* <sup>2</sup>*Kumamoto University, Japan;* <sup>3</sup>*Harbor-UCLA Medical Center, Torrance, California*

**Targetting Pancreatic Calcineurin to Prevent Post-ERCP Pancreatitis**

S. Jin, A.I. Orabi, T.A. Javed<sup>1</sup>, S. Sah, J.F. Eisses, and S.Z. Husain. *Department of Pediatric Gastroenterology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania*

**Chronic ER-stress in AT-1 Transgenic Mice Results in a Loss of Zymogen Granules, Pancreatic Steatosis, Stellate Cell Activation and Collagen Deposition Characteristic of Chronic Pancreatitis**

K. Deans<sup>1</sup>, D.D. Thomas<sup>1</sup>, Y. Peng<sup>2</sup>, L. Puglielli<sup>2</sup>, G.E. Groblewski<sup>1</sup>. <sup>1</sup>*Department of Nutritional Science, University of Wisconsin, Madison, WI;* <sup>2</sup>*Department of Internal Medicine, University of Wisconsin, Madison, WI.*

**10:00-10:15 a.m.****Break***Location | Commodore Foyer*

**10:15-11:30 a.m. MINI SYMPOSIUM: Obesity, Metabolism and Pancreatic Diseases**

*Location: Commodore CDE*  
Moderators | Mark Lowe & Xingpeng Wang

**Nabeel Bardeesy, PhD** MGH, Harvard Medical School  
*Altered Metabolic Pathways in Pancreatic Cancer*

**Zobeida Cruz-Montserrat, PhD** The Ohio State University  
*Animal Models of Obesity and Pancreatic Cancer*

**Guido Eibl, MD** David Geffen School of Medicine at UCLA  
*Inflammation in Obesity-associated Pancreatic Cancer in Mice*

**Vijay P. Singh, MD** Mayo Clinic Arizona  
*Acute Lipotoxicity As an Outcome Determinant in Pancreatitis*

**11:30-12:00 p.m. Paul Webster Clinical State of the Art**

*Location | Commodore CDE*  
Introduction | Carlos Fernandez-del Castillo

**Pramod Garg, MD** All India Institute of Medical Sciences  
*Why Have We Failed in Developing a Therapy For Pancreatitis?*

**12:00-2:00 p.m. Lunch & Poster Session**

*Lunch Session*  
*Location | Pool/Marina Terrace*

*Poster Session*  
**Guided viewing of the posters of distinction, 1:00-2:00 p.m.**  
*Location | Commodore AB & Commodore Foyer*

Adjudicators— Guy Groblewski & John Williams, Ajith Siriwardina & Brett Sheppard  
Meet at Registration

**2:00-2:30 p.m. Business Meeting**

*Location | Commodore CDE*

**Presidential Address** *Anirban Maitra*  
**Secretary-Treasurer's Report** *Ashok Saluja*  
**Report from the Nominating Committee** *Carlos Fernandez-del Castillo*

**2:30-3:45 p.m. MINI SYMPOSIUM: Multimodality Management of Pancreatic Cancer**

*Location | Commodore CDE*  
Moderators: Joe Hines & Jens Werner

**Elliott K. Fishman MD FACP** Johns Hopkins Hospital  
*Optimal Imaging for Staging*

**Michael Levy, MD** Mayo Clinic  
*EUS Staging of Pancreatic Cancer*

**Margaret Tempero, MD** University of California, San Francisco  
*Options for Neoadjuvant Chemotherapy*



**Joseph Herman, MD, MSc** Johns Hopkins Medicine  
*Preoperative Radiation Therapy Improves Pathologic Outcomes in Patients with Localized Pancreas Cancer*

**3:45-4:00 p.m.** **Break**  
*Location | Commodore Foyer*

**4:00-5:15 p.m.** **Parallel Session: Clinical Controversy: Management of Branch Duct IPMNs**  
*Location: Commodore CDE*  
Moderators | Christopher Forsmark & Joe Hines

**Santhi Swaroop Vege, MD** Mayo Clinic  
*AGA Guidelines on Asymptomatic Neoplastic Cysts: Systemic Review and Graded Recommendations*

**Marcia Irene Canto, MD, MHS** Johns Hopkins Medicine  
*Pancreatic Cysts – Less is more?*

**Carlos Fernandez-del Castillo, MD** MGH, Harvard Medical School  
*A Surgeon's Perspective*

**4:00-5:15 p.m.** **Parallel Session: Basic Science Controversy: Does Alcohol Cause Pancreatitis?**  
*Location | Constellation Ballroom*  
Moderators | Ilya Gukovsky & Craig Logsdon

**Dhiraj Yadav, MD** University of Pittsburg Medical Center  
*No (Clinical, Epidemiology approach)*

**Steve Pandol, MD** Cedars Sinai Medical Center  
*Yes (Basic Science approach)*

**5:15-6:30 p.m.** **Parallel Session: Clinical Science Abstracts**  
*Location | Commodore CDE*  
Moderators: Vikesh Singh & Huaizhi Wang

*Featured Speaker*

**Xingpeng Wang, MD, PhD** Shanghai Jiaotong University, Shanghai General Hospital  
*Necroptosis Contributes to Pancreatic Damage in Acute Pancreatitis*

*Abstracts:*

**The Impact of Early Initiation of High-Dose Pancreatic Enzyme Supplementation for Prevention of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy**  
Y. Iizawa, H. Kato, A. Tanemura, Y. Murata, A. Yoshinori, N. Kuriyama, M. Kishiwada, S. Mizuno, M. Usui, H. Sakurai, S. Isaji. *Division of Hepatobiliary Pancreatic and Transplant Surgery, Mie University, Tsu, Mie, Japan*

**Margin Clearance and Survival in Resected Pancreatic Adenocarcinoma in the Era of Adjuvant Chemotherapy**

O. Strobel<sup>1</sup>, T. Hank<sup>1</sup>, U. Hinz<sup>1</sup>, F. Bergmann<sup>2</sup>, D. Jäger<sup>3</sup>, T. Hackert<sup>1</sup>, M.W. Büchler<sup>1</sup>.  
<sup>1</sup>Department of General Surgery; <sup>2</sup>Institute of Pathology; <sup>3</sup>National Center for Tumour Diseases, Heidelberg University Hospital, Heidelberg, Germany

**Open and Minimally Invasive Pancreaticoduodenectomy for Pancreatic Cancer: Perioperative, Oncologic, and Survival Outcomes**

M.F. Eskander, S.W.L. de Geus, L.A. Bliss, S.C. Ng, A.J. Moser, and J.F. Tseng. *Surgical Outcomes Analysis & Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts*

**Multidisciplinary Approach to Disconnected Pancreatic Duct Syndrome (DPDS) in Acute Pancreatitis (AP) - A Single Tertiary Center Experience**

G. Trikudanathan, E. Aby, R. Attam, S.K. Amateau, S. Mallery, M.L. Freeman, M.A. Arain. *GI Division, Department of Medicine, University of Minnesota.*

**Total Pancreatectomy and Islet Autotransplantation: A Decade Long Nationwide Analysis**

R. Fazl Alizadeh, Zh. Moghadamyeghaneh, A.N. Demirjian, D.K. Imagawa, C.E. Foster, M.J. Stamos, H. Ichii. *Department of Surgery, University of California, Irvine, CA*

**5:15-6:30 p.m.**

**Parallel Session: Basic Science Abstracts**

*Location | Constellation Ballroom*

*Moderators | Sulagna Banerjee & Aida Habtezion*

**Effect of Genetic Chymotrypsin C (Ctrc) Deficiency on Cerulein Induced Pancreatitis in the Mouse**

A. Geisz, B.C. Németh, Z. Jancsó, and M. Sahin-Tóth. *Department of Molecular and Cell Biology, Boston University Medical Center, Boston, MA.*

**The Ampulla is a Reservoir for Lgr5-Derived Secretory Cells that Migrate to the Pancreas Following Injury**

A. Nakagawa<sup>1</sup>, M. Mino-Kenudson<sup>2</sup>, S.P. Thayer<sup>1</sup>, K.D. Lillemoe<sup>1</sup>, C. Fernández-del Castillo<sup>1</sup>, A.L. Warshaw<sup>1</sup>, A.S. Liss.<sup>1</sup> *Departments of <sup>1</sup>Surgery and <sup>2</sup>Pathology and the Andrew L. Warshaw, MD Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA*

**The Ets-transcription Factor Etv1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer**

K.K. Das, S. Heeg, M. Reichert, B. Bakir, S. Takano, P. Hicks, and A.K. Rustgi. *Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA.*

**Microenvironment Mediated Altered Metabolic Pathways Confer Increased Chemo-resistance in CD133+ Tumor Initiating Cells**

S. Banerjee, A. Nomura, P. Dauer, B. Garg, V. Dudeja, S. Ramakrishnan, and A. Saluja. *Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN.*

**Profibrogenic Effects of Endothelin Axis in Pancreatic Cancer**

S. Gupta<sup>1</sup>, S. Rachagani<sup>1</sup>, X. Wang<sup>2</sup>, C. Guda<sup>2</sup>, S.K. Batra<sup>1,3</sup>, and M. Jain<sup>1,3</sup>. *<sup>1</sup>Department of Biochemistry & Molecular Biology; <sup>2</sup>Department of Genetics, Cell Biology & Anatomy; <sup>3</sup>The Fred and Pamela Buffett Cancer Center; University of Nebraska Medical Center, Omaha, Nebraska*

*Best of EPC*

**Zhengyu Jiang** *Interleukin IL-1 $\beta$  Overexpression Promotes Pancreatic Ductal Adenocarcinoma Development in Oncogenic KRAS Bearing Mice*

7:00 p.m.

**Women in Pancreas Reception & Dinner***Reception Location | Bay Terrace**Dinner Location | Britannia/Cambria*

Co-chairs | Diane Simeone, Aida Habtezion &amp; Kim Kelly

Keynote Speaker:

**Helen Torley, MB, ChB, MRCP** CEO & President*Halozyme Therapeutics***SATURDAY, NOVEMBER 7**

7:00-8:30 a.m.

**Breakfast***Location | Pool/Marina Terrace*

8:30-10:20 a.m.

**Pancreatic Cancer Abstract Session***Location | Commodore CDE*

Moderators | Paul Grippo &amp; Nipun Merchant

**Pancreatic Adenocarcinoma of the Young: Impaired Survival Caused by Genetic Changes?**A. Gluth<sup>1</sup>, F. Bergmann<sup>2</sup>, U. Hinz<sup>1</sup>, N. Giese<sup>1</sup>, J. Werner<sup>1</sup>, M.W. Büchler<sup>1</sup>, and W. Hartwig<sup>1</sup><sup>1</sup>Department of Surgery, University of Heidelberg, Germany; <sup>2</sup>Institute of Pathology, University of Heidelberg, Germany**Cytidine Deaminase (CDA) Transcript Analysis Complements hENT1 Protein Staining in Predicting Gemcitabine Response in the ESPAC-3 Pancreatic Cancer Cohort**N. Elander<sup>1,2</sup>, K. Aughton<sup>1</sup>, P. Ghaneh<sup>1</sup>, J.P. Neoptolemos<sup>1</sup>, E. Costello<sup>1</sup>, D. Palmer<sup>1</sup>, T. Cox<sup>1</sup>, F. Campbell<sup>1</sup>, E. Garner<sup>1</sup>, A.S. Evans<sup>1</sup>, N. Rimmer<sup>1</sup>, C. Halloran<sup>1</sup>, M.W. Büchler<sup>3</sup>, and W. Greenhalf<sup>1</sup>.<sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Department of Molecular & Clinical Cancer Medicine, University of Liverpool, UK; <sup>2</sup>Department of Oncology & Department of Clinical & Experimental Medicine, Linköping University, Sweden; <sup>3</sup>Department of Surgery, University of Heidelberg, Heidelberg, Germany**Arterial Resection Without Reconstruction Following Preoperative Arterial Embolization for Locally Advanced Pancreatic Head Cancer with Arterial Invasion**H. Yoshitomi, N. Sakai, H. Shimizu, M. Ohtsuka, A. Kato, K. Furukawa, T. Takayashiki, S. Takano, S. Kuboki, D. Suzuki, S. Kagawa, and M. Miyazaki. *Department of General Surgery, Chiba University, Chiba, Japan***New Biomarkers for the Detection of Early-Stage and CA19-9-Low Pancreatic Cancer**H. Tang<sup>1</sup>, K. Partyka<sup>1</sup>, D. Kletter<sup>2^</sup>, P. Hsueh<sup>1</sup>, Y. Huang<sup>4</sup>, R.E. Brand<sup>3</sup>, and B.B. Haab<sup>1</sup>. *Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan;*<sup>2</sup>Palo Alto Research Center, Palo Alto, California; <sup>3</sup>Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; <sup>4</sup>Division of Gastroenterology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; <sup>^</sup>Present address: Protein Metrics, Inc., San Carlos, California**Predictors of Malignancy in Main Duct and Mixed Type Intraductal Papillary Mucinous Neoplasms (IPMN)**R.P. Sah, N. Ahmed, S. Mukewar, N. Takahashi, and S.T. Chari. *Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota*

**p53 Gain-of-Function Mutations Promote Adenocarcinoma from Pancreatic Ductal Cells**  
 M.A. Pruski<sup>1</sup>, A.M. Hendley<sup>1</sup>, N.C. Jones<sup>1</sup>, M. Younes<sup>2</sup>, A. Maitra<sup>3</sup>, C. Iacobuzio-Donahue<sup>4</sup>, S.D. Leach<sup>4</sup>, and J.M. Bailey<sup>1</sup>. <sup>1</sup>*Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas*; <sup>2</sup>*Division of Pathology and Laboratory Medicine, The University of Texas Medical School at Houston, Houston, Texas*; <sup>3</sup>*Departments of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas*; <sup>4</sup>*The David Rubenstein Pancreatic Cancer Research Center, Memorial Sloan Kettering Cancer Center, New York, New York*

**Induction of R201C Mutant Gαs Facilitates Murine Pancreatic Tumorigenesis in Cooperation with G12D Mutant Kras**  
 H. Yamaguchi<sup>1</sup>, G. Dangol<sup>1</sup>, B. Ghosh<sup>1</sup>, J. S. Gutkind<sup>2</sup>, A. Maitra<sup>1</sup>. <sup>1</sup>*Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas, MD Anderson Cancer Center, Houston, Texas*; <sup>2</sup>*Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institute of Health, Bethesda, Maryland*

**Targeting CDK4/6 Overcomes Therapeutic Resistance Associated with KRAS-MEK Pathway Inhibition in Pancreatic Cancer (PDAC)**  
 J. Castellanos<sup>1</sup>, N. Nagathihalli<sup>2</sup>, M. VanSaun<sup>2</sup>, and N. Merchant<sup>2</sup>. <sup>1</sup>*Vanderbilt University Medical Center, Nashville, Tennessee*; <sup>2</sup>*Department of Surgery, University of Miami, Miami, Florida*

**FGF21 Delays Pancreatic Cancer Formation and Prevents Liver Metastasis in Oncogenic Kras Expressing Mice Fed on High-Fat Diet**  
 W. Lu<sup>1</sup>, Y. Yang<sup>2</sup>, Y. Luo<sup>3,4</sup>, Y. Liu<sup>2</sup>, X. Wang<sup>3</sup>, M. Liu<sup>2</sup>, R.A. Wolff<sup>1</sup>, J.L. Abbruzzese<sup>5</sup>, and C.D. Logsdon<sup>1,2</sup>. <sup>1</sup>*Department of GI Medical Oncology*, <sup>2</sup>*Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, Texas*; <sup>3</sup>*Wenzhou Medical School, Wenzhou, China*; <sup>4</sup>*Texas A&M University Health Science Center IBT, Houston, Texas*; <sup>5</sup>*Duke Cancer Institute, Durham, North Carolina*

**10:20-10:35 a.m. Break**  
 Location | Commodore Foyer

**10:35-12:00 p.m. MINI SYMPOSIUM: Management of Recurrent Acute Pancreatitis**  
 Location | Commodore CDE  
 Moderators | Marty Freeman & Bechien Wu

**Mario Pelaez-Luna, MD** Universidad Nacional Autonoma de Mexico, School of Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran  
*Genetics of Recurrent Acute Pancreatitis*

**Markus M. Lerch, MD, FRCP** University Medicine Greifswald  
*Possible Causes & Mechanisms of Recurrent Acute Pancreatitis*

**D. Nageshwar Reddy, MD, DM, DSc, FAMS, FRCP, FASGE, FACG, MWGO** Asian Institute of Gastroenterology  
*EUS and MRCP in iRAP*

**Hong Sik Lee, MD, PhD** Korea University Anam Hospital  
*The Role of ERCP and EUS in Acute Recurrent Pancreatitis*

**Gregory A. Coté, MD, MS** Medical University of South Carolina  
*Controversies in Endoscopic Therapy*

**Martin Freeman, MD** University of Minnesota  
*TPIAT for Refractory Cases*

**12:00-1:30 p.m.**

**MINI SYMPOSIUM: Biology and Translational Implications of Metastatic Pancreatic Cancer**

*Location | Commodore CDE*

*Moderators | Charles Brunnicardi & Vikas Dudeja*

**Michael Hollingsworth, PhD** University of Nebraska  
*Rapid Autopsy Program*

**Andrew D. Rhim, MD** University of Michigan  
*Circulating Pancreas Cells as a Beacon for Subclinical Pancreatic Cancer*

**David T. Ting, MD** MGH Cancer Center, Harvard Medical School  
*Pancreatic Circulating Tumor Cells: Window into the Metastatic Cascade*

**Tooru Shimosegawa, MD, PhD** Tohoku University Graduate School of Medicine  
*Metastasis of Pancreatic Cancer; Basic Mechanisms and Therapeutic Approaches*

**Min Li, PhD** University of Oklahoma Health Sciences Center  
*Combinational Therapy for Pancreatic Cancer*

**Ravikanth Maddipati, MD** Perelman School of Medicine, University of Pennsylvania  
*Clonal Origins of Pancreatic Cancer Metastasis*

**1:30 p.m.**

**Lunch**

*Location | Pool/Marina Terrace*

**POSTERS OF DISTINCTION | THURSDAY, NOVEMBER 5**

**P1-1**

Small Molecule Inhibitors of Cyclophilin D to Protect Mitochondrial Function as a Possible Treatment for Acute Pancreatitis. M. Awais,<sup>1</sup> E. Shore,<sup>2</sup> R. Gibson,<sup>3</sup> M.A. Javed,<sup>1</sup> L. Wen,<sup>1</sup> D. Latawiec,<sup>1</sup> N. Kershaw,<sup>2</sup> S. Pandalaneni,<sup>3</sup> D.N. Criddle,<sup>1,4</sup> A. Tepikin,<sup>1,4</sup> N. Berry,<sup>2</sup> L-Y. Lian,<sup>3</sup> P. O'Neill,<sup>2,5</sup> R. Sutton<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, <sup>2</sup>Department of Chemistry, <sup>3</sup>NMR Centre for Structural Biology, <sup>4</sup>Department of Cellular and Molecular Physiology, <sup>5</sup>MRC Centre for Drug Safety Science, University of Liverpool, UK

**P1-2**

Agency for Healthcare Research and Quality (AHRQ) Patient Safety Indicators (PSIs) are Associated with Increased Healthcare Utilization, Costs, and Mortality Among Patients Hospitalized with Acute Pancreatitis. J. Behzadi, S. El-Dika, A. Hinton, S. Krishna, S. Moffatt-Bruce, D. Conwell, P. Hart. The Ohio State University Wexner Medical Center, Columbus, Ohio

**P1-3**

Histone Deacetylases Act as Molecular Switches to Promote Pancreatic Regeneration Following Pancreatic Injury. J.F. Eisses<sup>1</sup>, A. Criscimana<sup>2</sup>, Z.R. Dionise<sup>1</sup>, T.A. Javed<sup>1</sup>, J.A. Ozolek<sup>3</sup>, A. Davis<sup>3</sup>, A.I. Orabi<sup>1</sup>, S. Sarwar<sup>1</sup>, S. Jin<sup>1</sup>, S.P.S. Monga<sup>4</sup>, F. Esni<sup>2</sup>, S.Z. Husain<sup>1</sup>, Department of Pediatric <sup>1</sup>Gastroenterology, <sup>2</sup>Surgery, <sup>3</sup>Pathology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; <sup>4</sup>Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA

**P1-4**

Fully Covered Lumen Apposing Metal Stent for the Management of Walled off Necrosis (WON): A Single Center Experience. S. Elwir, S. Amateau, S. Mallery, M. Freeman, M. Arain. Department of Gastroenterology, University of Minnesota, Minneapolis, MN.

**P1-5**

Evaluation of Proposed Biomarkers in Early Stage Pancreatic Ductal Adenocarcinoma. M.A. Firpo<sup>1</sup>, A. Rosati<sup>2</sup>, G.D. Khanderao<sup>1</sup>, D.G. Adler<sup>1</sup>, C.S. Scaife<sup>1</sup>, K.M. Boucher<sup>1</sup>, M.C. Turco<sup>2</sup>, S.J. Mulvihill<sup>1</sup>. <sup>1</sup>Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; <sup>2</sup>University of Salerno, Fisciano, Italy

**P1-6**

Human Pro-Elastase 3B but not 3A Forms Binary Complexes with Pro-Carboxypeptidases A1 and A2. A. Szabó<sup>1</sup>, C. Pilsak<sup>1,2</sup>, W. Heiko<sup>2</sup>, M. Sahin-Tóth<sup>1</sup>. <sup>1</sup>Department of Molecular and Cell Biology, Boston University Medical Campus, Boston, MA; <sup>2</sup>Pediatric Nutritional Medicine and Else Kröner-Fresenius-Zentrum für Ernährungsmedizin, Technische Universität München, Munich, Germany

**P1-7**

Rates of Malignancy in Side Branch IPMN are Underestimated - A Systematic Review of Recent Publications. M. Heckler, C. W. Michalski, S. Schaeffle, S. Fritz, M. W. Büchler, T. Hackert. Department of Surgery, University of Heidelberg, Heidelberg, Germany

**P1-8**

p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. A.M. Hendley<sup>1,4</sup>, Y.J. Wang<sup>1</sup>, J. Alsina<sup>1</sup>, K.J. Lafaro<sup>2</sup>, A. Maitra<sup>3</sup>, C.A. Iacobuzio-Donahue<sup>2</sup>, S.D. Leach<sup>2</sup> and J.M. Bailey<sup>4</sup>. The McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; <sup>2</sup>The David Rubenstein Pancreatic Cancer Research Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>3</sup>Departments of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>4</sup>Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.

**P1-9**

Regulation of Human Anionic Trypsinogen (PRSS2) by Chymotrypsin C. Zs. Jancsó, A. Szabó, and M. Sahin-Tóth. Department of Molecular and Cell Biology, Boston University, Boston, Massachusetts

**P1-10**

Evaluation of the Prognostic Significance of 'High-risk Stigmata' in the International Consensus Guidelines 2012 for Intraductal Papillary Mucinous Neoplasm. K. Kimura, R. Amano, S. Yamazoe, G. Ohira, K. Miura, K. Nishio, K. Sakurai, T. Toyokawa, M. Ohira, and K. Hirakawa. Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan



**P1-11**

Impact of the Anatomical Location of Necrosis on Outcome in Patients of Acute Pancreatitis. N. Dhaka<sup>1</sup>, A. Munit<sup>4</sup>, J. Samanta<sup>1</sup>, R. Prasada<sup>1</sup>, P Gupta<sup>2</sup>, V. Gupta<sup>3</sup>, TD Yadav<sup>3</sup>, S. K. Sinha<sup>1</sup>, R. Kochhar<sup>1</sup>. <sup>1</sup>Department of Gastroenterology, <sup>2</sup>Department of Radiodiagnosis, <sup>3</sup>Department of Surgery, Postgraduate Institute Of Medical Education And Research, Chandigarh, India; <sup>4</sup>John H Stroger Hospital of Cook, Chicago, IL, United States.

**P1-12**

Smoking and Alcohol Induce Pancreatic Acinar Cell Pathology via Inhibition of IRE1/XBP1. A. Lugea, R.T. Waldron, H.Y. Su, A. Go, A. Gerloff, S.J. Pandol. Cedars-Sinai Medical Center and UCLA-VAGLAHS, Los Angeles, California

**P1-13**

Intralobular Fat and Fibrosis Predict Development of Fistulae after Pancreatic Resection. R. Pannala<sup>1</sup>, V. Kommineni<sup>1</sup>, K. Patel<sup>1</sup>, D. Lam-Himlin<sup>2</sup>, A. Mathur<sup>3</sup>, N. Katariya<sup>3</sup>, A. Moss<sup>3</sup>, M. Crowell<sup>1</sup>, V. Singh<sup>1</sup> Divisions of <sup>1</sup>Gastroenterology, <sup>2</sup>Pathology, <sup>3</sup>Surgery, Mayo Clinic, Arizona

**P1-14**

Postoperative Pancreatic Fistula: We Need to Redefine Grades B and C. T. Hackert, U. Hinz, T. Pausch, I. Fesenbeck, O. Strobel, L. Schneider, S. Fritz, and M.W. Büchler. Department of Surgery, University of Heidelberg, Heidelberg, Germany

**P1-15**

Integrin-linked Kinase Pathway Plays an Important role in Initiating Acute Pancreatitis. Z. Yuan, J. George, C. Ulrich, U. Barlass, S. Garg, A. Sareen, A. K. Dixit, R. K. Dawra, A. K. Saluja. Division of Basic and Translational Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA.

**P1-16**

Factors Associated with Early Disease-related Mortality Following Contemporary Resection for Pancreatic Adenocarcinoma. A. Zanconato, H. Zheng, C.R. Ferrone, D. Dias-Santos, K.D. Lillemoe, C. Fernandez-del Castillo. Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

**P1-17**

Predictors of Early Complications in Acute Necrotizing Pancreatitis Patients with Invasive Intervention. A. Wei, Q. Guo, M. Wang, and W. Hu. Department of Pancreatic Surgery, West China Hospital, Chengdu, China.

**P1-18**

Triptolide Results in Accumulation of HIF-1 $\alpha$  but Reduces its Activity in Pancreatic Cancer. O. McGinn, N. Arora, P. Dauer, V. Gupta, A.K. Saluja, S. Banerjee. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN

**POSTERS****P1-19**

Undifferentiated Pancreatic Carcinoma with Osteoclast-like Giant Cells Showing Tumor Thrombus into the Main Pancreatic Duct: Report of a Case with Osteoid Formation. M. Sunahara, S. Ueki, Y. Ono, Y. Sakamoto, T. Sawano, T. Sato, H. Kasajima, M. Kurushima, S. Suzuki, and J. Kimura. Department of Surgery, Institute of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan

**P1-20**

The Role of Multidrug Resistant Bacterial Infection in Patients with Acute Pancreatitis. Q. Guo, H. Lu, and W. Hu. Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

**P1-21**

A New Panel of Serum Markers for Diagnosis and Differentiation of Inflammatory Gastrointestinal Diseases and Tumors. A. Brock<sup>1</sup>, T. Erben<sup>1</sup>, T. Herzog<sup>2</sup>, W. Uhl<sup>2</sup>, R. Ossig<sup>1</sup>, Jürgen Schneckeburger<sup>1</sup>, <sup>1</sup>Biomedical Technology Center of the Medical Faculty of the University Muenster, Germany; <sup>2</sup>Clinic for General and Visceral Surgery, St. Josef Hospital, Bochum, Germany; <sup>3</sup>Department of Surgery, University Hospital Muenster, Germany

**P1-22**

The CILIP-Project – Ciliate Enzymes with Recombinant Lipase for Treating Pancreatic Exocrine Insufficiency. A. Brock<sup>1</sup>, I. Aldag,<sup>3</sup> S. Edskes,<sup>3</sup> T. Herzog,<sup>2</sup> W. Uhl<sup>2</sup>, M. Hartmann,<sup>3</sup> Jürgen Schnekenburger<sup>1</sup>. <sup>1</sup>Biomedical Technology Center of the Medical Faculty of the University Muenster, Germany; <sup>2</sup>Clinic for General and Visceral Surgery, St. Josef Hospital Bochum, Germany; <sup>3</sup>Cilian AG, Muenster, Germany

**P1-23**

Cumulative Acute Pancreatitis Outcome Score for Clinical Trials in Acute Pancreatitis. W. Huang<sup>1,2</sup>, P. Szatmary<sup>1</sup>, D. Iglesia-Garcia<sup>1</sup>, A. Sud<sup>1</sup>, B. Lane<sup>1</sup>, Q. Nunes<sup>1</sup>, R. Mukherjee<sup>1</sup>, W. Greenhalf<sup>1</sup>, M. Raraty<sup>1</sup>, R. Sutton<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK; <sup>2</sup>Sichuan Provincial Pancreatitis Centre, Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China

**P1-24**

Early Prediction of Major Clinical Outcomes of Patients with Acute Pancreatitis by Circulating Histones. T. Liu<sup>1,2</sup>, W. Huang<sup>2</sup>, P. Szatmary<sup>2</sup>, S.T. Abrams<sup>1</sup>, W. Greenhalf<sup>2</sup>, I. Welters<sup>3</sup>, R. Sutton<sup>2</sup>, G. Wang<sup>1</sup>, and C.H. Toh<sup>1,4</sup>. <sup>1</sup>Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; <sup>2</sup>NIHR Liverpool Pancreas Biomedical Research Unit, and <sup>3</sup>Intensive Treatment Unit, and <sup>4</sup>Roald Dahl Haemostasis & Thrombosis Centre, Royal Liverpool University Hospital, Liverpool UK; <sup>5</sup>Sichuan Provincial Pancreatitis Centre, West China Hospital, Sichuan University, Chengdu, China

**P1-25**

Therapeutic Potential of Pyruvate in Acute Pancreatitis: In Vitro Findings and A Systematic Review W. Huang<sup>1,2,3</sup>, J. J. Xiong<sup>4</sup>, C. R. Cheng<sup>5</sup>, P. Szatmary<sup>1</sup>, M. Chvanov<sup>3</sup>, D. N. Criddle<sup>1,3</sup>, Q. Xia<sup>3</sup>, and R. Sutton<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, Liverpool, UK; <sup>2</sup>Department of Cellular and Molecular Physiology, University of Liverpool, Liverpool, UK; <sup>3</sup>Sichuan Provincial Pancreatitis Center, Departments of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China; <sup>4</sup>Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, China; <sup>5</sup>School of Chemistry and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong, China

**P1-26**

Comparison of Surgical Outcome of Radical Antegrade Modular Pancreatosplicectomy with Standard Retrograde Pancreatosplicectomy and Evaluation of the Prognostic Factors in Left Side Pancreatic Cancer. T. Abe, K. Ohuchida, M. Nakamura. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

**P1-27**

A Patient Specific PA Bio-Bank to Improve Personalized Treatment and Understand Chemotherapy Resistance Mechanism. E.M. Parasido<sup>1</sup>, P. Sripathan<sup>2</sup>, J. Brody<sup>3</sup>, R. Schlegel<sup>2</sup>, J. Winter<sup>3</sup>, C. Albanese<sup>1,2</sup>. <sup>1</sup>Department of Oncology, Georgetown University, Washington DC; <sup>2</sup>Department of Pathology, Georgetown University, Washington DC; <sup>3</sup>Department of Surgery, Thomas Jefferson University, Philadelphia, PA

**P1-28**

Selective Arterial Secretagogue Injection Test (SASI Test) in 15 Insulinoma Patients. K. Ueda,<sup>1</sup> L. Lee,<sup>1</sup> T. Fujiyama,<sup>1</sup> Y. Tachibana,<sup>1</sup> M. Masami,<sup>1</sup> K. Yasunaga,<sup>1</sup> K. Kawabe,<sup>1</sup> H. Honda,<sup>2</sup> M. Nakamura,<sup>3</sup> Y. Oda,<sup>4</sup> T. Ito,<sup>1</sup>. <sup>1</sup>Department of Medicine and Bioregulatory Science; <sup>2</sup>Department of Clinical Radiology; <sup>3</sup>Department of Surgery and Oncology; <sup>4</sup>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

**P1-29**

Pancreatic Human Fibroblast Expression Profiling Reveals Novel microRNAs and mRNAs in the Diseased Pancreas. L. Barrera<sup>1</sup>, B. Lane<sup>1</sup>, S. Brumskill<sup>2</sup>, F. Oldfield<sup>1</sup>, Q. Nunes<sup>1</sup>, F. Campbell<sup>3</sup>, T. Andrews<sup>3</sup>, P. Phillips<sup>4</sup>, C. Halloran<sup>1</sup>, W. Greenhalf<sup>1</sup>, J. Neoptolemos<sup>1</sup>, and E. Costello<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, UK; <sup>2</sup>Redx Oncology, UK; <sup>3</sup>Department of Pathology, Royal Liverpool University Hospital, UK; <sup>4</sup>The University of New South Wales, Sydney, Australia.

**P1-30**

Imaging Modalities in Chronic Pancreatitis: A Systematic Review and Meta-analysis. Y. Issa<sup>1</sup>, M.A. Kempeneers<sup>1</sup>, H.C. van Santvoort<sup>1</sup>, S. Bipat<sup>2</sup>, and M.A. Boermeester<sup>1</sup>. <sup>1</sup>Department of Surgery, Academic Medical Centre Amsterdam, The Netherlands; <sup>2</sup>Department of Radiology, Academic Medical Centre Amsterdam, The Netherlands

**P1-31**

Computer Tomography Versus Magnetic Resonance Cholangiopancreatography in Patients with Chronic Pancreatitis. Y. Issa<sup>1</sup>, U. Ahmed Ali<sup>1,2</sup>, T. Bollen<sup>3</sup>, M. van der Hoek<sup>1</sup>, Y. Keulemans<sup>4</sup>, H.C. van Santvoort<sup>1</sup>, C.Y. Nio<sup>1</sup>, and M.A. Boermeester<sup>1</sup>. <sup>1</sup>Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands; <sup>2</sup>Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands; <sup>3</sup>Department of Radiology, St Antonius Hospital, Nieuwegein, The Netherlands; <sup>4</sup>Department of Gastroenterology, University Hospital Maastricht, Maastricht, The Netherlands

**P1-32**

Hypocalcemic Tetany: A Simple Bedside Marker of Worst Outcome in Acute Pancreatitis – a prospective cohort study. P. Chhabra, S.S. Rana, V. Sharma, R. Sharma, D.K. Bhasin. Dept. of Gastroenterology, PGIMER, Chandigarh, India.

**P1-33**

Deregulation B-Catenin Gene Expression in Pancreatic Cancer. A. Botezatu<sup>1</sup>, I.V. Iancu<sup>1</sup>, A. Plesa<sup>1</sup>, C.C. Diaconu<sup>1</sup>, G. Anton<sup>1</sup>, R. Florea<sup>2</sup>, V. Ilie<sup>2</sup>, A. Sorop<sup>2</sup>, N. Bacalbasa<sup>2</sup>, V. Tica<sup>2</sup>, D.G. Duda<sup>3</sup>, S.O. Dima<sup>2</sup>, I. Popescu<sup>2</sup>. <sup>1</sup>“St. S. Nicolau” Institute of Virology, Romania; <sup>2</sup>Fundeni Clinical Institute, Gastroenterology and Hepatic Transplantation Center, Romania; <sup>3</sup>Edwin L. Steele Laboratory for Tumor Biology, Charlestown, MA, U.S.A.

**P1-34**

Triptolide Induces Pancreatic Cancer Cell Death by Reactivating p53 via Aurora Kinase A. N. Sharma, M.K. Singh, V. Dudeja, S. Banerjee, and A. Saluja. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, Minnesota.

**P1-35**

DPYSL3 Regulates TFF2/SMAD4 Tumor Suppressor Signaling in Pancreatic Cancer. S. Chowdhury<sup>1</sup>, M. Ali<sup>1</sup>, J. Yamaguchi<sup>2</sup>, A.S. Liss<sup>2</sup>, A. Sontheimer<sup>2</sup>, and S.P. Thayer<sup>1</sup>. <sup>1</sup>Department of Surgery, Fred and Pamela Buffett Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska; <sup>2</sup>Andrew L. Warshaw Institute for Pancreatic Cancer Research, MGH, Boston, Massachusetts

**P1-36**

Amelioration of Experimental Acute Pancreatitis with FK-506 and Tamoxifen. D. L. Clemens<sup>1,2</sup>, K. J. Schneider<sup>1</sup>, C. K. Arkfeld<sup>1</sup>, and S. Singh<sup>1</sup>. <sup>1</sup>Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE; <sup>2</sup>VAMC Omaha, NE

**P1-37**

Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. K. Date<sup>1</sup>, T. Ohtsuka<sup>1</sup>, T. Fujimoto<sup>1</sup>, Y. Gotoh<sup>1</sup>, Y. Nakashima<sup>1</sup>, H. Kimura<sup>1</sup>, T. Matsunaga<sup>1</sup>, N. Mochidome<sup>2</sup>, T. Miyazaki<sup>2</sup>, Y. Oda<sup>2</sup>, M. Tanaka<sup>1</sup>, and M. Nakamura<sup>1</sup>. <sup>1</sup>Departments of <sup>1</sup>Surgery and Oncology; <sup>2</sup>Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

**P1-38**

Role of miR-21-3p in Promoting Inflammation During Acute Pancreatitis. A.K. Dixit, J. George, U. Barlass, Z. Yuan, A. Sareen, V. Dudeja, R. Dawra, and A.K. Saluja. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis Minnesota

**P1-39**

New Therapeutic Approach in the Successful Surgical Therapy of Pancreatic Cancer. G. Farkas Jr., L. Leindler, and G. Lazar. Department of Surgery, University of Szeged, Szeged, Hungary

**P1-40**

Increased Nuclear Transport of  $\beta$  Catenin and LRP 6 Phosphorylation as Novel Prognostic Biomarkers for the Progression of Pancreatic Tumor. B. Garg, S. Modi, K. Majumder, S. Banerjee, V. Dudeja, and A. Saluja. Department of Surgery, University of Minnesota, Minneapolis, MN

**P1-41**

Cysts In The (de)Nude: What is the Significance of Pancreatic Cyst Epithelial Denudation? V. Gómez, S. Majumder, T. Smyrk, W. Harmsen, F. Enders, F. Gleeson, B. Abu Dayyeh, P. Iyer, R. Pearson, B. Petersen, E. Rajan, S. Vege, K. Wang, S. Chari, M. Topazian, and M. Levy. Mayo Clinic, Rochester, MN

**P1-42**

Pancreatic Gastrokine is a Secreted Biomarker with Putative Tumor Suppressor Role. G. Seleznik<sup>1</sup>, T. Reding<sup>1</sup>, A. Dittmann<sup>1</sup>, A. Perren<sup>2</sup>, E. Angst<sup>2</sup>, M. Heikenwälder<sup>3</sup>, and R. Graf<sup>1</sup>. <sup>1</sup>Visceral & Transplantation Surgery, University Hospital Zurich, Switzerland; <sup>2</sup>Institute of Pathology, University of Bern, Switzerland; <sup>3</sup>Institute for Virology, Helmholtz-Centre Munich, Germany

**P1-43**

Undifferentiated Carcinoma with Osteoclast-Like Giant Cells of the Pancreas Misdiagnosed as a Solid Pseudopapillary Tumor. H. Ham, I. Lee, C. Lim, J. Kim, M. Baeg, Y. Cho, J. Park, B. Lee, Y. Cho, M. Choi. Division of Gastroenterology, The Catholic University of Korea College of Medicine, Seoul, Korea

**P1-44**

A common deletion variant of chymotrypsin B2 (CTRB2) causes misfolding. E. Hegyi, M. Sahin-Tóth, Department of Molecular and Cell Biology, Boston University Medical Center, Boston MA

**P1-45**

Reprogramming Pancreatic Cancer to Induce Quiescence and Acinar Cell Fate. SW Kim\*<sup>1,2</sup>, J van Niekerk\*<sup>1,2</sup>, TAlmaleh<sup>1,2</sup>, R Lahmy<sup>1,2</sup>, and P Itkin-Ansari<sup>1,2</sup>. <sup>1</sup>Department of Pediatrics, University of California, San Diego, La Jolla, CA, <sup>2</sup>Development and Aging Program, Sanford-Burnham Medical Research Institute, La Jolla, CA.

**P1-46**

Fellows Symposium: Promoting Future Pancreatologists from Top Trainees. K Jeffers and M Lewis. Mayo Clinic Jacksonville, Jacksonville, FL.

**P1-47**

p120 Catenin is Required for Regeneration of the Exocrine Pancreas in Mice. N.C. Jones, A.M. Hendley, M.A. Pruski, J.M. Bailey. Division of Gastroenterology, Hematology, and Nutrition, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX.

**P1-48**

A Surgical Approach to Extrahepatic Bile Duct Carcinoma with Intestinal Non-rotation Presenting with Pre-duodenal Portal Vein. H. Karasaki<sup>1,2</sup>, Y. Mizukami<sup>2</sup>, T. Kono<sup>1,2</sup>, T. Maejima<sup>1</sup>, S. Fukahori<sup>1</sup>, N. Mukai<sup>1</sup>, S. Kasai<sup>1</sup>, Y. Matsubara<sup>3</sup>, H. Amizuka<sup>3</sup>, and K. Nagashima<sup>4</sup>. <sup>1</sup>Department of Surgery, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan; <sup>2</sup>Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan; <sup>3</sup>Department of Gastroenterology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan; <sup>4</sup>Department of Pathology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan

**P1-49**

Loganin Protects Against Pancreatitis by Inhibiting NF-Kb Activation. M.J. Kim<sup>1,2</sup>, I.J. Jo<sup>1,3</sup>, G.S. Bae<sup>1,3</sup>, S.B. Choi<sup>1,2</sup>, D.G. Kim<sup>1,2</sup>, J.Y. Shin<sup>3</sup>, S.K. Lee<sup>1,2</sup>, M.J. Kim<sup>1,2</sup>, J. Jun-Hyeok<sup>1,2</sup>, T.H. Kim<sup>4</sup>, S.H. Hong<sup>5</sup>, B.M. Choi<sup>6</sup>, and S.J. Park<sup>1,2,3</sup>. <sup>1</sup>Department of Herbology, <sup>2</sup>BK 21 plus team, <sup>3</sup>Habang Body-fluid Research Center, school of Korean medicine, <sup>4</sup>Department of Internal Medicine, College of Medicine, <sup>5</sup>Department of Oriental Pharmacy, College of Pharmacy, Wonkwang, Oriental Medicines Research Institute, <sup>6</sup>Department of Biochemistry, School of Medicine, Wonkwang University, Iksan, South Korea.

**P1-50**

Adequate and Timely Reduction of Pancreatic Ductal Hypertension as the Main Criterion for Successful Surgical Treatment of Chronic Pancreatitis. V. Klymenko, A. Klymenko, A. Steshenko. Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine.

**P1-51**

Pancreatic Stellate Cells Lead and Promote the Local Invasion of Cancer Cells, by Physically Remodeling the Extracellular Matrix with a Collagen Fiber Alignment in Pancreatic Cancer. K. Koikawa<sup>1</sup>, K. Ohuchida<sup>1</sup>, M. Sada<sup>1</sup>, T. Abe<sup>1</sup>, S. Endo<sup>1</sup>, K. Horioka<sup>1</sup>, T. Moriyama<sup>1</sup>, Y. Miyasaka<sup>1</sup>, T. Ohtuka<sup>1</sup>, R. Ohuchida<sup>2</sup>, T. Ueki<sup>1</sup>, E. Nagai<sup>1</sup>, K. Mizumoto<sup>1</sup>, and M. Nakamura<sup>1</sup>. <sup>1</sup>Department of Surgery and Oncology, Graduate School of Medical Sciences Kyushu University, Fukuoka, Japan; <sup>2</sup>Section of Fixed Prosthodontics, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.

**P1-52**

MUC5AC mediated Oncogenic Signaling in Pancreatic Cancer. S.R. Krishn<sup>1</sup>, S. Kaur<sup>1</sup>, S. Ayala<sup>1</sup>, S.L. Johansson<sup>3</sup>, and S.K. Batra<sup>1,2</sup>. <sup>1</sup>Department of Biochemistry & Molecular Biology; <sup>2</sup>Eppley Institute for Research in Cancer and Allied Diseases; <sup>3</sup>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.

**P1-53**

Increased Neutrophil to Lymphocyte Ratio is a Poor Prognostic Factor in Patients Undergoing Gemcitabine and Erlotinib Combination Chemotherapy for Pancreatic Adenocarcinoma. J.M. Lee, H.S. Lee, J.J. Hyun, C.D. Kim. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea

**P1-54**

Hypermethylation of the Mir-506 Gene Facilitates Pancreatic Cancer Progression and Chemoresistance via SPHK1/Akt/NF-Kb Signaling. J. Li, H. Wang. Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing PR China

**P1-55**

Epigenetic Therapeutics of Pancreatic Cancer: Inhibition of PDAC Growth by Targeting the HP1-G9a/GLP Histone Methyltransferase Pathway. A. Salmonson, M. Missfeldt, A. Mathison, and G. Lombert. Epigenetics and Chromatin Dynamics Laboratory, GI Research Unit, Department of Medicine, Mayo Clinic, Rochester, MN

**P1-56**

Survivin Is a Potential New Therapeutic Target in the Treatment of Pancreatic Cancer. Q.P. Ly<sup>1,2</sup>, G. Howell<sup>2</sup>, M. Mendick<sup>2</sup>, C. Murari<sup>2</sup>, S. Laschanzky<sup>2</sup> and M. Brattain<sup>2</sup>. <sup>1</sup>Department of Surgery, University of Nebraska Medical Center and <sup>2</sup>Fred & Pamela Buffett Cancer Center

**P1-57**

Actinomycin D Sensitises Chemotherapy Resistant Suit-2 Pancreatic Cancer Cell Lines To Gemcitabine. K. Mann, B. Rogoyski, P. Ghaneh, C. Rubbi, and W. Greenhalf. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Merseyside

**P1-58**

Activation of Pancreatic Stellate Cell Involves EMT-like Process: In Vitro Experiments. Z. Lu, L. Tian, B. Cai, L. Zhao, D. Qian, Q. Xu, P. Wu, Y. Zhu, J. Zhang, Q. Du, K. Jiang, Y. Miao. Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

**P1-59**

Multicenter Comparative Study of Laparoscopic and Open Distal Pancreatectomy Using Propensity Score-Matching. Y. Miyasaka<sup>1,9</sup>, M. Nakamura<sup>1,9</sup>, M. Tanaka<sup>1,9</sup>, T. Morikawa<sup>2,9</sup>, M. Unno<sup>2,9</sup>, G. Wakabayashi<sup>3,9</sup>, T. Beppu<sup>4,9</sup>, T. Takahara<sup>5,9</sup>, H. Yamaue<sup>6,9</sup>, M. Miyazaki<sup>7,9</sup>, and T. Takada<sup>8,9</sup>. <sup>1</sup>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; <sup>2</sup>Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan; <sup>3</sup>Department of Surgery, Ageo Central General Hospital, Ageo, Japan; <sup>4</sup>Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan; <sup>5</sup>Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan; <sup>6</sup>Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan; <sup>7</sup>Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan; <sup>8</sup>Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan; <sup>9</sup>Japanese Society of Hepato-Biliary-Pancreatic Surgery and Japanese Society for Endoscopic Pancreatic Surgery

**P1-60**

Minnelide Synergizes with Standard Chemotherapy in Pancreatic Cancer. S. Modi, B. Giri, K. Majumder, V. Dudeja, S. Banerjee, A.K. Saluja. Translational Research, Department of Surgery, University of Minnesota, Minneapolis, Minnesota

**P1-61**

Pancreatic Cysts: Diagnostic Accuracy and Risk of Inappropriate Resections. S. Mukewar, N. de Pretis, A. Aryal-Khanal, N. Takahashi, and S. Chari. Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota

**P1-62**

Histological Effect of Chemoradiotherapy Contributes to Securing a Surgical Margin and Improving Prognosis in Patients with Locally Advanced Pancreatic Cancer. Y. Murata, M. Kishiwada, N. Kuriyama, Y. Azumi, S. Mizuno, M. Usui, H. Sakurai, S. Isaji. Division of Hepato-biliary Pancreatic and Transplant Surgery, Mie University, Tsu, Mie, Japan

**P1-63**

Robotic Cystogastrotomy with Pancreatic Necrosectomy. I. Nassour<sup>1</sup>, and S. Kukreja<sup>2</sup>. <sup>1</sup>Department of Surgery, University Of Texas Southwestern, Texas; <sup>2</sup>Department of Surgery, VA North Texas Health Care System, Texas.

**P1-64**

Preoperative CT Assessments of the Pancreas Predict Fatty Liver after Pancreaticoduodenectomy. K. Ohgi, Y. Okamura, Y. Yamamoto, T. Sugiura, T. Ito, R. Ashida, and K. Uesaka. Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan

**P1-65**

Mean Brightness of Ultrasound Image Strongly Correlates with Degree of Pancreatic Steatosis. V. Komminenil, K. Patel<sup>1</sup>, M. Belohlavek<sup>2</sup>, D. Lam-Himlin<sup>3</sup>, N. Gades<sup>4</sup>, D. Faigel<sup>1</sup>, M. Alloush<sup>5</sup>, M. Sturek<sup>5</sup>, V. Singh<sup>1</sup>, R. Pannala<sup>1</sup> Divisions of <sup>1</sup>Gastroenterology; <sup>2</sup>Cardiology; <sup>3</sup>Pathology; <sup>4</sup>Comparative Medicine, Mayo Clinic Arizona; <sup>5</sup>Cellular and Integrative Physiology, Indiana University

**P1-66**

Serum Tumor Markers are not Useful to Select Patients with Mucinous Cystic Lesion Having Malignant Transformation. R. Pezzilli<sup>1</sup>, L. Calculli<sup>2</sup>, A. Barassi<sup>3</sup>, and G. Melzi d'Eril<sup>3</sup>. <sup>1</sup>Pancreas Unit, Department of Digestive System; <sup>2</sup>Department of Radiology, Sant'Orsola-Malpighi Hospital, Bologna, Italy; <sup>3</sup>Department of Health Sciences, San Paolo Hospital, University of Milan, Italy.

**P1-67**

Menstrual and Reproductive Factors and Risk of Pancreatic Cancer in Women. A. Pourshams, M. Bagheri, R. Shakeri, and R. Malekzadeh. Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran

**P1-68**

Sirtuin1 Promotes the Proliferation of Pancreatic Cancer Lesions. A.V. Pinho<sup>1,2</sup>, A. Mawson<sup>1</sup>, M. Giry-Laterriere<sup>1</sup>, A. Gill<sup>3</sup>, A.V. Biankin<sup>4</sup>, J. Wu<sup>1,2</sup>, and I. Rooman<sup>1,2</sup>. <sup>1</sup>Cancer Division, Garvan Institute of Medical Research, Sydney NSW, Australia; <sup>2</sup>St. Vincent's Clinical School, UNSW Australia, Sydney NSW, Australia; <sup>3</sup>University of Sydney, Sydney NSW, Australia; <sup>4</sup>Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland

**P1-69**

SBP-101 Induces Apoptosis in Mouse Pancreatic Acinar Cells and Inhibits Polyamines Induced Proliferation. A. Sareen<sup>1</sup>, A.Saluja<sup>1</sup>, A. Shah<sup>2</sup>, R. Dawra<sup>1</sup>. <sup>1</sup>Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis MN; <sup>2</sup>Sun BioPharma, Inc., Williston, FL.

**P1-70**

Enhanced Recovery After Surgery (ERAS) Versus Conventional Recovery Strategies for Pancreatic Surgery. N. Lv, Z. Lu, Q. Li, K. C. Dai, Jiang, J. Wu, W. Gao, F. Guo, J. Wei, J. Chen, and Y. Miao. The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

**P1-71**

Circulating Histones Target Acinar Cells and Exacerbate Injury in Experimental Acute Pancreatitis. P. Szatmary<sup>1,3</sup>, T. Liu<sup>1,2</sup>, S. Abrams<sup>2</sup>, L. Wen<sup>1</sup>, W. Huang<sup>1</sup>, G. Wang<sup>2</sup>, C.H. Toh<sup>2</sup>, D. Criddle<sup>3</sup>, A. Tepikin<sup>3</sup>, and R. Sutton<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit and <sup>2</sup>Department of Blood Sciences, Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, UK; <sup>3</sup>Dept. of Cellular and Molecular Physiology, University of Liverpool, Liverpool, UK

**P1-72**

Pattern of Infective Complications in Human Acute Pancreatitis. P. Szatmary<sup>1</sup>, W. Huang<sup>1</sup>, D. de la Iglesia-Garcia<sup>2</sup>, S. Parente<sup>1</sup>, G. Primo<sup>1</sup>, W. Greenhalf<sup>1</sup>, and R. Sutton<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, Liverpool UK; <sup>2</sup>Department. of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Spain.

**P1-73**

Prostaglandin E<sub>2</sub> Reduces ERK Activation and Growth in Cultured Pancreatic Cancer Cells. A.I. Schmidt, J. Sinnett-Smith, S.H. Young, O.J. Hines, G. Eibl, and H. Chang. Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

**P1-74**

Pancreatic Cancer Patients Express Elevated FVIII Levels and Metastasis-associated Fibrin Turnover Prior to Their Diagnosis. H. Seppänen<sup>2</sup>, N. Varkila<sup>1</sup>, C. Haglund<sup>2</sup>, and R. Lassila.<sup>3</sup> <sup>2</sup>Department of Surgery; <sup>3</sup>Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, <sup>1</sup>University of Helsinki, Finland

**P1-75**

Naïve T Helper Cell Subset Predominates in Severe Necrotizing Pancreatitis in Mice. A.I. Schmidt\*, R. Lauch, G. Wolff-Vorbeck, U.T. Hopt, U.A. Wittel. Department of General and Visceral Surgery, Universitätsklinik Freiburg, Freiburg, Germany



**P1-76**

Up-regulation of CXCR2 and its Ligands in Severe Acute Pancreatitis. A. Purohit, S. Kumar, S. Kaur, S. Rachagani, M. Varney, S.K. Batra, R.K. Singh. Buffett Cancer Center, Department of Pathology and Microbiology, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE

**P1-77**

Increased Visceral Unsaturated Triglycerides(UTG) Result in Severe Acute Pancreatitis(SAP) in Diet Induced Obesity(DIO). K. Patel, A. Singh, P. Noel, R. Trivedi, C. de Oliveria, and V.P. Singh. Department of Medicine, Mayo Clinic, Scottsdale, Arizona

**P1-78**

Is "Chronic" Long-term Intervention with Micronutrient Anti-Oxidant Therapy Required to Modulate the Disease Course of Chronic Pancreatitis? S.N. Rupasinghe, A.K. Siriwardena. Hepatobiliary Surgical Unit, Manchester Royal Infirmary, UK.

**P1-79**

Branched Duct Intraductal Papillary Mucinous Neoplasm (BD-IPMN) of Pancreas in Solid Organ Transplant Patients - A Single Tertiary Center Experience. G. Trikudanathan, U. Barlass, M.A. Arain, S.K. Amateau, R. Attam, M.L. Freeman, S. Mallery. GI Division, Department of Medicine, University of Minnesota.

**P1-80**

The Endoscopic Diagnosis and Treatment of Mass-type Autoimmune Pancreatitis. B. Xiao, K. Jiang, J. Wu, W. Gao, J. Chen, J. Wei, F. Guo, Z. Lu, Y. Miao. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China

**P1-81**

Insights into the Biochemical Behavior of Full length Human HP1 $\gamma$ , an Epigenetic Regulator Downstream of KRAS. G. Velez, M. Lin, W. A. Faubion, T. Christensen, G. Lomberk, and R. Urrutia. Epigenetics and Chromatin Dynamics Laboratory, Translational Epigenomics Program (CIM), GIH Division, Department of Medicine, Biophysics, Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN

**P1-82**

Outcomes in Acute Pancreatitis: A Systematic Review of the Medical Literature. D. Verma, B. Wu. Department of Gastroenterology, Kaiser Permanente, Los Angeles, CA

**P1-83**

Increased Neuroendocrine Heterogeneity in Pancreatic Ductal Adenocarcinoma is Associated with more Aggressive Biology. P.J. Worth, A.S. Farrell, J.M. Link, Z.P. Jenny, E.W. Gilbert, B.C. Sheppard, R.C. Sears. The Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon

**P1-84**

Use of Lifetime Drinking History (LDH) to Stratify Alcohol Exposure in Chronic Pancreatitis (CP) Patients. D. Yadav, B. Sandhu, S. Al-Kaade, Y. Tian, N. Guda, A. Gelrud, R. Brand, A. Slivka, C. Wilcox, and D. Whitcomb for the NAPS2-consortium, USA

**P1-85**

Extracellular Matrix Modulation Therapy of Pancreatic Cancer by 4-methylumbelliferone and 5-fluorouracil. E. Yoshida, D. Kudo, H. Nagase, A. Suto, T. Wakiya, K. Ishido, Y. Toyoki, K. Hakamada. Gastroenterological Surgery, Hirosaki University, Graduate School of Medicine, Hirosaki, Aomori, Japan

**P1-86**

Minnelide Treats Pancreatic Ductal Adenocarcinoma via Disrupting Tumor-Stroma Interactions. X. Zhao,<sup>1</sup> S. Modi,<sup>1</sup> O. McGinn,<sup>1</sup> P. Dauer,<sup>1</sup> V. Dudeja,<sup>1</sup> S. Banerjee,<sup>1</sup> A Saluja<sup>1</sup>. <sup>1</sup>Department of Surgery, University of Minnesota, Minneapolis, MN

**P1-87**

DPYSL3 Variant 1 Regulates Cell Survival in Pancreatic Cancer. S. Chowdhury<sup>1</sup>, M. Ali<sup>1</sup>, D. Maroni<sup>1</sup>, N. Woods<sup>2</sup> and S.P. Thayer<sup>1</sup>. <sup>1</sup>Department of Surgery, Fred and Pamela Buffett Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska; <sup>2</sup>Eppley Institute, University of Nebraska Medical Center, Omaha, Nebraska

**P1-88**

Verification of the Utility of International Consensus Guidelines 2012 for the Management of IPMN and MCN of the Pancreas. J. Akao,<sup>1</sup> K. Shimizu,<sup>1</sup> T. Ajihara,<sup>1</sup> K. Nagao,<sup>1</sup> J. Tahara,<sup>1</sup> Y. Takayama,<sup>1</sup> K. Shiratori,<sup>1</sup> M. Yamamoto,<sup>2</sup> T. Furukawa.<sup>3</sup> <sup>1</sup>Department of Gastroenterology; <sup>2</sup>Gastroenterological Surgery; <sup>3</sup>Institute for Integrated Medical Science, Tokyo Women's Medical University, Tokyo, Japan

**P1-89**

Evaluation of Human Pancreatic Cancer Cell Viability Following Administration of SBP-101 in the Presence and Absence of Gemcitabine and Nab-Paclitaxel. C. Baker<sup>1</sup>, S. Arora<sup>2</sup>, S. Gagnon<sup>2</sup>, M. Cullen<sup>2</sup> and A. Shah<sup>2</sup>. <sup>1</sup>Biocurity, Inc., New Smyrna Beach, Florida; <sup>2</sup>Sun BioPharma, Inc., Gainesville, Florida

**P1-90**

The Effect of Cystathionine-Gamma-Lyase Gene Deletion on the Renin-Angiotensin System in Caerulein-Induced Acute Pancreatitis in Mice. R.R. Gaddam<sup>1</sup>, A. Badieli, S.T. Chambers<sup>1</sup>, I. Ishii<sup>2</sup>, M. Bhatia.<sup>1</sup> <sup>1</sup>Department of Pathology, University of Otago, Christchurch, New Zealand; <sup>2</sup>Department of Biochemistry, Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan

**P1-91**

Inhibition of Hedgehog Pathway in 2D and 3D Co-cultures of CAFs and PDAC Cell Lines. S. Brumskill<sup>1,2,4</sup>, L. Barrera<sup>1</sup>, F. Campbell<sup>3</sup>, C. Halloran<sup>1,2</sup>, W. Greenhalf<sup>1,2</sup>, Christina Ghirelli<sup>4</sup>, R.Sutton<sup>2</sup>, M.-A. Campbell<sup>4</sup>, E. Costello<sup>1,2</sup>. <sup>1</sup>Liverpool NWCR Centre, Molecular and Clinical Cancer Medicine; <sup>2</sup>NIHR Pancreas Biomedical Research Unit; <sup>3</sup>Department of Pathology, Royal Liverpool University Hospital, UK ; <sup>4</sup>Redx Oncology, UK.

**P1-92**

Mechanistic Studies in the Inflammatory Response of Pancreatitis and Pancreatic Cancer - Role of Myeloid Derived Suppressor Cells. N. Cieza-Rubio<sup>1</sup>, T. Jie<sup>1</sup>, and R.L. Heimark<sup>1,2</sup>. <sup>1</sup>Department of Surgery, University of Arizona, Tucson, Arizona; <sup>2</sup>University of Arizona Cancer Center, Tucson, Arizona

**P1-93**

Oncolytic Adenovirus for Radioiodine Therapy of Pancreatic Cancer. B. Eidenschink<sup>1</sup>, J. Sell<sup>1</sup>, C. LaRocca<sup>1</sup>, K. Jacobsen<sup>1</sup>, M. Fernandez-Zapico<sup>2</sup>, J. C. Morris<sup>2</sup>, M. Yamamoto<sup>1</sup>, and J. Davydova<sup>1</sup>. <sup>1</sup>Department of Surgery, University of Minnesota, Minneapolis, Minnesota; <sup>2</sup> Mayo Clinic, Rochester, Minnesota.

**P1-94**

NFATc1-Dependent Downregulation of GLI1 Underlies Polyunsaturated Fatty Acids Cytotoxic Properties in Pancreatic Cancer. A. Combal<sup>1,2</sup>, M.E. Pasqualini<sup>2</sup>, E. Iguchi<sup>1</sup>, M.V. Messler<sup>2</sup>, R. Silva<sup>2</sup>, M.G. Fernandez-Barrena<sup>1</sup>, E.J. Tolosa<sup>1</sup>, E. Enriquez-Hesles<sup>1</sup>, A.L. Vrabel<sup>1</sup>, L.L. Almada<sup>1</sup>, D.L. Marks<sup>1</sup>, B. Botta<sup>3</sup>, L Di Marcotullio<sup>3</sup>, V. Ellenrieder<sup>4</sup>, A.R. Eynard<sup>2</sup>, M.E. Fernandez-Zapico.<sup>1</sup> <sup>1</sup>Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, USA; <sup>2</sup>INICSA, CONICET and Universidad Nacional de Córdoba, 5000 Córdoba, Argentina; <sup>3</sup>Department of Molecular Medicine, Sapienza University, 00161 Rome, Italy; <sup>4</sup>Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Goettingen, Germany

**P1-95**

Wnt-mediated Autophagy is Inhibited by Pigment Epithelium-Derived Factor. J. Gong<sup>1,2</sup>, G.S. Belinsky<sup>1,2</sup>, U. Sagheer<sup>1,2</sup>, A. Rhim<sup>3</sup>, and C. Chung<sup>1,2</sup>. <sup>1</sup>Sections of Digestive Diseases; Endocrinology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut; <sup>2</sup>Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut; <sup>3</sup>University of Michigan Medical School, Ann Arbor, Michigan

**P1-96**

Intratatumoral Expression of Tenascin C is a Potential Surrogate Marker for Histological Effect of Chemoradiotherapy in Locally Advanced Pancreatic Cancer Patients. A. Hayasaki<sup>1</sup>, Y. Murata<sup>1</sup>, M. Usui<sup>1</sup>, M. Kishiwada<sup>1</sup>, S. Mizuno<sup>1</sup>, H. Sakurai<sup>1</sup>, T. Yoshida<sup>2</sup>, S. Isaji.<sup>1</sup> <sup>1</sup>Division of Hepato-biliary Pancreatic and Transplant Surgery; <sup>2</sup>Division of Matrix Biology, Mie University, Tsu, Mie, Japan

**P1-97**

Continuous Glucose Monitoring Following Total Pancreatectomy and Islet Autotransplantation. J.M. Jimenez-Vega<sup>1</sup>, D.A. Elder<sup>1</sup>, R.S. Chima<sup>2</sup>, M. Abu-El-Haija<sup>3</sup>, J. Palermo<sup>3</sup>, L.N. Hornung<sup>4</sup>, J.D. Nathan<sup>5</sup>. <sup>1</sup>Division of Endocrinology, Cincinnati Children's Hospital Medical Center/University of Cincinnati, Cincinnati, OH; <sup>2</sup>Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center/University of Cincinnati, Cincinnati, OH; <sup>3</sup>Division of Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital Medical Center/University of Cincinnati, Cincinnati, OH; <sup>4</sup>Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati, Cincinnati, OH; <sup>5</sup>Division of Pediatric, General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center/University of Cincinnati, Cincinnati, OH.

**P1-98**

Pancreatectomy with Artery-first Approach for Borderline Resectable Pancreatic Cancer; Surgical Technique to Secure Negative Tangential Margins and its Outcome. Y. Kawabata, and Y. Tajima. Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Japan

**P1-99**

Gremlin Mediates Pro-fibrogenic Activity of TGF- $\beta$  in Chronic Pancreatitis. K. Liu, Y. Cao, and T.C. Ko. Department of Surgery, University of Texas, Houston, Texas.

**P1-100**

Impact of Comorbidity on the Natural History of Pancreatic Cystic Neoplasms – A Competing Risk Analysis. K Kwok<sup>1</sup>, B Wu<sup>1</sup>. <sup>1</sup>Center for Pancreatic Care, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA

**P1-101**

IL-8 and HGF in Predicting Development of Severe Acute Pancreatitis (SAP). O. Lindström,<sup>1</sup>A. Penttilä,<sup>1</sup>K. Kuuliala,<sup>2</sup>H. Mustonen,<sup>1</sup>P. Puolakkainen,<sup>1</sup>A. Kuuliala,<sup>2</sup>M. Salmi,<sup>3</sup>M. Hämäläinen,<sup>4</sup>E. Moilanen,<sup>4</sup>H. Repo,<sup>2</sup>L. Kylänpää<sup>1</sup>. <sup>1</sup>Department of GI Surgery; <sup>2</sup>Department of Bacteriology and Immunology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; <sup>3</sup>Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland; <sup>4</sup>The Immunopharmacology Research Group, University of Tampere, Tampere, Finland

**P1-102**

Evaluation of the Role of NF $\kappa$ B in Tumor Microenvironment Using a Novel Mouse Model of Pancreatic Cancer. K. Majumder, N. Arora, S. Modi, A. Nomura, B. Garg, M.K.Singh, S. Ramakrishnan, S. Banerjee, A. Saluja, and V. Dudeja. Department of Surgery, University of Minnesota, Minneapolis

**P1-103**

Modified One-layer Duct-to-mucosa Pancreaticojejunostomy Reduces Pancreatic Fistula after Pancreaticoduodenectomy. Y. Miao, C. Dai, K. Jiang, J. Wu, W. Gao, Q. Li, J. Wei, J. Chen, F. Guo, Z. Lu, X. Liu, W. Xu. Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

**P1-104**

Pancreatic Insulinoma: Diagnosis and Surgical Management of 33 cases. J. Wei<sup>1</sup>, X. Liu<sup>1</sup>, W. Xu<sup>1</sup>, K. Jiang<sup>1</sup>, C. Dai<sup>1</sup>, Z. Zhang<sup>2</sup>, and Y. Miao<sup>1</sup>. <sup>1</sup>Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China; <sup>2</sup>Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

**P1-105**

Plasma DNA genotyping using Digital PCR for Early Detection of Pancreatic neoplasm. Y. Mizukami, Y. Ono, H. Karasaki, M. Ogata, T. Kono, K. Nagashima. Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan

**P1-106**

Impact of National Pancreas Foundation's (NPF) Animated Pancreas Patient (APP) Metrics on Pancreas Education and Awareness Nation and World Wide. S. Munigala<sup>1</sup>, J. Holt<sup>2</sup>, T. Gardner MD<sup>2</sup>, and M. Alsante<sup>2</sup>, A Gelrud MD<sup>2</sup>. <sup>1</sup>St. Louis University, St. Louis, MO; <sup>2</sup>National Pancreas Foundation, Bethesda, MD

**P1-107**

A Single p53 Mutation May Predict Survival in Intraductal Papillary Mucinous Neoplasms of the Pancreas. J. Nicholson<sup>1</sup>, N. Howes<sup>1</sup>, S. Harrison<sup>1</sup>, T. Hanna<sup>1</sup>, L. Yan<sup>1</sup>, B. Lane<sup>1</sup>, E. Garner<sup>1</sup>, K. Bullock<sup>1</sup>, C. Halloran<sup>1</sup>, P. Ghaneh<sup>1</sup>, R. Sutton<sup>1</sup>, F. Campbell<sup>1</sup>, M. Büchler<sup>2</sup>, J. Neoptolemos<sup>1</sup>, W. Greenhalf<sup>1</sup>. <sup>1</sup>Liverpool Pancreas Biomedical Research Unit, Liverpool, UK, <sup>2</sup>Department of General Surgery, University of Heidelberg, Heidelberg, Germany

**P1-108**

Mechanism Of Necroptosis In Mouse Experimental Acute Pancreatitis. J. Louhimo,<sup>1</sup>M.L. Steer,<sup>2</sup>G. Perides<sup>2</sup>. <sup>1</sup>Department of Surgery, University of Helsinki, Helsinki, Finland, <sup>2</sup>Department of Surgery, Tufts Medical Center and Tufts University School of Medicine, Boston, MA.

**P1-109**

Overexpression of DCLK1 in Pancreatic Cancer Cells Supports Tumorigenesis, Invasiveness, and Stemness. D. Qu, N. Weygant, W. Berry, R. May, P. Chandrakesan, S. M. Sureban, C. W. Houchen. Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

**P1-110**

Gli2 Protein is a Precision Marker for the Canonical Hedgehog Signaling in Pancreatic Tumor. J. Sasajima<sup>1</sup>, Y. Sugiyama<sup>1</sup>, T. Kawamoto<sup>1</sup>, K. Koizumi<sup>1</sup>, H. Karasaki<sup>2</sup>, Y. Mizukami<sup>2</sup>. <sup>1</sup>Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan; <sup>2</sup>Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan

**P1-111**

Cadmium Induced Transformation Leads to Pancreatic Cancer. W. Yu<sup>1</sup>, Y. Ma<sup>1</sup>, R.K. Srivastava,<sup>\*1</sup> S Shankar.<sup>\*1,2</sup> <sup>1</sup>Kansas City VA Medical Center, 4801 Linwood Boulevard, Kansas City, MO, 66128, USA; <sup>2</sup>Department of Pathology, School of Medicine, University of Missouri-Kansas City, Kansas City, MO

**P1-112**

In Vivo Imaging of Non-Radioactive Near Infra-Red 2-Deoxyglucose During Mild and Severe Acute Pancreatitis (AP) in Rats. C. de Oliveira, K. Patel, P. Noel, R. N. Trivedi, A. Singh, V.P. Singh. Department of Medicine, Mayo Clinic - Arizona, Scottsdale, Arizona.

**P1-113**

Fisetin, A Flavonol, has Limited Inhibitory Effect on Human Pancreatic Cancer Cells. S H Lee<sup>1</sup>, N Kim<sup>2</sup>, J H Son<sup>1</sup>, D K Jang<sup>1</sup>, J W Lee<sup>1</sup>, J K Ryu<sup>1</sup>, Y Kim<sup>1</sup>. <sup>1</sup>Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea; <sup>2</sup>Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

**P1-114**

Problems in the Diagnosis of Pancreatic Neuroendocrine Tumors (PNETs) in Clinical Practice. Y. Takayama,<sup>1</sup> K. Shimizu,<sup>1</sup> M. Yamamoto,<sup>2</sup> T. Furukawa,<sup>3</sup> <sup>1</sup>Department of Internal Medicine; <sup>2</sup>Department of Surgery, Institute of Gastroenterology; <sup>3</sup>Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan

**P1-115**

Role of Mitochondria Dynamics During Selective Autophagy Induced by Acute Pancreatitis. V. Vanasco, D. Grasso, S. Alvarez, and M.I. Vaccaro. Institute of Biochemistry and Molecular Medicine (UBA-CONICET), School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.

**P1-116**

Using Affymetrix Gene Chip, Screening the Biomarkers to Evaluate the Severity of Acute Pancreatitis in the Early Stage. W.W. Chen<sup>1,2</sup>, L.H.Deng<sup>1</sup>, X.X. Zhang<sup>1</sup>, N. Shi<sup>1</sup>, Y. Ma<sup>1</sup>, X.N. Yang<sup>1</sup>, and Q. Xia<sup>1</sup>. <sup>1</sup>Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China; <sup>2</sup> Department of Gastroenterology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu Province, China

**P1-117**

Activating Transcription Factor 3 Promotes De-differentiation of Acinar Cells During Cerulein-induced Pancreatitis in Mice. C.C. Young, and C.L. Pin; Departments of <sup>1</sup>Paediatrics, <sup>2</sup>Physiology and Pharmacology, and <sup>3</sup>Oncology, University of Western Ontario, <sup>4</sup>Children's Health Research Institute, London, Ontario, Canada

**P1-118**

Incidence of Tumor Multicentricity in Patients with Ductal Adenocarcinoma of the Pancreatic Head. A. Andreou<sup>1</sup>, T. Denecke<sup>2</sup>, F. Klein<sup>1</sup>, J. Pratschke<sup>1</sup>, and M. Baha<sup>1</sup>. <sup>1</sup>Department of General, Visceral and Transplantation Surgery, Charité - Campus Virchow-Klinikum, Berlin, Germany; <sup>2</sup>Department of Diagnostic and Interventional Radiology, Charité - Campus Virchow-Klinikum, Berlin, Germany

**P1-119**

Does a Pancreatic Duct Above 3 mm Warrant Diagnostic Workup? Clues From a Population Based Cohort. G. Beyer<sup>1</sup>, F. Kasproicz<sup>1</sup>, A. Aghdassi<sup>1</sup>, H. Völzke<sup>2</sup>, T Kohlmann<sup>2</sup>, M.M. Lerch<sup>1</sup>, J. Kühn<sup>3</sup>, J. Mayerle<sup>1</sup>. <sup>1</sup>Department of Medicine A; <sup>2</sup>Department of Community Medicine; <sup>3</sup>Center of Radiology; University Medicine, Ernst-Moritz-Arndt-University, Greifswald, Germany

**P1-120**

The Transcription Factor TFEB Supports Pancreatic Cancer Cell Growth. B. Marchand, D. Arsenault, M.J. Boucher. Gastroenterology Unit, Dept. of Medicine, Univ. of Sherbrooke, Sherbrooke, Canada

**P1-121**

Pancreatic Cancer Development is Dramatically Accelerated by a High Fat, High Calorie Diet in Male and Female Mice. H. Chang, A. Moro, K. Hertzler, A. Stark, C.E. Chou, M. Xu, X. Jung, A.I. Schmidt, D. Dawson, O.J. Hines, and G. Eibl. Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

**P1-122**

Dectin-1 Signaling Promotes Pancreatic Oncogenesis by the Induction of Peritumoral Immune Suppression. D. Daley, L. Tomkötter, A. Ochi, D. Tippens, S. Jonnadula, S. Chang, N. Akkad, R. Barilla, and A. Torres-Hernandez, G. Miller Department of Surgery, New York University School of Medicine, New York, New York

**P1-123**

The Role of Prolactin and its Cognate Receptor in Pancreatic Cancer Progression. A. Criscimanna,<sup>1</sup> M. Socorro,<sup>1</sup> M. Tandon,<sup>1</sup> A. Singhi,<sup>2</sup> F. Esni<sup>1,3</sup>. Departments of <sup>1</sup>Surgery; and <sup>2</sup>Pathology; <sup>3</sup>University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA.

**P1-124**

Morphine analgesia Worsens Chronic Pancreatitis in Mice. J. George, U. Barlass, A. Dixit, Z. Yuan, A. Sareen, S.K Garg, V. Dudeja, R. Dawra, S. Roy, and A. Saluja. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis MN

**P1-125**

Endosomal Regulatory Protein D52 Specifically Interacts with the Autophagy Protein ATG16L1 Beta Isoform to Induce Autophagy in Acinar Cells. M. Cooley, S.W. Messenger, D.D.H. Thomas, G.E. Groblewski. Department of Nutritional Sciences, University of Wisconsin, Madison, WI

**P1-126**

Surgical Resection for Adenosquamous Carcinoma of the Pancreas. T. Ito, T. Sugiura, Y. Okamura, Y. Yamamoto, R. Ashida, and K. Uesaka, Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan

**P1-127**

Early Imaging in Acute Pancreatitis: Has Utilization Decreased? P.A. Banks<sup>1</sup>, V. Kadiyala<sup>1</sup>, S.L. Suleiman<sup>1</sup>, J.Y. McNabb-Baltar<sup>1</sup>, B.U. Wu<sup>2</sup>, R. Khorasani<sup>3</sup>, V.K. Singh<sup>4</sup>. <sup>1</sup>Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts; <sup>2</sup>Division of Gastroenterology, Pancreatic Disease Center, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California; <sup>3</sup>Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; <sup>4</sup>Pancreatitis Center, Division of Gastroenterology, Johns Hopkins Medical Institutions, Baltimore, Maryland

**P1-128**

BioGlue® sealed Fish-mouth Closure of the Pancreatic Remnant During Distal Pancreatectomy. F. Klein, I. Sauer, J. Pratschke, M. Bahra. Department of General, Visceral and Transplantation Surgery, Charité Universitätsmedizin - Campus Virchow, Berlin, Germany

**P1-129**

Preoperative Biomarkers are Beneficial in Predicting Postoperative Survival in Pancreatic Ductal Adenocarcinoma. A. Koski<sup>1</sup>, H. Mustonen<sup>1</sup>, U.H. Stenman<sup>2</sup>, P. Puolakkainen<sup>1</sup>, E. Kempainen<sup>1</sup>, H. Seppänen<sup>1</sup>, and C. Haglund<sup>1</sup>. <sup>1</sup>Department of Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland; <sup>2</sup>Department of Clinical Chemistry, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

**P1-130**

Long-term Outcomes and Prognostic Factors in 78 Japanese Patients with Advanced Pancreatic Neuroendocrine Tumors: A Single-center Retrospective Study. L. Lee<sup>1</sup>, T. Ito<sup>1</sup>, H. Igarashi<sup>1</sup>, K. Kawabe<sup>1</sup>, Y. Oda<sup>2</sup>, and R.T. Jensen<sup>3</sup>. <sup>1</sup>Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; <sup>2</sup>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; <sup>3</sup>Digestive Diseases Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.

**P1-131**

Second Primary Malignancy Among Pancreatic Cancer Patients. R. Luketina, C.W. Michalski, C. Tjaden, M.W. Büchler, and T. Hackert. Department of Surgery, University of Heidelberg, Heidelberg, Germany

**P1-132**

The SNARE Priming Factor Calcium-dependent Activator Protein for Secretion 2 (CAPS2) Regulates VAMP8-dependent Premature Intracellular Trypsinogen Activation. SW Messenger<sup>1,2</sup>, GE Groblewski<sup>2</sup>, TF Martin<sup>1</sup>. <sup>1</sup>Department of Biochemistry, <sup>2</sup>Department of Nutritional Sciences, University of Wisconsin, Madison, WI

**P1-133**

Analysis of Surgical Management and Pathological Features of Pancreatic Neuroendocrine Neoplasms. J. Wu, C. Dai, K. Jiang, W. Gao, Q. Li, W. Xu, J. Wei, J. Chen, F. Guo, Z. Lu, Y. Miao. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

**P1-134**

The Impact of Curative Resection for Pancreatic Adenocarcinoma with Lymph Node Metastasis Status. A. Miki, Y. Sakuma, H. Sasanuma, M. Koizumi, K. Endo, and N. Sata. Department of Surgery, Jichi Medical University, Tochigi, Japan.

**P1-135**

Thrombin-Dependent Pathways Drive Pancreatic Ductal Adenocarcinoma Disease. Y. Yang<sup>1</sup>, C.L. Rewerts<sup>2</sup>, M.J. Flick<sup>2</sup>, and S.F. Konieczny<sup>1</sup>. <sup>1</sup>Department of Biological Science & the Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana; <sup>2</sup>Division of Experimental Hematology & Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio.

**P1-136**

Islet Neogenesis Associated Protein (INGAP) Protects  $\beta$ -cells from Cytokine-induced Toxicity. E. Nano, and L. Rosenberg. Department of Surgery, McGill University, Montréal, Quebec, Canada.

**P1-137**

Acute Pancreatitis is Diminished by a Pre-treatment with the Hepatocyte Growth Factor in a Mouse Model. M. Palestino-Dominguez<sup>1</sup>, M. Peláez-Luna<sup>2</sup>, R. Lazzarini<sup>3</sup>, L.E. Gomez-Quiroz<sup>1</sup>, J. Marquardt<sup>4</sup>, and M.C. Gutierrez-Ruiz<sup>1</sup>. <sup>1</sup>Department of Health Sciences, Universidad Autonoma Metropolitana-Iztapalapa, Mexico City, Mexico; <sup>2</sup>Department of Gastroenterology. INCMNSZ, Mexico City, Mexico; <sup>3</sup>Department of Biology of Reproduction, Universidad Autonoma Metropolitana-Iztapalapa, Mexico City, Mexico; <sup>4</sup>Department of Internal Medicine, Johannes Gutenberg University I, Mainz, Germany.

**P1-138**

$\beta$ III-Tubulin Regulates Sensitivity to Nab-Paclitaxel (Abraxane<sup>®</sup>) in Pancreatic Cancer. G. Sharbeen<sup>1</sup>, J. McCarroll<sup>2,3</sup>, J. Liu<sup>1</sup>, J. Youkhana<sup>1</sup>, D. Goldstein<sup>1</sup>, M. Kavallaris<sup>2,3</sup>, and P. Phillips<sup>1,3</sup>. <sup>1</sup>Pancreatic Cancer Translational Research Group, Lowy Cancer Research Centre, UNSW Australia, Sydney, Australia; <sup>2</sup>Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia; <sup>3</sup>Australian Centre for NanoMedicine, UNSW Australia.

**P1-139**

RCAD is a Key Post-Translational Modification for the Proper Sorting of Digestive Enzymes and the Secretory Function of the Exocrine Pancreas. M.E. Sabbatini<sup>1</sup>, Y. Cai<sup>2</sup>, and H. Li<sup>2</sup>. <sup>1</sup>Department of Biological Sciences, Georgia Regents University, Augusta, Georgia; <sup>2</sup>Department of Biochemistry and Molecular Biology, Georgia Regents University, Augusta, Georgia.

**P1-140**

Dual PI3K/mTOR Inhibitors Induce Rapid Over-Activation Of The MEK/ERK Pathway In Human Pancreatic Cancer Cells Through Suppression of mTORC2. HP Soares, Q Xu, SH Young, J Sinnet-Smith, E Rozengurt. Division of Hematology-Oncology and Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine; CURE: Digestive Diseases Research Center, University of California at Los Angeles

**POSTERS OF DISTINCTION | FRIDAY, NOVEMBER 6**

**P2-1**

Using a Combination of Molecular and Clinical Features to Improve the Classification of Pancreatic Cysts: a Multicenter Retrospective Study. S. Springer<sup>\*1,2</sup>, Y. Wang<sup>\*1,2</sup>, M. Dal Molin<sup>\*2,3</sup>, D.L. Masica<sup>\*2,4,10</sup>, Y. Jiao<sup>1,2</sup>, I. Kinde<sup>1,2</sup>, A. Blackford<sup>5</sup>, S.P. Raman<sup>6</sup>, C.L. Wolfgang<sup>2,7,8</sup>, T. Tomita<sup>4,10</sup>, N. Niknafs<sup>4,10</sup>, C. Douville<sup>4,10</sup>, J. Ptak<sup>1,2</sup>, L. Dobbyn<sup>1,2</sup>, P.J. Allen<sup>11</sup>, D.S. Klimstra<sup>12</sup>, M.A. Schattner<sup>13</sup>, C.M. Schmidt<sup>14</sup>, M. Yip-Schneider<sup>15</sup>, O.W. Cummings<sup>15</sup>, R.E. Brand<sup>16</sup>, H.J. Zeh<sup>17</sup>, A.D. Singhi<sup>18</sup>, A. Scarpa<sup>19,20</sup>, R. Salvia<sup>21</sup>, G. Malleo<sup>21</sup>, G. Zamboni<sup>20,22</sup>, M. Falconi<sup>23</sup>, J. Jang<sup>24</sup>, S. Kim<sup>24</sup>, W. Kwon<sup>24</sup>, S. Hong<sup>25</sup>, K. Song<sup>26</sup>, S.C. Kim<sup>26</sup>, N. Swan<sup>27</sup>, J. Murphy<sup>27</sup>, J. Geoghegan<sup>28</sup>, W. Brugge<sup>29</sup>, C. Fernandez-Del Castillo<sup>30</sup>, M. Mino-Kenudson<sup>31</sup>, R. Schulick<sup>32</sup>, B.H. Edil<sup>32</sup>, V. Adsay<sup>33</sup>, J. Paulino<sup>34</sup>, J. van Hooft<sup>35</sup>, S. Yachida<sup>36</sup>, S. Nara<sup>36</sup>, N. Hiraoka<sup>36</sup>, K. Yamao<sup>37</sup>, S. Hijioka<sup>37</sup>, S. van der Merwe<sup>38</sup>, M. Goggins<sup>2,8,9</sup>, M.I. Canto<sup>9</sup>, N. Ahuja<sup>7</sup>, K. Hirose<sup>7</sup>, M. Makary<sup>7</sup>, M.J. Weiss<sup>7</sup>, J.L. Cameron<sup>7</sup>, M. Pittman<sup>2,3</sup>, J.R. Eshleman<sup>1,2</sup>, L.A. Diaz, Jr.<sup>1,2,8</sup>, N. Papadopoulos<sup>1,2</sup>, K.W. Kinzler<sup>1,2</sup>, R. Karchin<sup>2,4,8,10</sup>, R.H. Hruban<sup>1,2,3,8</sup>, B. Vogelstein<sup>1,2</sup>, A.M. Lennon<sup>2,7,9</sup>. The Ludwig Center and Howard Hughes Medical Institute at the Sidney Kimmel Cancer Center<sup>1</sup>, The Sol Goldman Pancreatic Cancer Research Center<sup>2</sup>, the Departments of Pathology<sup>3</sup>, Biomedical Engineering<sup>4</sup>, Biostatistics and Bioinformatics<sup>5</sup>, Radiology<sup>6</sup>, Surgery<sup>7</sup>, Oncology<sup>8</sup>, Medicine<sup>9</sup>, The Johns Hopkins Medical Institutions and the Institute for Computational Medicine<sup>10</sup>, The Johns Hopkins University, Baltimore, MD, USA. The Departments of Surgery<sup>11</sup>, Pathology<sup>12</sup>, and Gastroenterology<sup>13</sup>, Memorial Sloan-Kettering Cancer Center. The Department of Surgery<sup>14</sup>, and Pathology<sup>15</sup>, University of Indiana. The Department of Medicine<sup>16</sup>, Surgery<sup>17</sup> and Pathology<sup>18</sup>, University of Pittsburgh. ARC-Net Research Centre and Department of Pathology and Diagnostics<sup>19</sup>, University and Hospital Trust of Verona, Italy. Department of Pathology<sup>20</sup>, General Surgery B, University and Hospital Trust of Verona, Italy. Department of Surgery<sup>21</sup>, University and Hospital Trust of Verona, and the Department of Pathology<sup>22</sup>, Ospedale Sacro Cuore-Don Calabria, Negrar, Italy. Division of Pancreatic Surgery, Department of Surgery<sup>23</sup>, IRCCS San Raffaele Scientific Institute, Milan, Italy. The



Department of Surgery and Cancer Research Institute<sup>24</sup>, Seoul National University College of Medicine, Seoul, Korea. The Departments of Pathology<sup>25</sup> and Hepatobiliary and Pancreas Surgery<sup>26</sup>, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. The Department of Histopathology<sup>27</sup>, and Surgery<sup>28</sup>, St. Vincent's University Hospital, Dublin, Ireland. The Departments of Gastroenterology<sup>29</sup>, Surgery<sup>30</sup> and Histopathology<sup>31</sup>, Massachusetts General Hospital. The Department of Surgery<sup>32</sup>, University of Colorado. The Department of Pathology<sup>33</sup>, Emory University. The Department of Pathology<sup>34</sup>, Centro Hepatobiliopancreático e Transplantação - Hospital Curry Cabral, Lisbon, Portugal. The Department of Gastroenterology and Hepatology<sup>35</sup>, Amsterdam Medical Center, Netherlands. The Department of Hepatobiliary and Pancreatic Surgery, Pathology and Cancer Genomics<sup>36</sup>, National Cancer Center Hospital and National Cancer Center Research Institute, Tokyo, Japan. The Department of Gastroenterology<sup>37</sup>, Aichi Cancer Center Hospital, Nagoya, Japan. The Department of Hepatology<sup>38</sup>, University Hospitals KU Leuven, Belgium.

**P2-2**

Lymphotoxin Accelerates Pre-neoplastic Conversion in Pancreatic Tumorigenesis by Promoting Acinar Cell Reprogramming. G. Seleznik<sup>1</sup>, T. Reding<sup>1</sup>, E. Diamantis<sup>3</sup>, A. Perren<sup>3</sup>, M. Heikenwälder<sup>2</sup>, R. Graf<sup>1</sup>. <sup>1</sup>Visceral & Transplantation Surgery, University Hospital Zurich, Switzerland; <sup>2</sup>Institute for Virology, Helmholtz-Centre Munich, Germany; <sup>3</sup>Institute of Pathology, University of Bern, Switzerland

**P2-3**

Direct Chemical Inhibition of Nuclear Factor  $\kappa$ B only Ameliorates Local Pancreatic but not Remote Lung Inflammation via Up-regulating Pancreatitis Associated Protein 1. C. Ulrich\*, Z. Yuan\*, J. George, U. Barlass, S. Garg, A. Sareen, A. K. Dixit, R. K. Dawra, A. K. Saluja. Division of Basic and Translational Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA.\*Equal contribution.

**P2-4**

Minimally Invasive Versus Open Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A National Perspective on Survival. M. Adam, S. Roman, and J. Sosa. Department of Surgery, Duke University Medical Center, Durham, North Carolina.

**P2-5**

Smoking Worsens the Fibrosis of Alcoholic Chronic Pancreatitis via Activation of Pancreatic Stellate Cells. Z. Xu<sup>1,2</sup>, S. Pothula<sup>1,2</sup>, S. Pandolfi<sup>3</sup>, R.C. Pirola<sup>1,2</sup>, J.S. Wilson<sup>1,2</sup>, M.V. Apte<sup>1,2</sup>. <sup>1</sup>Pancreatic Research Group, SWS Clinical School, UNSW and <sup>2</sup>Ingham Institute, Sydney, Australia and <sup>3</sup>Cedars Sinai Medical Center, USA

**P2-6**

Prognostic Scoring System for Patients who Present with Gastric Outlet Obstruction Due to Advanced Pancreatic Adenocarcinoma. T. Sugiura, Y. Okamura, T. Ito, Y. Yamamoto, R. Ashida, and K. Uesaka. Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan

**P2-7**

Epigenetic Regulation of Mitotic Cell Division in Pancreatic Cancer Cells by a Novel EGF-RAF-MEK-ERK-Aurora B-HP1 $\alpha$  Pathway. M. Williams, A. Mathison, J. Willenborg, G. Lomberk and Raul Urrutia. Epigenetics and Chromatin Dynamics Laboratory, Translational Epigenomics Program (CIM), GIH Division, Department of Medicine, Biophysics, Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN

**P2-8**

Extended Pancreatectomies in Locally Advanced Pancreatic Cancer: Are there any Limits? W. Hartwig\*<sup>1</sup>, A. Gluth\*<sup>1</sup>, D. Koliogiannis<sup>1</sup>, U. Hinz<sup>1</sup>, T. Hackert<sup>1</sup>, J. Werner<sup>1</sup>, and M.W. Büchler<sup>1</sup>. <sup>1</sup>Department of Surgery, University of Heidelberg, Germany

**P2-9**

Defective Lysosomal Hydrolase Trafficking Causes Spontaneous Pancreatitis. E.T. Vegh,<sup>1,2</sup> E.M. Lotshaw,<sup>1</sup> N. Shalbueva,<sup>1</sup> O.A. Mareninova,<sup>1</sup> J.M. Elperin,<sup>1</sup> S.W. French,<sup>3</sup> P. Hegyi,<sup>2</sup> Z. Rakonczay,<sup>2</sup> I. Gukovsky,<sup>1</sup> A.S. Gukovskaya.<sup>1</sup> <sup>1</sup>VA Greater Los Angeles Healthcare System and University of California at Los Angeles; <sup>2</sup>First Department of Medicine, University of Szeged, Hungary; <sup>3</sup>Harbor-UCLA Medical Center, Torrance, CA

**P2-10**

IPMN and Cyst Fluid CEA: The Journey Beyond Diagnosis. V. Gómez, S. Majumder, T.C. Smyrk, W.S. Harmsen, F.T. Enders, F. Gleeson, B.K. Abu Dayyeh, P.G. Iyer, R.K. Pearson, B.T. Petersen, E. Rajan, S.S. Vege, K.K. Wang, S.T. Chari, M.D. Topazian, and M.J. Levy. Mayo Clinic, Rochester, Minnesota

**P2-11**

Primary Pre-adipocytes Stimulate DNA Synthesis of Pancreatic Intraepithelial Neoplasia in the KrasG12D Mouse Model. M. Xu, H.-H. Chang, A. Moro, X. Jung, A. Stark, A. Schmidt, O.J.Hines, and G. Eibl. Department of Surgery, University of California, Los Angeles, Los Angeles, California

**P2-12**

MMPs-7, -8, -9 and TIMP-1 in Acute Pancreatitis. E. Nukarinen,<sup>1</sup> O. Lindström,<sup>2</sup> K. Kuuliala,<sup>3</sup> L. Kylänpää,<sup>2</sup> V. Pettilä,<sup>1</sup> P. Puolakkainen,<sup>2</sup> A. Kuuliala,<sup>3</sup> M. Hämäläinen,<sup>4</sup> E. Moilanen,<sup>4</sup> H. Repo,<sup>3</sup> J. Hästbacka<sup>1</sup>. <sup>1</sup>Department of Anesthesiology and Intensive Care Medicine; <sup>2</sup>Department of GI Surgery; <sup>3</sup>Department of Bacteriology and Immunology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; <sup>4</sup>The Immunopharmacology Research Group, University of Tampere, Tampere, Finland

**P2-13**

TFF2/SMAD4 Tumor Suppressor Signaling in Pancreatic Cancer is Regulated by Promoter Methylation S. Chowdhury<sup>1</sup>, D. Klinkebiel<sup>2</sup>, J. Yamaguchi<sup>3</sup>, A.S. Liss<sup>3</sup>, and S.P. Thayer<sup>1</sup>. <sup>1</sup>Department of Surgery, Fred and Pamela Buffett Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska; <sup>2</sup>Department of Biochemistry, Fred and Pamela Buffett Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska; <sup>3</sup>Andrew L. Warshaw Institute for Pancreatic Cancer Research, MGH, Boston, Massachusetts

**P2-14**

Antibiotic use Early in Acute Pancreatitis: International Overview of Compliance with Guidelines. M. Baltatzis, S. Jegatheeswaran, and A.K. Siriwardena. Regional Hepato-Pancreato-Biliary Surgery Unit, Manchester Royal Infirmary, Manchester UK.

**P2-15**

Diabetes Mellitus is Associated with an Exocrine Pancreatopathy (EP) that is Distinct from Chronic Pancreatitis (CP). S. Majumder, L. Zhang, T.C. Smyrk, S. Mohapatra, Y.C. Kudva, A. Matveyenko, and S.T. Chari. Mayo Clinic, Rochester, Minnesota

**P2-16**

Angiogenic Signature Points to JAK/STAT and TGF- $\beta$  as Therapeutic Targets in Pancreatic Cancer. J Gore,<sup>1,3</sup> KE Craven,<sup>2</sup> JL Wilson,<sup>1</sup> M Korc<sup>1,2,3</sup>. Departments of <sup>1</sup>Medicine, and <sup>2</sup>Biochemistry and Molecular Biology, Indiana University School of Medicine, and the <sup>3</sup>Pancreatic Cancer Signature Center at Indiana University Simon Cancer Center, Indianapolis, IN 46202, USA.

**P2-17**

Chronic Pancreatitis: An International Multidisciplinary Survey and Case Vignette Study. Y. Issa<sup>1</sup>, H.C. van Santvoort<sup>1</sup>, P. Fockens<sup>2</sup>, M.G. Besselink<sup>1</sup>, T.L. Bollen<sup>3</sup>, M.J. Bruno<sup>4</sup>, and M.A. Boermeester<sup>1</sup>. <sup>1</sup>Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands; <sup>2</sup>Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands; <sup>3</sup>Department of Radiology, St Antonius Hospital, Nieuwegein, The Netherlands; <sup>4</sup>Department of Gastroenterology, Erasmus Medical Center, Rotterdam, The Netherlands

**Best of EPC: P2-18**

Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer. D Vernerey<sup>1</sup>, D Goldstein<sup>2</sup>, F Huguet<sup>3</sup>, S Paget-Bailly<sup>1</sup>, J-L Van Laethem<sup>4</sup>, B Glimelius<sup>5</sup>, P Artru<sup>6</sup>, M. J. Moore<sup>7</sup>, T André<sup>8</sup>, L Mineur<sup>9</sup>, B Chibaudel<sup>8</sup>, C Louvet<sup>10</sup>, P Hammel<sup>11</sup>, F Bonnetain<sup>1</sup>; <sup>1</sup>Methodological and Quality of Life in Oncology Unit, EA 3181, University Hospital of Besancon, France, <sup>2</sup>Prince of Wales hospital and Prince of Wales Clinical school, UNSW, Australia, <sup>3</sup>Service d'Oncologie Radiothérapie, Hôpital Tenon, Hôpitaux Universitaires Est Parisien, PARIS, France, <sup>4</sup>Hôpital Erasme, Bruxelles, Belgium, <sup>5</sup>Department of Radiology, Oncology and Radiation Science, Uppsala university, Sweden, <sup>6</sup>Institut de Cancérologie, Hôpital privé Jean Mermoz, LYON, France, <sup>7</sup>Princess Margaret Hospital, University Ave Toronto, Ontario Canada, <sup>8</sup>Service d'Oncologie Médicale, Hôpital St Antoine, PARIS, France, <sup>9</sup>Institut Ste Catherine, AVIGON, France, <sup>10</sup>Département d'Oncologie Médicale, Institut Mutualiste Montsouris, PARIS, France, <sup>11</sup>Service de Gastroentérologie, Hôpital Beaujon, CLICHY, France

**Best of EPC: P2-19**

CFTR loss of function after alcohol consumption and in alcoholic pancreatitis. J Maléth<sup>1</sup>, P Pallagi<sup>1</sup>, LV.Kemény<sup>1</sup>, Z Balla<sup>1</sup>, B Kui<sup>1</sup>, A Balázs<sup>1</sup>, L Judák<sup>2</sup>, I Németh<sup>3</sup>, Z Rakonczay Jr.<sup>1</sup>, V Venglovecz<sup>2</sup>, I Földesi<sup>4</sup>, Á Somorác<sup>5</sup>, K Borka<sup>5</sup>, D Perdomo<sup>6</sup>, GL Lukacs<sup>6</sup>, MA Gray<sup>7</sup>, S Monterisi<sup>8</sup>, M Zaccolo<sup>9</sup>, MM Lerch<sup>9</sup>, M Sahin-Tóth<sup>10</sup>, P Hegyi<sup>1</sup>; <sup>1</sup>First Dept. of Medicine, <sup>2</sup>Pharmacology and Pharmacotherapy, <sup>3</sup>Dermatology and Allergology, <sup>4</sup>Laboratory Medicine, University of Szeged, Hungary, <sup>5</sup>2nd Department of Pathology, Semmelweis University, Budapest, Hungary, <sup>6</sup>Department of Physiology McGill University, Montréal, Canada, <sup>7</sup>Institute for Cell & Molecular Biosciences, Newcastle University, Newcastle upon Tyne, United Kingdom, <sup>8</sup>Department of Physiology, Anatomy and Genetics, Oxford University, Oxford, United Kingdom, <sup>9</sup>Department of Medicine A, University Medicine Greifswald, Greifswald, Germany, <sup>10</sup>Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, United States

## POSTERS

## P2-21

Elevated Intracellular Trypsin Activity Increased the Severity of Acute Pancreatitis and Promoted the Development of Chronic Pancreatitis in Transgenic Mice. X. Zhan<sup>1</sup>, G. Zhang<sup>1</sup>, Y. Wang<sup>1</sup>, Y. Zhang<sup>1</sup>, Y. Liu<sup>2</sup>, R.K. Dawra<sup>3</sup>, L. Zhang<sup>4</sup>, A. K. Saluja<sup>3</sup>, C.D. Logsdon<sup>2</sup>, Y. Bi,<sup>5</sup> B. Ji.<sup>1\*</sup> <sup>1</sup> Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota; <sup>2</sup> Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX; <sup>3</sup> Division of Basic and Translational Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota; <sup>4</sup> Department of Pathology, Mayo Clinic, Rochester, Minnesota; <sup>5</sup> Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

## P2-21

Even Stage IIB Operated Pancreatic Ductal Adenocarcinoma (PDA) Can Achieve over 5 Year Survival: The Finnish Register Study 2000-2013 with Pathological Re-evaluation. R. Ahola,<sup>1</sup> A. Siiki,<sup>1</sup> K. Vasama,<sup>2</sup> J. Sand,<sup>1</sup> J. Laukkarinen.<sup>1</sup> <sup>1</sup>Dept of Gastroenterology and alimentary tract surgery, Tampere University Hospital, Tampere, Finland; <sup>2</sup>Dept. of Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland

## P2-22

Predictors of 30-Day Readmission in Patients Undergoing Pancreatic Resections for Neoplastic and Inflammatory Diseases of the Pancreas in a Single Tertiary Healthcare Institution. L.I. Amodu<sup>1</sup>, A. Levy<sup>1</sup>, M. Akerman<sup>2</sup>, M. Tiwari<sup>1</sup>, G.I. Georgiev<sup>1</sup>, M. Beltran Del Rio<sup>1</sup>, J. Nicastrò<sup>1</sup>, G.F. Coppa<sup>1</sup>, E. Molmenti<sup>1</sup>, H.L. Rilo<sup>1</sup>. <sup>1</sup>Center for Diseases of the Pancreas, Department of General Surgery, Hofstra North Shore-LIJ School of Medicine, Manhasset, New York; <sup>2</sup>Department of Biostatistics, Feinstein Institute for Medical Research, Manhasset, New York.

## P2-23

Preoperative Independent Prognostic Factors in Patients with “Resectable” Pancreatic Ductal Adenocarcinoma Following Curative Resection: Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio. S. Asari, H. Toyama, T. Goto, S. Terai, T. Ajiki, T. Matsumoto, K. Shinozaki, M. Kido, A. Takebe, M. Tanaka, K. Kuramitsu, H. Kinoshita, T. Fukumoto, and Y. Ku. Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

## P2-24

A Personal History of Pancreatic Cancer and Another Lynch-Related Cancer: A New Indication for Germline Genetic Panel Testing. B. Dudley<sup>1</sup>, F. Monzon<sup>2</sup>, A. Singhi<sup>3</sup>, S. Lincoln<sup>2</sup>, N. Bahary<sup>1</sup>, and R. Brand<sup>1</sup>. <sup>1</sup>Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, <sup>2</sup>Invitae Corporation, San Francisco, California <sup>3</sup>Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania;

## P2-25

Analysis of Novel Ciliate Lipases as Candidates for Enzyme Substitution in Pancreatic Exocrine Insufficiency. A. Brock,<sup>1</sup> I. Aldag,<sup>2</sup> S. Edskes,<sup>2</sup> M.Hartmann,<sup>2</sup> J.Schnekenburger,<sup>1</sup> <sup>1</sup>Biomedical Technology Center of the Medical Faculty, University of Muenster, Germany; <sup>2</sup>Cilian AG, Muenster, Germany

## P2-26

Molecular Architecture of Mouse and Human Pancreatic Zymogen Granules: Proteins Components and Their Copy Numbers. J. Lee, J. Caruso, G. Hubbs, P. Schnepf, J. Woods, P. Stemmer, B. Jena, and X. Chen. Wayne State University, Detroit, MI

## P2-27

Gasotransmitters in Acute Necrotizing Pancreatitis: Friend or Foe? S. Chooklin, Ya. Pidhirnyy, S. Chuklin, O. Usach Department of Surgery, Regional Clinical Hospital, Lviv, Ukraine

## P2-28

The Role of Receptor Interacting Protein Kinase 1 (RIPK1) in Fatty Acid Ethyl Ester (FAEE)-Acute Pancreatitis. Y. Ouyang<sup>1,2</sup>, L. Wen<sup>1,2</sup>, J. Bertin<sup>3</sup>, P.J. Gough<sup>3</sup>, R. Mukherjee<sup>2</sup>, R. Sutton<sup>2</sup>, and D.N. Criddle<sup>1,2</sup>. <sup>1</sup>Department of Cellular and Molecular Physiology, University of Liverpool, Liverpool, UK; <sup>2</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, Liverpool, UK; <sup>3</sup>Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Pennsylvania

## P2-29

Targeting the Tumor-associated Microenvironment: The Clinical Impact of Integrin Alpha 5 (ITGA5) in Patients with Pancreatic Ductal Adenocarcinoma. S.W.L. de Geus<sup>1</sup>, P.J.K. Kuppen<sup>1</sup>, H.A.J.M. Prevoo<sup>1</sup>, R.L. Vlierberghe<sup>1</sup>, R-J. Swijnenburg<sup>1</sup>, J.S. Mieog<sup>1</sup>, B.A. Bonsing<sup>1</sup>, H. Morreau<sup>2</sup>, C.J.H. van de Velde<sup>1</sup>, A.L. Vahrmeijer<sup>1</sup>, C.F.M. Sier<sup>1</sup>. <sup>1</sup>Department of Surgery, University of Leiden, Leiden, The Netherlands; <sup>2</sup>Department of Pathology, University of Leiden, Leiden, The Netherlands.

**P2-30**

Pancreatic Surgery Trends in the United States between 1998-2011. A. Dudekula<sup>1</sup>, S. Munigala<sup>2</sup>, A. H. Zureikat<sup>3</sup>, D. Yadav<sup>1</sup> Division of <sup>1</sup>Gastroenterology and <sup>2</sup>Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>3</sup>Department of Internal Medicine, St. Louis University, MO

**P2-31**

TFII-I-Mediated Polymerase Pausing Antagonizes TGF $\beta$  Induction of the Pancreatic Oncogene GLI2. A.L. McCleary-Wheeler<sup>1,2</sup>, L.L. Almada<sup>1</sup>, D.L. Marks<sup>1</sup>, A.L. Vrabel<sup>1</sup>, R. Olson<sup>1</sup>, M.E. Fernandez-Zapico<sup>1</sup> <sup>1</sup>Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, USA; <sup>2</sup>College of Veterinary Medicine, Cornell University, Ithaca, NY, USA

**P2-32**

GLI1-GLI2 Interaction Is Required for the Regulation of Collagen Gene Expression in Pancreatic Cancer-Derived Stellate Cells. A.L. McCleary-Wheeler<sup>1,2</sup>, M.G. Fernandez-Barrena<sup>1</sup>, E. Iguchi<sup>1</sup>, L.L. Almada<sup>1</sup>, D.L. Marks<sup>1</sup>, E.J. Tolosa, M. Erkan<sup>3</sup>, R.F. Huang<sup>4</sup>, and M.E. Fernandez-Zapico.<sup>1</sup> <sup>1</sup>Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota; <sup>3</sup>Department of Surgery, Technical University of Munich, Munich, Germany; <sup>4</sup>Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. \*These authors contributed equally to this work.

**P2-33**

PEDF Inhibits Pancreatic Tumorigenesis by Attenuating a Fibro-Inflammatory Reaction. D. Principe<sup>1</sup>, B. DeCant<sup>1</sup>, A. Diaz<sup>1</sup>, R. Mangan<sup>1</sup>, E. Wayne<sup>1</sup>, B. Jung<sup>1</sup>, B. Sreekumar<sup>2</sup>, C. Chung<sup>2</sup>, D. Bentrem<sup>3</sup>, H. Munshi<sup>3</sup>, F. Bishehsari<sup>4</sup>, and P. Grippo<sup>1</sup>. <sup>1</sup>Department of Medicine, University of Illinois at Chicago, Chicago, Illinois; <sup>2</sup>Department of Medicine, Yale University School of Medicine, New Haven, Connecticut; <sup>3</sup>Feinberg School of Medicine, Northwestern University, Chicago, Illinois; <sup>4</sup>Department of Medicine, Rush University Medical Center, Chicago, Illinois

**P2-34**

Left-sided Portal Hypertension following Pancreatoduodenectomy with Resection of the Superior Mesenteric-portal Vein Confluence for Locally Advanced Pancreatic Ductal Adenocarcinoma: Benefit of Concomitant Resection of the Splenic Artery. K. Gyoten, S. Mizuno, H. Kato, A. Tanemura, Y. Murata, N. Kuriyama, Y. Azumi, M. Kishiwada, M. Usui, H. Sakurai, S. Isaji. Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, Mie, Japan

**P2-35**

Sex-specific Responses of the Corticotropin-releasing Factor (CRF) System in Exocrine Pancreas. B. Hasdemir<sup>1</sup>, J. A. Oses-Prieto<sup>2</sup>, A.L. Burlingame<sup>2</sup>, A. Bhargava<sup>1</sup>. <sup>1</sup>Department of Ob-Gyn and The Osher Center; <sup>2</sup>Pharmaceutical Chemistry, University of California San Francisco

**P2-36**

Clinical and Biological Features of Patients of Acute Pancreatitis with Transient Organ Failure or Acute Peripancreatic Fluid Collection. W. Huang<sup>1,2</sup>, D. Iglesia-Garcia<sup>1</sup>, P. Szatmary<sup>1</sup>, L. Fleming-Bird<sup>1</sup>, K. Altaf<sup>1</sup>, Q. Nunes, R. Mukherjee<sup>1</sup>, W.Greenhalf<sup>1</sup>, M.Raraty<sup>1</sup>, and R.Sutton<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK; <sup>2</sup>Sichuan Provincial Pancreatitis Centre, Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China

**P2-37**

Early Prediction of Persistent Organ Failure in Patients with Acute Pancreatitis. W. Huang<sup>1,2</sup>, P. Szatmary<sup>1</sup>, D. Iglesia-Garcia<sup>1</sup>, L. Fleming-Bird<sup>1</sup>, S. Parente<sup>1</sup>, G. Primo<sup>1</sup>, E. Agnew<sup>1</sup>, K. Altaf<sup>1</sup>, Q. Nunes<sup>1</sup>, R. Mukherjee<sup>1</sup>, W. Greenhalf<sup>1</sup>, M. Raraty<sup>1</sup>, and R. Sutton<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK; <sup>2</sup>Sichuan Provincial Pancreatitis Centre, Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China

**P2-38**

Clinical Analysis of Agalactosyl Immunoglobulin-G (IgG) in Chronic Pancreatitis (CP) Patients. T. Ito<sup>1</sup>, M. Hamano<sup>1</sup>, T. Kawai<sup>1</sup>, A. Ishimi<sup>1</sup>, Y. Tokuda<sup>1</sup>, C. Hibino<sup>1</sup>, M. Kato<sup>1</sup>, H.Saiki<sup>1</sup>, K. Yamamoto<sup>1</sup>, M. Naito<sup>1</sup>, and E. Miyoshi<sup>2</sup>. <sup>1</sup>Japan Community Healthcare Organization, Osaka Hospital, Osaka, Japan; <sup>2</sup>Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

**P2-39**

Impact of EUS-FNA in the Assessment of Peri-Arterial Soft Tissue in Locally Advanced Pancreatic Cancer. N. Jamaluddin<sup>1</sup>, and R. Watson<sup>2</sup>. <sup>1</sup>Department of Internal Medicine, UCLA Medical Center, Los Angeles, California; <sup>2</sup>Division of Digestive Diseases, UCLA Medical Center, Los Angeles, California

**P2-40**

Is “180° Rule” in Artery Invasion Still Validate for Defining Unresectable Pancreatic Cancer? Y. Miao, C. Dai, K. Jiang, B. Cai, Z. Lu, J. Wu, W. Gao, Q. Li, J. Wei, J. Chen, F. Guo. Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

**P2-41**

Vascular Enhancement Pattern of Mass in Computed Tomography may Predict Chemo-Responsiveness in Advanced Pancreatic Cancer. J. Park<sup>1</sup>, S. Kim<sup>1</sup>, S. Jeong<sup>1</sup>, D.H. Lee<sup>1</sup>, H.J. Choi<sup>2</sup>, J.H. Moon<sup>2</sup>, C. Kwon.<sup>3</sup><sup>1</sup>Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea; <sup>2</sup>Digestive Disease Center and Research Institute, Department of Internal Medicine, SoonChunHyang University School of Medicine, Bucheon, Korea; <sup>3</sup>Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea

**P2-42**

Endosomally Directed Acinar Differentiation. E.K. Jones, N.Y. Ly, S.W. Messenger, and G.E. Groblewski. University of Wisconsin, Madison, WI.

**P2-43**

The role of nab-Paclitaxel plus Gemcitabine Therapy for Recurrent Pancreatic Cancer Refractory to Gemcitabine and S-1. S. Kagawa, H. Yoshitomi, H. Shimizu, M. Ohtsuka, A. Kato, K. Furukawa, T. Takayashiki, S. Takano, S. Kuboki, D. Suzuki, N. Sakai, and M. Miyazaki. Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

**P2-44**

Effect of Fetal Membrane-Derived Mesenchymal Stem Cell Transplantation in Rats with Acute and Chronic Pancreatitis. K. Kawakubo<sup>1</sup>, S. Ohnishi<sup>1</sup>, H. Fujita<sup>2</sup>, M. Kuwantani<sup>1</sup>, R. Onishi<sup>1</sup>, A. Masamune<sup>3</sup>, H. Taked<sup>2</sup>, and N. Sakamoto<sup>1</sup>. <sup>1</sup>Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; <sup>2</sup>Laboratory of Pathophysiology and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan; <sup>3</sup>Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan

**P2-45**

Elevated Levels of IL-6 and IL-8 have Predictive Role in the Development of Respiratory Failure in Patients with Acute Pancreatitis. J. Samanta<sup>1</sup>, S. Singh<sup>2</sup>, R. Prasada<sup>1</sup>, N. Dhaka<sup>1</sup>, M. Ashat<sup>5</sup>, S.K. Arora<sup>2</sup>, S.K. Sinha<sup>1</sup>, A.N. Aggarwal<sup>3</sup>, V. Gupta<sup>4</sup>, T.D. Yadav<sup>4</sup>, R. Kochhar.<sup>1</sup> <sup>1</sup>Department of Gastroenterology; <sup>2</sup>Department of Immunopathology; <sup>3</sup>Department of Pulmonary medicine; <sup>4</sup>Department of Surgery, Postgraduate Institute of Medical Education and Research(PGIMER) Chandigarh India; <sup>5</sup>John H Stroger Hospital of Cook, Chicago, IL, United States.

**P2-46**

Jak2/STAT3 Inhibition Limits the Activation of Pancreatic Stellate Cells In Vitro. H.M. Komar,<sup>1</sup> G. Serpa,<sup>1</sup> T. Mace,<sup>1</sup> O. Elnaggar,<sup>1</sup> M. Bloomston,<sup>2</sup> D. Conwell,<sup>3</sup> G.B. Lesinski.<sup>1</sup> <sup>1</sup>Division of Medical Oncology;<sup>2</sup>Division of Surgical Oncology, Department of Surgery;<sup>3</sup>Division of Gastroenterology, Hepatology, & Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH

**P2-47**

Pancreatitis after Pancreas Resection Predicts Clinically Relevant Postoperative Pancreatic Fistula. C. M. Kühlbrey, O. Sick, N. Samiei, F. Makowiec, U. T. Hopt, U. A. Wittel. Department of Surgery, Clinic for General und Visceral Surgery, Freiburg, Germany

**P2-48**

Quality of Life (QoL) after Pancreaticoduodenectomy (PD) in Patients with Pancreatic Ductal Adenocarcinoma (PDA). I. Laitinen, J. Sand, P. Peromaa, I. Nordback, J. Laukkarinen. Dept of Gastroenterology and Alimentary tract surgery, Tampere University Hospital, Finland

**P2-49**

The Effect of an Integrated Health System Algorithm Based on 2012 International Consensus Guideline on the Local Practice Pattern for the Management of Pancreatic Cystic Neoplasms. A. Eskandari<sup>1</sup>, E. Alonso<sup>1</sup>, A. Ko<sup>1,3</sup>, and B. Lim<sup>1,2</sup>. <sup>1</sup>School of Medicine, University of California, Riverside, California; <sup>2</sup>Department of Gastroenterology, Kaiser Permanente Riverside Medical Center, Riverside, California; <sup>3</sup>Department of Surgery, Kaiser Permanente Riverside Medical Center, Riverside, California

**P2-50**

Initial Attempts at Enhanced Recovery After Surgery (ERAS) Program for Pancreatic Surgery in a High-volume Center in China. Q. Li, N. Lv, Z. Lu, C. Dai, K. Jiang, J. Wu, W. Gao, F. Guo, J. Wei, J. Chen, and Y. Miao. The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

**P2-51**

Exosomes Released from Pancreatic Carcinoma Cells Are Ca<sup>2+</sup> Regulated and Dependent on the SNARE- and Ca<sup>2+</sup>-binding Protein, Munc13-4. S.W. Messenger, T.F. Martin. Department of Biochemistry, University of Wisconsin, Madison, WI.

**P2-52**

Decreased Serum Thrombospondin-1 Levels in Pancreatic Ductal Adenocarcinoma Patients: An Early Indicator of Cancer or Diabetes Development? C. Jenkinson<sup>1,2</sup>, V.L. Elliott<sup>1,2</sup>, A. Evans<sup>1,2</sup>, L. Oldfield<sup>1,2</sup>, J.F. Timms<sup>3</sup>, A. Gentry-Maharaj<sup>3</sup>, U. Menon<sup>3</sup>, T. Cox<sup>1</sup>, F. Campbell<sup>1</sup>, R. Sutton<sup>1,2</sup>, S.P. Pereira<sup>3</sup>, D.A. Tuveson<sup>4</sup>, W. Greenhalf<sup>1,2</sup>, J.P. Neoptolemos<sup>1,2</sup> and E. Costello<sup>1,2</sup>. <sup>1</sup>Department of Molecular and Clinical Cancer Medicine, University of Liverpool, UK; <sup>2</sup>National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, UK; <sup>3</sup>Department of Women's Cancer, Institute for Women's Health, University College London, UK; <sup>4</sup>Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

**P2-53**

Effects of LC3 Overexpression on Pancreatic Acinar Cell Homeostasis and Pancreatitis Responses  
O.A. Mareninova<sup>1</sup>, W. Jia<sup>1,2</sup>, J.M. Elperin<sup>1</sup>, E.M. Lotshaw<sup>1</sup>, M. Pimental<sup>1</sup>, G.E. Groblewski<sup>3</sup>, A.S. Gukovskaya<sup>1</sup>, I. Gukovsky<sup>1</sup>. <sup>1</sup>VAGLAHS & University of California Los Angeles,; <sup>2</sup>Beijing Hospital, Beijing, China; <sup>3</sup>University of Wisconsin, Madison, Wisconsin

**P2-54**

Pancreatic Ductal Adenocarcinoma without High-grade Pancreatic Intraepithelial Neoplasia (PanIN) may Develop Via a Pathway other than PanIN-carcinoma Sequence. T. Miyazaki<sup>1,2</sup>, Y. Ohishi<sup>1</sup>, Y. Miyasaka<sup>2</sup>, K. Ozono<sup>1,2</sup>, A. Abe<sup>1,2</sup>, N. Mochidome<sup>1,2</sup>, K. Saeki<sup>1,2</sup>, E. Nagai<sup>2</sup>, Y. Oda<sup>1</sup>, and M. Nakamura<sup>2</sup>. <sup>1</sup>Department of Anatomical Pathology, Kyushu University, Fukuoka, Japan; <sup>2</sup>Department of Surgery and Oncology, Kyushu University, Fukuoka, Japan

**P2-55**

DPYSL3 Variant 1 Regulates Cell Survival in Pancreatic Cancer. S. Chowdhury<sup>1</sup>, M. Ali<sup>1</sup>, D. Maroni<sup>1</sup>, N. Woods<sup>2</sup> and S.P. Thayer<sup>1</sup>. <sup>1</sup>Department of Surgery, Fred and Pamela Buffett Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska; <sup>2</sup>Eppley Institute, University of Nebraska Medical Center, Omaha, Nebraska

**P2-56**

Adverse Outcomes of Pancreatic Cysts with Fukuoka Positive Features. S. Mukewar, N. de Pretis, R. Sah, A. Aryal, N. Takahashi, S. Vege, and S. Chari. Department of Gastroenterology, Mayo Clinic, Rochester, MN

**P2-57**

Investigating Gemcitabine-loaded Superparamagnetic Iron Oxide Nanoparticles against Pancreatic Cancer Cells in Artificial Circulation. S. Nandi<sup>1</sup>, P.D. Sykes<sup>1</sup>, E. Hasan<sup>2</sup>, M. Barrow<sup>2</sup>, E. Costello<sup>1</sup>, M.J. Rosseinsky<sup>2</sup>, J.A. Hunt<sup>3</sup>, C.M. Halloran<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit; <sup>2</sup>Department of Chemistry, University of Liverpool, UK; <sup>3</sup>Department of Musculoskeletal Biology, University of Liverpool, UK.

**P2-58**

The Current Management of Mucinous Cystic Neoplasms (MCN) of the Pancreas. A Systematic Review  
L.N. Nilsson,<sup>1</sup>A. Antila,<sup>2</sup>J. Millastre Bocos,<sup>3</sup>M. Marijinissen Van Zanten,<sup>4</sup>A. Shamali,<sup>5</sup>C. Verdejo Gil,<sup>6</sup>M.G. Keane,<sup>7</sup>J. Laukkarinen,<sup>2</sup>M. Del Chiaro.<sup>1</sup>Department of Surgery, Karolinska University Hospital, Sweden; <sup>2</sup>Tampere University Hospital, Finland; <sup>3</sup>Miguel Servet University Hospital, Zaragoza, Spain; <sup>4</sup>Nijmegen University Hospital, Netherlands; <sup>5</sup>Southampton University Hospital, United Kingdom; <sup>6</sup>Ciudad Real University Hospital, Spain; <sup>7</sup>Institute for Liver and Digestive Health, University College London, United Kingdom

**P2-59**

Minnelide Decreases Neural Invasion and Pain Signaling in Pancreatic Cancer. A. Nomura, S. Modi, K. Majumder, P. Dauer, N. Aurora, S. Banerjee, S. Roy, A.K. Saluja. Department of Surgery, University of Minnesota, Minneapolis, MN

**P2-60**

Laparoscopic Pancreaticoduodenectomy (LPD) With Uncinate Process First Approach. W. Gao, K. Jiang, J. Wu, Q. Li, F. Guo, J. Chen, J. Wei, Z. Lu, M. Tu, X. Dai, C. Dai, Y. Miao. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

**P2-61**

Potential Biomarkers of Pancreatic Ductal Adenocarcinoma-Associated Diabetes. L. Oldfield<sup>1</sup>, C. Jenkinson<sup>1</sup>, T. Purewal<sup>2</sup>, R. Sutton<sup>1</sup>, J. P. Neoptolemos<sup>1</sup>, W. Greenhalf<sup>1</sup> and E. Costello<sup>1</sup>. <sup>1</sup>National Institute for Health Research, Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, UK; <sup>2</sup>Department of Diabetes and Endocrinology, Royal Liverpool University Hospital



**P2-62**

Examining the Effect of Anacardic Acid Alone or in Combination with Chemotherapeutics on Pancreatic Cancer Cells. M. Park<sup>1</sup>, M.M. Blackmon<sup>1</sup>, S. Craver<sup>1</sup>, V.S. Eversole<sup>2</sup>, and D. Upton<sup>3</sup>. <sup>1</sup>Kentucky College of Osteopathic Medicine, University of Pikeville, Pikeville, Kentucky; <sup>2</sup>Department of Biology, University of Pikeville, Pikeville, Kentucky; <sup>3</sup>Department of Chemistry, University of Pikeville, Pikeville, Kentucky

**P2-63**

A Non Dilated Main Pancreatic Duct Predicts AIP. A Comparison Study of Resected Focal AIP, Chronic Pancreatitis and Pancreatic Adenocarcinoma. C Medina,<sup>1</sup> M. Peláez-Luna,<sup>1,4</sup> L. Uscanga,<sup>1</sup> C. Chan,<sup>2</sup> E. Negrete,<sup>1</sup> A. Ángeles<sup>3</sup>. <sup>1</sup>Department of Gastroenterology. <sup>2</sup>Department of Surgery. <sup>3</sup>Department of Pathology. INCMNSZ. <sup>4</sup>Research Division, School of Medicine, UNAM. Mexico City.

**P2-64**

Leukotriene B<sub>4</sub> Receptor Expression Are Increased in Chronic Pancreatitis and Activated Primary Pancreatic Stellate Cells. H. Pham\*, R.T. Waldron, J. Yang, H. Su, S. J. Pandol, A. Lugea. Department of Medicine, Cedars-Sinai, Los Angeles, CA.

**P2-65**

Pancreatic Cancer: Stromal Re-programming Offers a Novel Therapeutic Approach. S.Pothula, Z.Xu, D.Goldstein, R.Pirola, J.Wilson, M.Apte. Pancreatic Research Group, South Western Sydney Clinical School, Ingham Institute for Applied Medical Research and the Faculty of Medicine, The University of New South Wales, Sydney, Australia.

**P2-66**

Comparison of different classification tools for the diagnosis of chronic pancreatitis. Y. Issa<sup>1</sup>, U. Ahmed Ali<sup>1,2</sup>, S. van Dieren<sup>1</sup>, H.C. van Santvoort<sup>1</sup>, M.A. Boermeester<sup>1</sup>. <sup>1</sup>Department of Surgery, Academic Medical Center, Amsterdam; <sup>2</sup>Department of Surgery, University Medical Center Utrecht, Utrecht

**P2-67**

The Prognostic Influence of Intrapancreatic Tumor Location on Survival after Resection of Pancreatic Cancer. D.A. Ruess<sup>1</sup>, S. Chikhladze<sup>1</sup>, O. Sick<sup>1</sup>, H. Riediger<sup>2</sup>, U.T. Hopt<sup>1</sup>, F. Makowiec<sup>1</sup>, U.A. Wittel<sup>1</sup>. <sup>1</sup>Department of Surgery, University of Freiburg, Germany; <sup>2</sup>Department of Surgery, Vivantes-Humboldt-Clinic, Berlin, Germany

**P2-68**

Use Of Oncolytic Adenovirus Expressing IFN-α To Treat Pancreatic Cancer. A. Salzwedel, C. LaRocca, J. Davydova, and M. Yamamoto. Department of Surgery, University of Minnesota, Minneapolis, Minnesota

**P2-69**

The First Series of Spiral Vein Graft Reconstruction Technique for Venous Resection in Borderline Operable Pancreatic Cancer. H. Seppänen, A. Kokkola, H. Mustonen, C. Haglund, I. Kantonen. Dept. of Surgery, Helsinki University Hospital, Helsinki University, Finland

**P2-70**

Correlation between CEACAM6 Expression and Clinicopathological Characteristics, Progression of Pancreatic Cancer. J. Chen, N. Lv, K. Jiang, C. Dai, W. Gao, Q. Li, J. Wu, J. Wei, F. Guo, Z. Lu, Y. Miao. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

**P2-71**

Efficacy of SBP-101 With or Without Gemcitabine and/or Nab-paclitaxel in a Murine Xenograft Model of Human Pancreatic Ductal Adenocarcinoma. A. Shah<sup>1</sup>, S. Gagnon<sup>1</sup>, P. Milani de Marval<sup>2</sup>, A. Kiorpes<sup>1</sup>, and M. Cullen<sup>1</sup>; <sup>1</sup>Sun BioPharma, Inc., Gainesville, Florida; <sup>2</sup>Charles River Discovery Services, Morrisville, North Carolina

**P2-72**

Plasma MicroRNA-127's Early Warning Of Acute Pancreatitis With Respiratory Failure. N. Shi, L.H. Deng, W.W. Chen, X.X. Zhang, Y. Ma, R.J. Luo, K. Jiang, X.N. Yang, Q. Xia. Department of Integrated Traditional Chinese and Western Medicine, West China Hospital of Sichuan University, Chengdu, People's Republic of China.

**P2-73**

Novel patient-derived CTC-xenograft models for the study of pancreatic cancer biology, metastasis and therapy. R.X. Wang<sup>1</sup>, C.Y. Chu<sup>1</sup>, N.N. Nissen<sup>2</sup>, M.S. Lewis<sup>3</sup>, N. Palanisamy<sup>4</sup>, M. Edderkaoui<sup>2</sup>, A. Annamalai<sup>2</sup>, S. Lewis<sup>2</sup>, H.E. Zhou<sup>1</sup>, S.J. Pandol<sup>2</sup>, and L.W.K. Chung<sup>1</sup>. Departments of <sup>1</sup>Medicine and <sup>2</sup>Surgery, Cedars-Sinai Medical Center; <sup>3</sup>Department of Pathology, VA Greater Los Angeles Health System, Los Angeles, CA; and <sup>4</sup>Department of Pathology, Henry Ford Health System, Detroit, MI

**P2-74**

Circulating Inflammatory Cells (CICs) Undergo Lipotoxic Cell Death During Severe Acute Pancreatitis (SAP). P. Noel, K. Patel, R.N. Trivedi, C. de Oliveira, A. Singh, V. P. Singh. Department of Medicine, Mayo Clinic, Scottsdale, AZ.

**P2-75**

Immune Modulation of Pancreatic Cancer with CCK-receptor Blockade. J.P. Smith, S. Wang, S.A. Jablonski, and L.M. Weiner. Departments of Oncology & Medicine, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.

**P2-76**

Circulating Annexin II Predicts Rapid Recurrence after Surgery in Pancreatic Cancer. S. Takano<sup>1</sup>, K. Sogawa<sup>2</sup>, H. Yoshitomi<sup>1</sup>, S. Kagawa<sup>1</sup>, H. Shimizu<sup>1</sup>, M. Ohtsuka<sup>1</sup>, A. Kato<sup>1</sup>, K. Furukawa<sup>1</sup>, T. Takayashiki<sup>1</sup>, S. Kuboki<sup>1</sup>, D. Suzuki<sup>1</sup>, N. Sakai<sup>1</sup>, F. Nomura,<sup>2</sup> M. Miyazaki<sup>1</sup>. <sup>1</sup>Department of General Surgery; <sup>2</sup>Department of Molecular Diagnosis, Chiba University, Chiba, Japan.

**P2-77**

Preoperative Neutrophil to Lymphocyte Ratio Predict Overall Survival after Macroscopic Curative Resection for Pancreatic Cancer. Y. Toyoki, K. Ishido, D. Kudo, T. Wakiya, Y. Wakasa, D. Kasai, and K. Hakamada. Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine

**P2-78**

Adiponectin Receptor Agonists Inhibit Pancreatic Cancer Cell Growth. A.M. Mendonsa<sup>1</sup>, C. Shi<sup>2</sup>, J. Castellanos<sup>3</sup>, A.M. Lowy<sup>4</sup>, N. Nagathihalli<sup>5</sup>, N. Merchant<sup>5</sup>, L. Gorden<sup>1,3</sup>, and M.N. VanSaun<sup>5</sup>. Departments of <sup>1</sup>Cancer Biology, <sup>2</sup>Pathology, <sup>3</sup>Surgery, Vanderbilt University Medical Center, Nashville, Tennessee; <sup>4</sup>Department of Surgery, University of California San Diego, La Jolla, California; <sup>5</sup>Department of Surgery, University of Miami, Miami, Florida.

**P2-79**

Novel Mechanism of Wnt Signaling Activation Mediated by Dickkopf-1 Methylation in Pancreatic Cancer. Z. Wang, Q. Xu, W. Duan, J. Lei, and Q. Ma. Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China

**P2-80**

Acute Pancreatitis Associated with Pancreatectomy: Clinical Analysis of 10 Cases. D. Huang, Q. Li, C. Dai, K. Jiang, J. Wu, W. Gao, J. Wei, J. Chen, F. Guo, Z. Lu, Y. Miao. Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

**P2-81**

Resveratrol Inhibits Hypoxia Induced PSC Activation and Pancreatic Cancer Cell Viability and Invasion. Q. Xu, W. Duan, J. Lei, and Q. Ma. Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China

**P2-82**

Adverse Effect of Re-elevation of Postoperative Inflammatory Reaction on Recurrence Free Survival Time of Patients Undergoing Potentially Curative Resection for Distal Pancreatic Cancer. S. Yamazoe, R. Amano, K. Kimura, G. Ohira, K. Nishio, K. Miura, M. Ohira and K. Hirakawa. Department of Surgical Oncology (First Department of Surgery), Osaka City University, Graduate School of Medicine, Osaka, Japan

**P2-83**

The Value of MicroRNA-216a as a Marker for Severity of Acute Pancreatitis. X.X. Zhang, L.H. Deng, W.W. Chen, N. Shi, Y. Ma, K. Jiang, X.N. Yang, and Q. Xia. Department of Integrated Traditional Chinese and Western Medicine, West China Hospital of Sichuan University, Chengdu, China.

**P2-84**

Development of a Novel Biocompatible Bond for the Prevention of Pancreatic Fistulas. M. Aikawa, M. Miyazawa, S. Ishida, K. Okada, Y. Watanabe, K. Okamoto, I. Koyama, T. Taguchi. Saitama Medical University, International Medical Center, Hidaka, Saitama, Japan.

**P2-85**

Prospective Study of Diabetes, Smoking, Diet and Risk of Pancreatitis: The Multiethnic Cohort. V.W. Setiawan<sup>1,2</sup>, S.J. Pandolf<sup>3</sup>, J. Porcel<sup>2</sup>, L.R. Wilkens<sup>4</sup>, L. Le Marchand<sup>4</sup>, M.C. Pike<sup>1,5</sup>, K.R. Monroe<sup>1</sup>. <sup>1</sup>Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA, <sup>2</sup>Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Los Angeles, CA, <sup>3</sup>Division of Gastroenterology, Departments of Medicine, Cedars-Sinai Medical Center and Department of Veterans Affairs, Los Angeles, CA, <sup>4</sup>Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York, NY

**P2-86**

A High Meat Intake Is Associated with an Increased Risk of Pancreatic Cancer: a Prospective Cohort Study (EPIC-Norfolk) Using Data from Food Diaries. A. Beaney<sup>1</sup>, P. Banim<sup>2</sup>, R. Luben<sup>3</sup>, M. Lentjes<sup>3</sup>, K.T. Khaw<sup>3</sup>, A. Hart<sup>1</sup>. <sup>1</sup>Norwich Medical School, UK; <sup>2</sup>James Paget Hospital, UK; <sup>3</sup>Institute of Public Health, University of Cambridge, UK.

**P2-87**

Covering the Cystic Duct Orifice with Self Expanding Metal Stents for Biliary Obstruction Secondary to Pancreatic Adenocarcinoma: Is there an Increased Risk of Cholecystitis? V. Gohil, Y. Wu, S. Rashid, V. Chitnavis, P. Yeaton, and A. Brijbassie. Department of Gastroenterology, Virginia Tech Carilion School of Medicine, Roanoke, Virginia.

**P2-88**

Pre-diagnosis Cachexia Rather than BMI is Associated with Worse Survival Outcomes in Patients with Pancreatic Cancer. J.I. Chang<sup>1</sup>, B. Z. Huang<sup>2</sup>, and B.U. Wu<sup>3</sup>. <sup>1</sup>Internal Medicine, Kaiser Permanente Los Angeles, California; <sup>2</sup>Research and Evaluation, Kaiser Permanente Southern California; <sup>3</sup>Center for Pancreatic Care, Gastroenterology, Kaiser Permanente Los Angeles, California.

**P2-89**

NecroX-7 Ameliorate the Severity of Cerulein-induced Acute Pancreatitis (CIP) through Inhibition of Necroptosis/necrosis via Reciprocal Regulation of Mitochondrial ROS and Pro-inflammatory Cytokines. Y.T. Kim,<sup>1</sup> M.Y. Kim,<sup>1</sup> D.W. Jun,<sup>1</sup> O.Y. Lee,<sup>1</sup> B.C. Yoon,<sup>1</sup> K.S. Yoo,<sup>1</sup> H.S. Choi,<sup>1</sup> K.G. Lee,<sup>2</sup> D.H. Lee<sup>3</sup> and S.H. Kim.<sup>4</sup> <sup>1</sup>Department of Internal Medicine; <sup>2</sup>General Surgery, Hanyang University College of Medicine, Seoul; <sup>3</sup>Department of Internal Medicine, Inha University College of Medicine, Incheon; <sup>4</sup>LG Life Sciences Ltd., R&D Park, Daejeon, Korea

**P2-90**

Surgical Treatment Choice for Pancreatic Ductal Stone-An Institutional Experience. J. Wei, X. Liu, W. Xu, Z. Lu, J. Chen, F. Guo, K. Jiang, C. Dai, Y. Miao. Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, China.

**P2-91**

Are the Current Physician Quality Reporting System (PQRS) Measures Adequate for Academic Pancreatic Centers of Excellence (APCOE)? D.L. Conwell<sup>1</sup>, P. Hart<sup>1</sup>, M. DiMagno<sup>2</sup>, M. Alsante<sup>3</sup>, C.M. Wilcox<sup>4</sup>, J. Barkin<sup>5</sup>, B. Kisloff<sup>6</sup>, D. Whitcomb<sup>6</sup> and the PancreasFest 2015 Academic Pancreatic Centers of Excellence Ad Hoc Working Groups. <sup>1</sup>The Ohio State University Wexner Medical Center; <sup>2</sup>University of Michigan; <sup>3</sup>National Pancreas Foundation; <sup>4</sup>University of Alabama-Birmingham; <sup>5</sup>University of Miami; <sup>6</sup>University of Pittsburgh

**P2-92**

The Unfolded Protein Response and Overcoming Chemoresistance. P. Dauer, O. McGinn, X. Zhao, N. Arora, M. Singh, V. Dudeja, S. Banerjee, A. Saluja. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN 55455.

**P2-93**

Role of Pre-operative CA19-9 in Predicting Long and Short Term Progression Free Survival in Patients Undergoing Pancreatic Cancer Resection. S. Desai<sup>1</sup>, C. Langmead<sup>2</sup>, H. Zeh<sup>3</sup>, A. Zureikat<sup>3</sup>, N. Bahary<sup>1</sup>, and R. Brand<sup>1</sup>. <sup>1</sup>Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; <sup>2</sup>School of Computer Science, Carnegie Mellon University, Pittsburgh, Pennsylvania; <sup>3</sup>Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania;

**P2-94**

The MET Receptor Tyrosine Kinase is Required for the Repair of Pancreatic Acinar Cells Following Acute and Chronic Injury. I. Gaziova<sup>1</sup>, D. Jackson<sup>2</sup>, P. Boor<sup>3</sup>, D. Carter<sup>2</sup>, Z. Cruz-Montserrat<sup>4</sup>, C. Elferink<sup>2</sup>, A. Joshi<sup>2</sup>, B. Kaphalia<sup>3</sup>, C.D. Logsdon<sup>4</sup>, L. Soong<sup>3</sup>, X. Tao<sup>1</sup>, S. Qiu<sup>3</sup>, and L. Elferink<sup>1</sup>. <sup>1</sup>Departments of Neuroscience and Cell Biology, <sup>2</sup>Pharmacology, <sup>3</sup>Pathology, University of Texas Medical Branch, Galveston, TX; <sup>4</sup>Department of Cancer Biology, University of Texas MD Anderson Cancer Center<sup>5</sup>, Houston, TX

**P2-95**

Pancreas-specific Secretory Pathway Ca<sup>2+</sup>-ATPase 2 Affects GPCR-mediated Ca<sup>2+</sup> Signalling. M. Fenech<sup>1,2</sup>, and C. Pin<sup>1,2,3</sup>.  
<sup>1</sup>Department of Paediatrics, Western University, Children's Health Research Institute, London, Ontario, Canada; <sup>2</sup>Department of Physiology, Western University, Children's Health Research Institute, London, Ontario, Canada; <sup>3</sup>Department of Pharmacology, Western University, Children's Health Research Institute, London, Ontario, Canada; <sup>3</sup>Oncology, Western University, Children's Health Research Institute, London, Ontario, Canada

**P2-96**

Covering the Cystic Duct Orifice with Self Expanding Metal Stents for Malignant Biliary Obstruction: Is there an Increased Risk of Cholecystitis? V. Gohil, Y. Wu, S. Rashid, V. Chitnavis, P. Yeaton, A. Brijbassie. Department of Gastroenterology, Virginia Tech Carilion School of Medicine, Roanoke, VA.

**P2-97**

Evaluation of Minnelide on Granulocyte Differentiation and Apoptosis. V. K. Gupta, A. Sareen, S. Modi, B. Giri, S. Banerjee and A. K. Saluja. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis MN.

**P2-98**

Overexpressed SMG-1 Inhibited the Proliferation, Invasion, and Chemoresistance of Human Pancreatic Carcinoma Cells by Regulating mTOR. L.L. Han<sup>1</sup>, T.H. Hu<sup>2</sup>, J. Wang<sup>1</sup>, L. Jing<sup>1</sup>, M.C. Wang<sup>1</sup>, M.J. Liu<sup>3</sup>, and K.J. Nan<sup>1</sup>.<sup>1</sup>Department of Oncology and <sup>2</sup>Respiratory, First Affiliated Hospital, College of Medicine of Xi'an Jiaotong University, Xi'an, Shaanxi, China; <sup>3</sup>Department of Ultrasound, Second Affiliated Hospital, College of Medicine of Xi'an Jiaotong University, Xi'an, Shaanxi, China

**P2-99**

Suppression of CD51 in Pancreatic Stellate Cells Inhibits Tumor Growth by Reducing Stroma and Altering Tumor-Stromal Interaction in Pancreatic Cancer. K. Horioka, K. Ohuchida, M. Sada, B. Zheng, T. Ohtsuka T. Ueki, E Nagai, K. Mizumoto, Y. Oda, M. Nakamura, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

**P2-100**

Treatment Strategy for Locally Invasive Pancreatic Cancer. J. Itakura, M. Watanabe, N. Hosomura, H. Amemiya, H. Kawaida, H. Okamoto, and H. Kohno. Surgery, University of Yamanashi, Cyuo-shi, Yamanashi, Japan

**P2-101**

Determining the Role of RND2 in Pancreatic Cancer Progression. B. Jakubison, Y. Sun & S.F. Konieczny. Department of Biological Sciences & the Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana

**P2-102**

Comparison of Cytological and Histological Examinations in the Diagnosis of Pancreatic Malignancy Using Endoscopic Ultrasound-guided Fine Needle Aspiration. S.H. Lee, D.K. Jang, J.H. Son, J.W. Lee, J.K. Ryu, and Y.T. Kim. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

**P2-103**

Applying Healthcare Utilization Data to Predict Pancreatic Cancer. A. Baecker<sup>1,2</sup>, S.J. Pandol<sup>1</sup>, A. Hendifar<sup>1</sup>, N. Nissen<sup>1</sup>, B. Wu<sup>3</sup>, and C.Y. Jeon<sup>1,2</sup>. <sup>1</sup>Cedars-Sinai Medical Center, Los Angeles, California; <sup>2</sup>UCLA Fielding School of Public Health, Los Angeles, California; <sup>3</sup>Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

**P2-104**

ERK Kinase Phosphorylates and Destabilizes the Tumor Suppressor FBW7 in Pancreatic Cancer. S.R. Ji<sup>1,2,3</sup>, Y. Qin<sup>1,2,3</sup>, C. Liang<sup>1,2,3</sup>, S. Shi<sup>1,2,3</sup>, J. Xu<sup>1,2,3</sup>, B. Zhang<sup>1,2,3</sup>, Q.X. N<sup>1,2,3</sup>, X.J. Yu<sup>1,2,3,1</sup> <sup>1</sup>Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; <sup>2</sup>Department of Oncology, Shanghai Medical College, Fudan University; <sup>3</sup>Pancreatic Cancer Institute, Fudan University, Shanghai P.R. China.

**P2-105**

Enucleation: a Safe Treatment Alternative for BD-IPMN. J. Kaiser<sup>1</sup>, S. Fritz<sup>1</sup>, M. Klauss<sup>2</sup>, F. Bergmann<sup>3</sup>, U. Hinz<sup>1</sup>, O. Strobel<sup>1</sup>, L. Schneider<sup>1</sup>, M.W. Büchler<sup>1</sup>, and T. Hackert<sup>1</sup>. <sup>1</sup>Department of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Department of Radiology, University of Heidelberg, Heidelberg, Germany; <sup>3</sup>Department of Pathology; University of Heidelberg, Heidelberg, Germany

**P2-106**

Intrabiliary Metastasis from Pancreatic Cancer: a Presentation Similar to Hilar Cholangiocarcinoma. T. Kachaamy<sup>1</sup>, J. Weber<sup>1</sup>, V. Khemka<sup>1</sup>, M. Kundranda.<sup>2</sup> <sup>1</sup>WRMC-CTCA, Goodyear, Arizona; <sup>2</sup>Banner-MD Anderson, Gilbert, Arizona

**P2-107**

Long Term Surveillance and Risk of Progression of Low-Intermediate Risk Intraductal Papillary Mucinous Neoplasms. M. Kayal, L. Luk, F. Gress, A. Sethi, J. Poneris, E. Hecht, and T. Gonda. Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, New York

**P2-108**

Management of Pancreatic Anastomotic Leakage by Measuring Drainage Amylase and Volume after Pylorus Preserving Pancreatoduodenectomy. M. Koizumi, N. Sata, M. Taguchi, A. Miki, H. Endo, H. Sasanuma, Y. Sakuma, H. Horie, Y. Hosoya, and A.K. Lefor. Department of Surgery, Jichi Medical University, Shimotsuke, Japan

**P2-109**

Evaluation of Vitamin D, A, E Status in Patients with Pancreatic Disorders. S. Siminkovitch<sup>1</sup>, M. Kovacheva-Slavova<sup>1</sup>, B. Vladimirov<sup>1</sup>, J. Genov<sup>1</sup>, R. Mitova<sup>1</sup>, P. Gecov<sup>2</sup>, D. Svinarov<sup>3</sup>, B. Golemanov<sup>1</sup>. <sup>1</sup>Department of Gastroenterology; <sup>2</sup>Department of Medical Imaging, University Hospital "Tsaritsa Ioanna-ISUL", Sofia, Bulgaria; <sup>3</sup>Central Laboratory of Therapeutic Drug Management and Clinical Pharmacology, Alexandrovska University Hospital, Medical University of Sofia, Bulgaria

**P2-110**

Deficiency of Lipocalin-2 Protect Against Cerulein-Induced Severe Acute Pancreatitis. S Kumar,<sup>1</sup> S Rachagani,<sup>1</sup> S Joshi,<sup>1</sup> S Gupta,<sup>1</sup> M Varney,<sup>2</sup> AC Cannon,<sup>1</sup> K Mallya,<sup>1</sup> S.Kaur,<sup>1</sup> M Jain,<sup>1</sup> S Akira,<sup>3</sup> RK Singh,<sup>2</sup> and SK Batra<sup>1</sup>. <sup>1</sup>Departments of Biochemistry and Molecular Biology; <sup>2</sup>Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE; <sup>3</sup>Immunology Frontier Research Center (IFReC), Osaka University, Japan

**P2-111**

Microrna-33a-Mediated Downregulation of Pim-3 Kinase Expression Confers Sensitivity to Gemcitabine on Human Pancreatic Cancer Cells. C. Liang. Department of Pancreas and Hepatobiliary, Pancreatic Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

**P2-112**

Identification of a Novel Monomeric Form of the Histone Code Reader HP1g in PDAC Cells Generated by Alternative Splicing of the CBX3 Gene. A. Mathison, M. Williams, T. Berent, S. Buttar, M. Hege, K. Bharucha, R. Urrutia, G. Lomberk. Epigenetics and Chromatin Dynamics Laboratory, Translational Epigenomics Program (CIM), GIH Division, Department of Medicine, Biophysics, Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN.

**P2-113**

Clinicopathological Characteristics of In Situ Carcinoma of the Pancreas. Y. Matsuda<sup>1</sup>, A. Suzuki<sup>1</sup>, A. Seki<sup>1</sup>, K. Nonaka<sup>1</sup>, M. Nishimura<sup>2</sup>, T. Ishiwata<sup>3</sup>, H. Yoshimura<sup>4</sup>, N. Izumiyama<sup>5</sup>, K. Nakamura<sup>5</sup>, N. Ishikawa<sup>5</sup>, J. Aida<sup>5</sup>, K. Takubo<sup>5</sup>, and T. Arai<sup>1</sup>. <sup>1</sup>Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan; <sup>2</sup>Endoscopy, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan; <sup>3</sup>Department of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo, Japan; <sup>4</sup>Department of Applied Science, Nippon Veterinary and Life Science University, Tokyo, Japan; <sup>5</sup>Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.

**P2-114**

Is Anaplastic Pancreatic Cancer Originated from Invasive Ductal Carcinoma of Pancreas? K. Miura, K. Kimura, R. Amano, S. Yamazoe, G. Ohira, K. Nishio, M. Shibutani, K. Sakurai, H. Nagahara, T. Toyokawa, N. Kubo, H. Tanaka, K. Muguruma, H. Otani, M. Yashiro, K. Maeda, M. Ohira, and K. Hirakawa. Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan

**P2-115**

Repression of p38 pathway and cachexia underlies ZIP4 regulation of post-surgical survival of pancreatic cancer. J. Yang, <sup>1</sup> Y. Zhang,<sup>1</sup> G. Zhang,<sup>3</sup> X. Ni,<sup>4</sup> C. D. Logsdon,<sup>2</sup> Y. Li,<sup>3</sup> Min Li<sup>1,3</sup>; <sup>1</sup>Department of Internal Medicine, the University of Oklahoma Health Sciences Center, Oklahoma City, OK; <sup>2</sup>Department of Cancer Biology, University of Texas, M.D. Anderson Cancer Center, Houston, TX; <sup>3</sup>Department of Integrative Biology & Pharmacology, University of Texas Medical School at Houston, Houston, TX; <sup>4</sup>Department of General Surgery, Zhongshan Hospital, Shanghai, China

**P2-116**

Effect of Chronic Ethanol Feeding on Expression and Enzymatic Activity of Pancreatic Digestive Enzymes. Y Ryu, A Bekolay, A Saluja, R Dawra. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN.

**P2-117**

GM-CSF induces CREB through MEK Signaling and Modulates Tobacco Carcinogen-induced Pancreatic Tumorigenesis. K. Honnenahally<sup>1</sup>, J. Castellanos<sup>1</sup>, C. Shi<sup>1</sup>, M. VanSaun<sup>2</sup>, N. Merchant<sup>2</sup>, and N. Nagathihalli<sup>2</sup>. <sup>1</sup>Vanderbilt University, Nashville, Tennessee; <sup>2</sup>Department of Surgery, University of Miami, Miami, Florida

**P2-118**

Prediction of the Severity of Acute Alcohol Pancreatitis by Systemic Levels of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR). N. Anssi<sup>1,2</sup>, A. Janne<sup>3</sup>, H. Reetta<sup>4</sup>, R. Linnea<sup>2</sup>, N. Isto<sup>1</sup>, S. Juhani<sup>1</sup>, and L. Johanna<sup>1</sup>. <sup>1</sup>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland; <sup>2</sup>University of Tampere, School of Medicine, Tampere, Finland; <sup>3</sup>Fimlab Laboratories, Tampere, Finland; <sup>4</sup>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland

**P2-119**

Analysis of Clinicopathological Features of Early Recurrence after Curative Resection for Pancreatic Cancer. K. Nishio, K. Kimura, R. Amano, K. Miura, G. Ohira, S. Yamazoe, M. Ohira, and K. Hirakawa Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan

**P2-120**

Therapeutic Management of Disconnected Pancreatic Duct Syndrome (DPDS). H. Okamoto<sup>1,2</sup>, J. Itakura<sup>2</sup>, and H. Fujii<sup>2</sup>. <sup>1</sup>Department of Surgery, Tsuru Municipal Hospital, Yamanashi, Japan <sup>2</sup>Department Gastrointestinal Surgery, University of Yamanashi, Yamanashi, Japan

**P2-121**

Risk Factors Associated with Early Readmission following Sentinel Admission with Acute Pancreatitis. J. Park, J. Kuo, J. Skeans, A. Hinton, S. Krishna, D. Conwell, P. Hart. The Ohio State University Wexner Medical Center, Columbus, OH

**P2-122**

IL-10 Induced By Sulfuretin Regulates the Severity of Pancreatitis. I.J. Jo<sup>1,2</sup>, G.S. Bae<sup>1,2</sup>, S.B. Choi<sup>1,3</sup>, D.G. Kim<sup>1,3</sup>, J-Y Shin<sup>2</sup>, S-K Lee<sup>1,3</sup>, M-J Kim<sup>1,2</sup>, M.J. Kim<sup>1,3</sup>, J. Jun-Hyeok<sup>1,3</sup>, and S.J. Park<sup>1,2,3</sup>. <sup>1</sup>Department of Herbology, <sup>2</sup>Habang Body-fluid Research Center, <sup>3</sup>BK 21 plus team, School of Korean Medicine, Wonkwang University, Iksan, South Korea

**P2-123**

Inflammatory Monocytes Regulate Acute Pancreatitis Resolution. A New Model of Chronic Pancreatitis. G. Perides<sup>1</sup>, J. Louhimo<sup>2</sup>, Z. Knotts<sup>1</sup>, M.L. Steer<sup>1</sup>. <sup>1</sup>Department of Surgery, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, <sup>2</sup>Department of Surgery, University of Helsinki, Helsinki, Finland.

**P2-124**

βIVb-Tubulin is a Novel Therapeutic Target for the Treatment of Pancreatic Cancer. G. Sharbeen<sup>\*</sup>, J. Liu<sup>\*1</sup>, J. McCarroll<sup>\*2</sup>, L. Limbri, J. Youkhana<sup>1</sup>, D. Goldstein<sup>1</sup>, M. Kavallaris<sup>2</sup>, and P. Phillips<sup>1</sup>. <sup>1</sup>Pancreatic Cancer Translational Research Group, Lowy Cancer Research Centre, UNSW Australia, Sydney, Australia; <sup>2</sup>Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia; <sup>3</sup>Australian Centre for NanoMedicine, UNSW Australia.

**P2-125**

MiR-1247 Inhibits Pancreatic Cancer Cell Proliferation by Targeting Neuropilins. S. Shi, X. Yu. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Pancreatic Cancer Institute, Fudan University, Shanghai, China.

**P2-126**

Low Dose Ciprofloxacin Nanoparticles Decrease Bacterial Translocation During Severe Acute Pancreatitis. O.Rotar<sup>1</sup>, I.Khomiak<sup>2</sup>, V.Rotar<sup>1</sup>, M.Fishbach<sup>1</sup>, K. Taneja<sup>1</sup>. <sup>1</sup>Bukovinian State Medical University, Chernivtsi, Ukraine, <sup>2</sup>A.A.Shalimov National Institute of Surgery and Transplantation, Kiev, Ukraine.

**P2-127**

High-intensity Focused Ultrasound (HIFU) Therapy Combined with Chemotherapy has an Effect of Survival Time Elongation for the Pancreatic Cancer. F. Moriyasu, A. Sofuni, T. Sano, M. Fujita, and T. Itoi. Department of Gastroenterology & Hepatology, Tokyo Medical University, Shinjuku, Tokyo, Japan



**P2-128**

Identification of Met Inhibitor-Responding Tumors in Gastrointestinal Cancer. V. Sangwan<sup>1,4</sup>, P. Peschard<sup>1</sup>, M. Gigoux<sup>1</sup>, N. Chughtai<sup>1</sup>, A. Monast<sup>1</sup>, M. Leimanis<sup>2</sup>, V. Marcus<sup>5</sup>, L. Ferri<sup>1,2,4</sup>, and M. Park<sup>1,3,4</sup>. <sup>1</sup>Goodman Cancer Research Center, McGill University, Montreal, Canada; <sup>2</sup>Department of Surgery, McGill University Health Center, Montreal, Canada; <sup>3</sup>Department of Medicine, McGill University Health Center, Montreal, Canada; <sup>4</sup>Department of Oncology, McGill University Health Center, Montreal, Canada; <sup>5</sup>Department of Pathology, McGill University Health Center, Montreal, Canada

**P2-129**

Serum Trypsinogen Levels As a Biomarker of Pancreatic Exocrine Insufficiency (PEI) In Chronic Pancreatitis (CP): Results from The NAPS2 Study. D. Whitcomb, B. Sandhu, C. Wilcox, S. Alkaade, M. Anderson, D. Yadav for the NAPS2 Consortium, USA

**P2-130**

Proteomic Characterization of Acinar Cells Isolated Using Laser Capture Microdissection From Pancreata of Mice With Caerulein-Induced Chronic Pancreatitis. J.P. Shapiro<sup>1</sup>, H. Komar<sup>2</sup>, P. Hart<sup>1</sup>, D. Conwell<sup>1</sup>, G.B. Lesinski.<sup>1,2</sup> <sup>1</sup>Division of Gastroenterology, Hepatology & Nutrition; <sup>2</sup>Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus OH.

**P2-131**

Pancreas Transection with Linear Stapler and Bipolar Cautery Forceps in Distal Pancreatectomy. Y. Shindo, T. Ueno, N. Suzuki, H. Matsui, M. Nakajima, S. Matsukuma, Y. Tokumitsu, Y. Tokuhisa, K. Sakamoto, T. Tamesa, S. Takeda, S. Yoshino, S. Hazama, and H. Nagano. Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.

**P2-132**

Colipase (CLPS) Mediates Adipocyte Death and Inflammation: an In-Vitro Model of Fat Necrosis(FN). R.N. Trivedi, K. Patel, P. Noel, A. Singh, C. de Oliveira, and V.P. Singh Department of Medicine, Mayo Clinic, Scottsdale, Arizona

**P2-133**

Role of AMPK in the inhibitory effects of metformin and berberine in humane pancreatic cancer cells. J. Wang, L.L. Han, Sinnett-Smith, S. Young, E. Rozengurt. Division of Digestive Diseases, Department of Medicine, CURE: Digestive Diseases Research Center, David Geffen School of Medicine, University of California at Los Angeles.

**P2-134**

Pattern and Impact of Organ Failure on Human Acute Pancreatitis. P. Szatmary<sup>1</sup>, W. Huang<sup>1</sup>, T. Liu<sup>1</sup>, D. de la Iglesia-Garcia<sup>2</sup>, S. Parente<sup>1</sup>, G. Primo<sup>1</sup>, W. Greenhalf<sup>1</sup>, and R. Sutton<sup>1</sup>. <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, The Royal Liverpool University Hospital, Liverpool, UK; <sup>2</sup>Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Spain.

**P2-135**

Solid-pseudopapillary Neoplasm (SPN) – Aspects of a Rare Disease. C. Tjaden, U. Hinz, T. Kehayova, M.W Büchler, Th. Hackert. Department of Surgery, University of Heidelberg, Heidelberg, Germany

**P2-136**

Prevalence and In-Hospital Mortality Trends of Clostridium difficile Among Patients admitted with Acute Pancreatitis: A Nationwide Study of Hospitalized patients in the United States. G. Trikudanathan, S. Munigala, M.A. Arain, M.L. Freeman. GI Division, Department of Medicine, University of Minnesota.

**P2-137**

Role of the MSP-RON Signaling Pathway in Pancreatic Stellate Cell Activation and in Transformation from Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). S. Morvaridi, C. Chheta, S. Pandol, and Q. Wang. Pancreatic Research Program; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

**P2-138**

Neoadjuvant Chemoradiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma. S Shafi<sup>1</sup>, A Kaubisch<sup>2</sup>. <sup>1</sup>Department of Medicine, Albert Einstein Montefiore New Rochelle Hospital, New Rochelle, NY, <sup>2</sup>Department of Oncology, Albert Einstein Montefiore Medical Centre, Bronx, NY.

**P2-139**

Duodenal Display of Extended Field of Pancreatic Cancer: Potential Role of Galectin-3. N. Momi,<sup>1</sup>H. Subramanian,<sup>2</sup>R. Wali,<sup>1</sup>M. Delacruz,<sup>1</sup>V. Backman,<sup>2</sup>H. Roy,<sup>1</sup> <sup>1</sup>Dept of Medicine, Boston University Medical Center, Boston, MA; <sup>2</sup>Northwestern University, Evanston, IL

